iSign Solutions (ISGN) S-1/A 26 Jan 16 2015 Q3 IPO registration (amended) Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	iSign Solutions Inc.	iSign Solutions Inc.
Entity Central Index Key	727,634	727,634
Document Type	S1	S1
Document Period End Date	Sep. 30, 2015	Dec. 31, 2014
Amendment Flag	true	true
Amendment Description		All common stock share and per share information and all exercise prices with respect to options and warrants reflect, on a retroactive basis, a 1-for-1,250 reverse stock split of common stock, which became effective on January 22, 2016.
Document Fiscal Year Focus	2,015	2,014
Document Fiscal Period Focus	Q3	FY
Entity Filer Category	Smaller Reporting Company	Smaller Reporting Company

Consolidated Balance Sheets (10

Consolidated Balance Sheets (10K) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 358	$ 775	$ 641	$ 945	$ 486
Accounts receivable, net of allowance of $22 and $22 at December 31, 2014 and 2013	159	122		410
Prepaid expenses and other current assets	125	80		57
Total current assets	642	977		1,412
Property and equipment, net	17	11		17
Intangible assets, net	673	933		1,290
Other assets	29	29		29
Total assets	1,361	1,950		2,748
Current liabilities:
Accounts payable	420	328		327
Accrued compensation	272	293		315
Other accrued liabilities	477	338		232
Deferred revenue	353	257		490
Total current liabilities	1,772	1,216		1,364
Deferred revenue long-term	490	700		74
Deferred rent	2	41		86
Derivative liability		18		25
Other long-term liabilities	21	28
Total liabilities	$ 2,285	$ 2,003		$ 1,549
Commitments and Contingencies (Note 10)
Equity (deficit):
Common stock, $.01 par value; 2,000,000 shares authorized; 187 and 186 shares issued and outstanding at December 31, 2014 and 2013, respectively	$ 2	$ 2		$ 2
Treasury shares, 5 at December 31, 2014 and December 31, 2013 respectively	(325)	(325)		(325)
Additional paid in capital	96,009	97,400		98,560
Accumulated deficit	(126,082)	(123,199)		(119,184)
Accumulated other comprehensive loss	(14)	(14)		(14)
Total iSign stockholder' equity	(388)	483		1,735
Non-Controlling interest	(536)	(536)		(536)
Total equity (deficit)	(924)	(53)		1,199	1,387
Total liabilities and equity (deficit)	1,361	1,950		2,748
Series A-1 Preferred Stock [Member]
Equity (deficit):
Preferred stock by class of stock	929	875		1,031
Total equity (deficit)	929	875		1,031	953
Series B Preferred Stock [Member]
Equity (deficit):
Preferred stock by class of stock	11,320	10,381		9,232
Total equity (deficit)	11,320	10,381		9,232	8,188
Series C Preferred Stock [Member]
Equity (deficit):
Preferred stock by class of stock	5,934	5,553		5,086
Total equity (deficit)	5,934	5,553		5,086	4,753
Series D-1 Preferred Stock [Member]
Equity (deficit):
Preferred stock by class of stock	6,724	5,139		3,345
Total equity (deficit)	6,724	5,139		3,345	2,159
Series D-2 Preferred Stock [Member]
Equity (deficit):
Preferred stock by class of stock	5,115	4,671		4,002
Total equity (deficit)	$ 5,115	$ 4,671		$ 4,002	$ 3,073

Consolidated Balance Sheets (13

Consolidated Balance Sheets (10K) (Parenthetical) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Accounts receivable, allowance	$ 22,000	$ 22,000
Equity (deficit):
Common Stock, par value	$ 0.01	$ 0.01
Common Stock, shares authorized	2,000,000,000	1,500,000,000
Common Stock, shares issued	187,000	186,000
Common Stock, shares outstanding	187,000	186,000
Treasury shares	5,000	5,000
Series A-1 Preferred Stock [Member]
Equity (deficit):
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	875,000	1,031,000
Preferred stock, shares outstanding	875,000	1,031,000
Preferred stock, liquidation preference	$ 875,000
Series B Preferred Stock [Member]
Equity (deficit):
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	14,000,000	14,000,000
Preferred stock, shares issued	12,251,000	11,102,000
Preferred stock, shares outstanding	12,251,000	11,102,000
Preferred stock, liquidation preference	$ 18,377,000
Series C Preferred Stock [Member]
Equity (deficit):
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	9,000,000	9,000,000
Preferred stock, shares issued	4,975,000	4,508,000
Preferred stock, shares outstanding	4,975,000	4,508,000
Preferred stock, liquidation preference	$ 7,462,000
Series D-1 Preferred Stock [Member]
Equity (deficit):
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	6,000,000
Preferred stock, shares issued	5,800,000	3,415,000
Preferred stock, shares outstanding	5,800,000	3,415,000
Preferred stock, liquidation preference	$ 5,800,000
Series D-2 Preferred Stock [Member]
Equity (deficit):
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	9,000,000
Preferred stock, shares issued	5,720,000	4,783,000
Preferred stock, shares outstanding	5,720,000	4,783,000
Preferred stock, liquidation preference	$ 5,779,000

Consolidated Statements of Oper

Consolidated Statements of Operations (10K) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenue:
Product	$ 766	$ 728
Maintenance	749	690
Total revenues	1,515	1,418
Cost of sales:
Product	199	64
Maintenance	191	280
Research and development	1,931	2,073
Sales and marketing expense	1,264	1,272
General and administrative expense	1,743	2,026
Total operating costs and expenses	5,328	5,715
Loss from operations	(3,813)	(4,297)
Other income (expense), net	50	(23)
Interest expense:
Related party		(436)
Other	(259)
Amortization of debt discount and deferred financing cost:
Related party		(44)
Loss on extinguishment of debt, related party		(67)
Gain on derivative liability	7	103
Net loss	(4,015)	(4,764)
Accretion of beneficial conversion feature:
Related party	(208)	(599)
Other	(444)	(648)
Preferred stock dividends:
Related party	(1,364)	(1,140)
Other	$ (1,348)	$ (948)
Income tax
Net loss before non-controlling interest	$ (7,379)	$ (8,099)
Net loss attributable to non-controlling interest
Net loss attributable to common stockholders	$ (7,379)	$ (8,099)
Basic and diluted loss per common share	$ (39.61)	$ (44.75)
Weighted average common shares outstanding, basic and diluted	181	186

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (10K) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Comprehensive income:
Net loss	$ (853)	$ (912)	$ (2,883)	$ (3,139)	$ (4,015)	$ (4,764)
Foreign currency translation adjustment						15
Total comprehensive loss					$ (4,015)	$ (4,749)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) (10K) - USD ($) shares in Thousands, $ in Thousands	Total	Series A-1 Preferred Shares	Series B Preferred Shares	Series C Preferred Shares	Series D-1 Preferred Shares	Series D-2 Preferred Shares	Common Stock	Treasury Stock	Additional Paid in Capital	Accumulated Deficit	Non-Controlling Interest	Accumulated Other Comprehensive Income (Loss)
Beginning balance at Dec. 31, 2012	$ 1,387	$ 953	$ 8,188	$ 4,753	$ 2,159	$ 3,073	$ 2	$ (325)	$ 97,569	$ (114,420)	$ (536)	$ (29)
Beginning balance (in shares) at Dec. 31, 2012		953	10,058	4,175	1,124	3,302	180
Stock-based employee compensation	819								819
Common shares issued in connection with the cashless exercise of warrants							$ 0		0
Common shares issued in connection with the cashless exercise of warrants. shares							2
Common shares issued in connection with the exercise of warrants for cash	29						$ 0		29
Common shares issued in connection with the exercise of warrants for cash. shares							1
Common shares issued in connection with the conversion of Series C preferred shares				$ (100)			$ 0		100
Common shares issued in connection with the conversion of Series C preferred shares, shares				(100)			3
Series D-1 preferred shares issued in a private placement upon the conversion of short-term debt plus accrued interest, value	786				$ 786
Series D-1 preferred shares issued in a private placement upon the conversion of short-term debt plus accrued interest, shares					786
Cost of warrants issued with Series D-1 preferred shares issued in a private placement upon the conversion of short-term debt plus accrued interest					$ (391)				391
Beneficial conversion feature on Series D-1 preferred shares issued in a private placement upon conversion of short term debt plus accrued interest					(395)				395
Accretion of beneficial conversion feature on Series D-1 preferred shares issued in private placement upon conversion of short term debt plus accrued interest					395				(395)
Series D-2 preferred shares issued in a private placement upon the conversion of short-term debt plus accrued interest, value	393					$ 393
Series D-2 preferred shares issued in a private placement upon the conversion of short-term debt plus accrued interest, shares						393
Cost of warrants issued with Series D-2 preferred shares issued in a private placement upon the conversion of short-term debt plus accrued interest						$ (196)			196
Beneficial conversion feature on Series D-2 preferred shares issued in private placement upon conversion of short term debt plus accrued interest						(39)			39
Accretion of beneficial conversion feature on Series D-2 preferred shares issued in a private placement upon the conversion of short term debt plus accrued interest						39			(39)
Series D-1 preferred shares issued in a private placement for cash, net of offering expenses, value	810				$ 810
Series D-1 preferred shares issued in a private placement for cash, net of offering expenses, shares					837
Cost of warrants issued with Series D-1 preferred shares issued in a private placement for cash					$ (302)				302
Beneficial conversion feature on Series D-1 preferred shares issued in private placement for cash					(381)				381
Accretion of beneficial conversion feature on Series D-1 preferred shares issued in a private placement for cash					381				(381)
Series D-2 Preferred Shares issued in a private placement for cash, net of offering expenses, value	1,210					$ 1,210
Series D-2 Preferred Shares issued in a private placement for cash, net of offering expenses, shares						1,223
Cost of warrants issued with Series D-2 preferred shares issued in a private placement for cash						$ (151)			151
Beneficial conversion feature on Series D-2 preferred shares issued in private placement for cash					(30)				30
Accretion of beneficial conversion feature on Series D-2 preferred shares issued in a private placement for cash					$ 30				(30)
Exchange of Series D-2 Preferred Stock for shares of Series D-1 Preferred Stock issued in May 2014, shares					537	(537)
Exchange of Series D-2 Preferred Stock for shares of Series D-1 Preferred Stock issued in May 2013, value					$ 537	$ (537)
Cost of warrants issued on exchange of Series D preferred stock					(385)	(192)			577
Beneficial Conversion Feature On Exchange Of Series D Preferred Stock					(152)				152
Accretion of beneficial conversion feature on exchange of series D preferred stock					152				(152)
Preferred shares dividends, paid in kind		$ 78	$ 1,044	$ 433	$ 131	$ 402			(2,088)
Preferred share dividends, paid-in-kind, shares		78	1,044	433	131	402
Benefitial conversion feature on preferred shares dividends issued in kind				$ (191)	$ (59)				250
Accretion of beneficial conversion feature on preferred shares dividends issued in kind				191	59				(250)
Warrants issued with short term debt	403								403
Loan discount on demand notes	$ 111								111
Net loss attributable to non-controlling interest
Comprehensive income:
Net loss	$ (4,764)									(4,764)
Foreign currency translation adjustment	15											15
Total comprehensive loss	(4,749)
Ending balance at Dec. 31, 2013	1,199	$ 1,031	$ 9,232	$ 5,086	$ 3,345	$ 4,002	$ 2	(325)	98,560	(119,184)	(536)	(14)
Ending balance (in shares) at Dec. 31, 2013		1,031	11,102	4,508	3,415	4,783	186
Stock-based employee compensation	298								298
Common shares issued in connection with the exercise of warrants for cash	29
Common shares issued in connection with the conversion of Series A-1 Preferred Shares		$ (238)					$ 0		238
Common shares issued in connection with the conversion of Series A-1 Preferred Shares, shares		(238)					1
Common shares issued in connection with the conversion of Series C preferred shares				$ (1)					1
Common shares issued in connection with the conversion of Series C preferred shares, shares				(1)			0
Series D-1 preferred shares issued in a private placement for cash, net of offering expenses, value	1,828				$ 1,828
Series D-1 preferred shares issued in a private placement for cash, net of offering expenses, shares					1,913
Cost of warrants issued with Series D-1 preferred shares issued in a private placement for cash					$ (506)				506
Beneficial conversion feature on Series D-1 preferred shares issued in private placement for cash					(253)				253
Accretion of beneficial conversion feature on Series D-1 preferred shares issued in a private placement for cash					253				(253)
Series D-2 Preferred Shares issued in a private placement for cash, net of offering expenses, value	381					$ 381
Series D-2 Preferred Shares issued in a private placement for cash, net of offering expenses, shares						397
Cost of warrants issued with Series D-2 preferred shares issued in a private placement for cash						$ (253)			253
Beneficial conversion feature on Series D-2 preferred shares issued in private placement for cash						(52)			52
Accretion of beneficial conversion feature on Series D-2 preferred shares issued in a private placement for cash						52			(52)
Preferred shares dividends, paid in kind		$ 82	$ 1,149	$ 468	$ 472	$ 541			(2,712)
Preferred share dividends, paid-in-kind, shares		82	1,149	468	472	540
Benefitial conversion feature on preferred shares dividends issued in kind				$ (152)	$ (195)				347
Accretion of beneficial conversion feature on preferred shares dividends issued in kind				152	195				(347)
Cost of warrants issued in connection with line of credit	258								258
Change in derivative value of expired warrants	$ (2)								(2)
Net loss attributable to non-controlling interest
Comprehensive income:
Net loss	$ (4,015)									(4,015)
Total comprehensive loss	(4,015)
Ending balance at Dec. 31, 2014	(53)	$ 875	$ 10,381	$ 5,553	$ 5,139	$ 4,671	$ 2	$ (325)	$ 97,400	$ (123,199)	$ (536)	$ (14)
Ending balance (in shares) at Dec. 31, 2014		875	12,251	4,975	5,800	5,720	187
Stock-based employee compensation	487
Comprehensive income:
Net loss	(2,883)
Ending balance at Sep. 30, 2015	$ (924)	$ 929	$ 11,320	$ 5,934	$ 6,724	$ 5,115

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholder's Deficit (10K) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Series D-1 Preferred Stock for Cash [Member]
Stock Transactions, Parenthetical Disclosures [Abstract]
Offering expenses	$ 26	$ 82
Series D-2 Preferred Stock for Cash [Member]
Stock Transactions, Parenthetical Disclosures [Abstract]
Offering expenses	$ 13	$ 16

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (10K) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	$ (4,015)	$ (4,764)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization	367	381
Amortization of debt discount and deferred financing costs		44
Loss on extinguishment of debt		67
Stock-based employee compensation	298	819
Warrants issued in connection with line of credit	258
Warrants issued with demand notes		436
Gain on derivative liability	(7)	(103)
Gain on sale of trademark	(50)
Changes in operating assets and liabilities:
Accounts receivable, net	288	291
Prepaid expenses and other assets	(23)	16
Accounts payable	1	252
Accrued Compensation	(22)	26
Other accrued liabilities	87	54
Deferred revenue	393	(254)
Net cash used in operating activities	(2,425)	(2,735)
Cash flows from investing activities:
Acquisition of property and equipment	(4)	(5)
Net cash used in investing activities	(4)	(5)
Cash flows from financing activities:
Net proceeds from issuance of short-term debt		1,460
Proceeds from exercise of warrants for cash		29
Proceeds from sale of trademark	50
Principal payments on short term notes payable		(310)
Net cash provided by financing activities	2,259	3,199
Net decrease in cash and cash equivalents	(170)	459
Cash and cash equivalents at beginning of period	945	486
Cash and cash equivalents at end of period	775	945
Supplemental disclosure of cash flow information:
Interest paid	1	1
Non-cash financing and investing transactions:
Cashless exercise of warrants		23
Dividends on preferred shares	2,712	2,088
Debt discount recorded in connection with short-term debt		111
Conversion of short term notes plus accrued interest into Series D-1 preferred shares		786
Conversion of short term notes plus accrued interest into Series D-2 preferred shares		393
Warrants issued in connection with the Series D financing
Subscription Agreements	759	453
Debt Conversion		587
Exchange of May Series D financing		575
Series A Preferred Stock [Member]
Non-cash financing and investing transactions:
Dividends on preferred shares	82	78
Conversion of Preferred Stock into Common Stock	238
Series B Preferred Stock [Member]
Non-cash financing and investing transactions:
Dividends on preferred shares	1,149	1,044
Series C Preferred Stock [Member]
Non-cash financing and investing transactions:
Dividends on preferred shares	468	433
Conversion of Preferred Stock into Common Stock	1	100
Accretion of beneficial conversion feature on Preferred Share dividends	152	191
Series D One Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of Preferred shares	1,828	810
Non-cash financing and investing transactions:
Dividends on preferred shares	472	131
Accretion of beneficial conversion feature on Preferred Share dividends	195	59
Accretion of beneficial conversion feature on Preferred Shares issued	253	958
Series D Two Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of Preferred shares	381	1,210
Non-cash financing and investing transactions:
Dividends on preferred shares	541	402
Accretion of beneficial conversion feature on Preferred Shares issued	$ 52	$ 39

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (10Q) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 358	$ 775	$ 641	$ 945	$ 486
Accounts receivable, net of allowance of $86 at September 30, 2015 and $22 at December 31, 2014	159	122		410
Prepaid expenses and other current assets	125	80		57
Total current assets	642	977		1,412
Property and equipment, net	17	11		17
Intangible assets, net	673	933		1,290
Other assets	29	29		29
Total assets	1,361	1,950		2,748
Current liabilities:
Short-term debt	250
Accounts payable	420	328		327
Accrued compensation	272	293		315
Other accrued liabilities	477	338		232
Deferred revenue	353	257		490
Total current liabilities	1,772	1,216		1,364
Deferred revenue long-term	490	700		74
Deferred rent	2	41		86
Derivative liability		18		25
Other long-term liabilities	21	28
Total liabilities	$ 2,285	$ 2,003		$ 1,549
Commitments and Contingencies
Equity (Deficit)
Common stock	$ 2	$ 2		$ 2
Treasury shares	(325)	(325)		(325)
Additional paid in capital	96,009	97,400		98,560
Accumulated deficit	(126,082)	(123,199)		(119,184)
Accumulated other comprehensive loss	(14)	(14)		(14)
Total iSign stockholder' equity	(388)	483		1,735
Non-Controlling interest	(536)	(536)		(536)
Total equity (deficit)	(924)	(53)		1,199	1,387
Total liabilities and equity (deficit)	1,361	1,950		2,748
Series A-1 Preferred Stock [Member]
Equity (Deficit)
Preferred Stock	929	875		1,031
Total equity (deficit)	929	875		1,031	953
Series B Preferred Stock [Member]
Equity (Deficit)
Preferred Stock	11,320	10,381		9,232
Total equity (deficit)	11,320	10,381		9,232	8,188
Series C Preferred Stock [Member]
Equity (Deficit)
Preferred Stock	5,934	5,553		5,086
Total equity (deficit)	5,934	5,553		5,086	4,753
Series D-1 Preferred Stock [Member]
Equity (Deficit)
Preferred Stock	6,724	5,139		3,345
Total equity (deficit)	6,724	5,139		3,345	2,159
Series D-2 Preferred Stock [Member]
Equity (Deficit)
Preferred Stock	5,115	4,671		4,002
Total equity (deficit)	$ 5,115	$ 4,671		$ 4,002	$ 3,073

Condensed Consolidated Balanc10

Condensed Consolidated Balance Sheets (10Q) (Parenthetical) - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Accounts receivable, allowance	$ 86,000	$ 22,000	$ 22,000	$ 22,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (10Q) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Revenue:
Product	$ 127	$ 85	$ 510	$ 491	$ 766	$ 728
Maintenance	224	200	654	568	749	690
Total revenues	351	285	1,164	1,059	1,515	1,418
Cost of sales:
Product	40	26	185	69	199	64
Maintenance	29	20	102	111	191	280
Research and development	446	476	1,467	1,549	1,931	2,073
Sales and marketing expense	216	303	756	942	1,264	1,272
General and administrative expense	470	410	1,551	1,325	1,743	2,026
Total operating costs and expenses	1,201	1,235	4,061	3,996	5,328	5,715
Loss from operations	(850)	(950)	(2,897)	(2,937)	(3,813)	(4,297)
Other income, net		49		51	50	(23)
Interest expense	(3)	(13)	(3)	(258)	(259)
Gain on derivative liability	0	2	17	5	7	103
Net loss	(853)	(912)	(2,883)	(3,139)	(4,015)	(4,764)
Accretion of beneficial conversion feature: Preferred Stock:
Related party		(103)	(458)	(186)	(208)	(599)
Other		(68)	(69)	(416)	(444)	(648)
Preferred stock dividends:
Related party	(408)	(345)	(1,154)	(1,014)	(1,364)	(1,140)
Other	(411)	(363)	(1,181)	(975)	(1,348)	(948)
Net loss attributable to common stockholders	$ (1,672)	$ (1,791)	$ (5,745)	$ (5,730)	$ (7,379)	$ (8,099)
Basic and diluted loss per common share	$ (8.92)	$ (9.62)	$ (30.65)	$ (30.79)	$ (39.61)	$ (44.75)
Weighted average common shares outstanding, basic and diluted	187	186	187	186	181	186

Condensed Consolidated Statem12

Condensed Consolidated Statements of Cash Flows (10Q) $ in Thousands	9 Months Ended
	Sep. 30, 2014USD ($)
Cash flows from operating activities:
Net loss	$ (3,139)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization	278
Stock-based employee compensation	242
Warrants cost issued as interest expense	258
Gain on derivative liability	(5)
Changes in operating assets and liabilities:
Accounts receivable, net	195
Prepaid expenses and other assets	(31)
Accounts payable	(106)
Accrued compensation	(50)
Other accrued and long-term liabilities	15
Deferred revenue	(165)
Net cash used in operating activities	(2,508)
Cash flows from investing activities:
Acquisition of property and equipment	(4)
Net cash used in investing activities	(4)
Cash flows from financing activities:
Net cash provided by financing activities	2,208
Net decrease in cash and cash equivalents	(304)
Cash and cash equivalents at beginning of period	945
Cash and cash equivalents at end of period	641
Non-cash financing and investing transactions:
Dividends on preferred shares	1,989
Accretion of beneficial conversion feature on issuance of convertible Preferred Stock	337
Accretion of beneficial conversion feature on issuance of Preferred Stock dividends	265
Conversion of Series C Preferred Stock into Common Stock	1
Series D-1 Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of Series D Preferred Stock, net of issuance costs	1,828
Non-cash financing and investing transactions:
Dividends on preferred shares	329
Accretion of beneficial conversion feature on issuance of Preferred Stock dividends	151
Series D-2 Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of Series D Preferred Stock, net of issuance costs	380
Non-cash financing and investing transactions:
Dividends on preferred shares	$ 400
Accretion of beneficial conversion feature on issuance of Preferred Stock dividends

Condensed Consolidated Statem13

Condensed Consolidated Statements of Cash Flows (10Q) (Parenthetical) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Series D-1 Preferred Stock [Member]
Series D Preferred Stock issuance costs	$ 37	$ 84
Series D-2 Preferred Stock [Member]
Series D Preferred Stock issuance costs		$ 17

Nature of business, Basis of Pr

Nature of business, Basis of Presentation and Summary of Significant Accounting Policies (10K)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies	1. Nature of business and summary of significant accounting policies Nature of Business iSign Solutions Inc., formerly known as Communication Intelligence Corporation, and its subsidiary (the “Company” or “iSign”) is a leading provider of digital transaction management (DTM) software enabling fully digital (paperless) business processes. The Company’s software solutions encompass a wide array of functionality and services, including electronic signatures, biometric authentication and simple-to-complex workflow management. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. The Company’s platform can be deployed both on-premise and as a cloud-based service, with the ability to easily transition between deployment models. To date, the Company primarily has delivered its solutions to channel partners and end-user customers in the financial services industry. The Company’s products include SignatureOne® Ceremony™ Server, the iSign® suite of products and services, including iSign® Enterprise and iSign® Console™, and Sign-it® programs. Basis of Presentation The financial information contained herein should be read in conjunction with the Company's consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2014. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company’s results of operations and cash flows for the periods presented. The Company’s interim results are not necessarily indicative of the results to be expected for the entire year. Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at September 30, 2015, the Company’s accumulated deficit was $126,082. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of September 30, 2015, the Company’s cash balance was $358. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accounting Changes and Recent Accounting Pronouncements Accounting Standards Issued But Not Yet Adopted Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies are not expected to have a material impact on the Company’s financial position, results of operations and cash flows.	1. Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies: The Company: iSign Solutions Inc., formerly known as Communication Intelligence Corporation (the “Company” or “iSign”), is a leading supplier of digital transaction management (DTM) software enabling the paperless, secure and cost-effective management of document-based transactions. iSign’s solutions encompass a wide array of functionality and services, including electronic signatures, biometric authentication and simple-to-complex workflow management. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. The Company’s products and services result in legally binding transactions that are compliant with applicable laws and regulations and that can provide a higher level of security than paper-based processes. The Company has been a leading supplier of enterprise software solutions within the financial services and insurance industries and has delivered significant expense reduction by enabling complete document and workflow automation and the resulting reduction in mailing, scanning, filing and other costs related to the use of paper. The Company’s research and development activities have given rise to numerous technologies and products. The Company’s core DTM technologies include various forms of electronic signatures, such as handwritten biometric, click-to-sign and others, as well as signature verification, cryptography and the logging of audit trails to show signers’ intent. These technologies can enable secure, legal and regulatory compliant electronic transactions that can enhance customer experience at a fraction of the time and cost required by traditional, paper-based processes. The Company’s products include SignatureOne®Ceremony™Server, Sign-it® and the iSign® family of products and services. Going concern and management plans: The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Except for 2004, the Company has incurred significant losses since its inception and, at December 31, 2014, the Company’s accumulated deficit was $123,199. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of December 31, 2014, the Company’s cash balance was $775. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company’s business, results of operations and ability to operate as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis of consolidation: The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America, and include the accounts of iSign Solutions Inc. and its 90%-owned Joint Venture in the People’s Republic of China. All inter-company accounts and transactions have been eliminated. All amounts shown in the accompanying consolidated financial statements are in thousands of dollars except per share amounts. Reclassification: Certain amounts in the consolidated financial statements for 2013 have been reclassified to conform to the 2014 presentation. These reclassifications have no effect on net income, earnings per share, or cash flows as previously reported. Use of estimates: The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates. Fair value measures: Fair value is the price that would be received to sell an asset, or paid to transfer a liability, in the principal or most advantageous market for the asset or liability in an ordinary transaction between market participants on the measurement date. Our policy on fair value measures requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The policy prioritizes the inputs into three levels that may be used to measure fair value: Level 1: Applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2: Applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3: Applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s assets and liabilities measured at fair value, whether recurring or non-recurring, at December 31, 2014 and December 31, 2013, and the fair value calculation input hierarchy level that we have determined applies to each asset and liability category. Fair Value of Financial Instruments: The Company carries financial instruments on the consolidated balance sheet at the fair value of the instruments as of the consolidated balance sheet date. At the end of each period, management assesses the fair value of each instrument and adjusts the carrying value to reflect its assessment. At December 31, 2014 and December 31, 2013, the carrying values of accounts receivable and accounts payable approximated their fair values. Treasury Stock: Shares of common stock returned to, or repurchased by, the Company are recorded at cost and are included as a separate component of stockholders’ equity (deficit). Under the cost method, the gross cost of the shares reacquired is charged to a contra equity account entitled treasury stock. The equity accounts that were credited for the original share issuance (common stock, additional paid-in capital, etc.) remain intact. When the treasury shares are reissued, proceeds in excess of cost are credited to additional paid-in capital. Any deficiency is charged to accumulated deficit (unless additional paid-in capital from previous treasury share transactions exists, in which case the deficiency is charged to that account, with any excess charged to accumulated deficit). Derivatives: The Company, from time to time, enters into transactions which contain conversion privileges, the settlement of which may entitle the holder or the Company to settle the obligation(s) by issuance of Company securities. The Company applies a two-step model in determining whether a financial instrument or an embedded feature is indexed to an issuer’s own stock and thus able to qualify for the scope exception. The fair value of each derivative is estimated each reporting period. Cash and cash equivalents: The Company considers all highly liquid investments with maturities at the date of purchase of three months or less to be cash equivalents. The Company’s cash and cash equivalents, at December 31, consisted of the following: 2014 2013 Cash in bank $ 775 $ 945 Money market funds — — Cash and cash equivalents $ 775 $ 945 Concentrations of credit risk: Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company maintains its cash and cash equivalents with various financial institutions. This diversification of risk is consistent with Company policy to maintain liquidity, and mitigate risk of loss as to principal. To date, accounts receivable have been derived principally from revenue earned from end users, manufacturers, and distributors of computer products in North America. The Company performs periodic credit evaluations of its customers, and does not require collateral. The Company maintains reserves for potential credit losses; historically, such losses have been within management’s expectations. The allowance for doubtful accounts is based on the Company’s assessment of the collectability of specific customer accounts and an assessment of international, political and economic risk as well as the aging of the accounts receivable. If there is a change in actual defaults from the Company’s historical experience, the Company’s estimates of recoverability of amounts due could be affected and the Company will adjust the allowance accordingly. Deferred financing costs: Deferred financing costs include costs paid in cash, such as professional fees and commissions. The costs are amortized to interest expense over the life of the notes or upon early payment using the effective interest method. There were $0 and $44 in cost amortized to interest expense for the years ended December 31, 2014 and 2013, respectively. Property and equipment, net: Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, ranging from three to five years. Leasehold improvements are amortized over their estimated useful lives, not to exceed the term of the related lease. The cost of additions and improvements is capitalized, while maintenance and repairs are charged to expense as incurred. Depreciation expense was $10 and $16 for the years ended December 31, 2014 and 2013, respectively. Intangible Assets: The Company’s core technologies can be referred to as “transaction-enabling,” “digital authentication” and “business process work flow.” These technologies include various forms of electronic signature methods, such as handwritten, biometric, click-to-sign and others, as well as technologies related to signature verification, authentication, cryptography and the logging of audit trails to prove signers’ intent. Our technologies enable the appending of secure, legal and regulatory compliant electronic signatures coupled with an enhanced user experience at a fraction of the time and cost required by traditional, paper-based processes for signature capture. The Company’s enterprise-class SignatureOne® and iSign® suite of electronic signature solutions enable businesses to implement paperless, electronic signature-driven business processes. The aggregate of the software functionality enabling the digitization of end-to-end work flow processes is sometimes referred to as “Digital Transaction Management” (“DTM”). Many applications provide electronic forms and allow users to fill-in information, but most of these applications still require users to print out a paper copy for the application of a handwritten, ink signature. Solutions powered by the Company’s products allow legally binding electronic signatures to be added to digitized documents, eliminating the need for paper to memorialize the completion, approval or authentication of the transaction. This allows users to reduce transaction times and processing costs. Intangible assets are stated at cost less accumulated amortization and reflect a portion of the value of the technologies described above. Amortization is computed using the straight-line method over the estimated lives of the related assets. Amortization expense was $357 and $365 for the years ended December 31, 2014 and 2013, respectively. The estimated remaining weighted average useful lives of the intangible assets are 3 years. Future intangible asset amortization is as follows: Year Ended December 31, 2015 $ 342 2016 323 2017 268 Total $ 933 Long-lived assets: The Company evaluates the recoverability of its long-lived assets, including intangible assets, at least annually or whenever circumstances or events indicate such assets might be impaired. The Company would recognize an impairment charge in the event the net book value of such assets exceeded the future undiscounted cash flows attributable to such assets. No such impairment charges have been recorded during the two years ended December 31, 2014 and 2013, respectively. Share-based payment: Share-based compensation expense is based on the estimated grant date fair value of the portion of share-based payment awards that are ultimately expected to vest during the period. The grant date fair value of share-based awards to employees and directors is calculated using the Black Scholes Merton valuation model. Forfeitures of share-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates and it is assumed no dividends will be declared. The estimated fair value of share-based compensation awards to employees is amortized over the vesting period of the options. Revenue recognition: The Company recognizes revenue from sales of software products upon shipment, provided that persuasive evidence of an arrangement exists, collection is determined to be probable, all non-recurring engineering work necessary to enable the Company’s product to function within the customer’s application has been completed and the Company’s product has been delivered according to specifications. Revenue from service subscriptions is recognized as costs are incurred or over the service period, whichever is longer. Software license agreements may contain multiple elements, including upgrades and enhancements, products deliverable on a when and if available basis and post contract support. Revenue from software license agreements is recognized upon delivery of the software, provided that persuasive evidence of an arrangement exists, collection is determined to be probable, all nonrecurring engineering work necessary to enable the Company’s products to function within the customer’s application has been completed, and the Company has delivered its product according to specifications. For arrangements with multiple deliverables, the Company allocates consideration at the inception of an arrangement to all of its deliverables based on their relative selling prices which is determined using vendor specific objective evidence. Maintenance revenue is recorded for post-contract support and upgrades or enhancements, which is paid for in addition to license fees, and is recognized as costs are incurred or over the support period whichever is longer. For undelivered elements where vendor specific objective evidence does not exist, revenue is deferred and subsequently recognized when delivery has occurred and when vendor specific evidence has been determined. Research and development: Research and development costs are charged to expense as incurred. Marketing: The Company expenses advertising (marketing) costs as incurred. These expenses are outbound marketing expenses associated with participation in industry events, related sales collateral and email campaigns aimed at generating customer participation in webinars. The expense for the years ended December 31, 2014 and 2013 was $46 and $15, respectively. Net loss per share: The Company calculates net loss per share under the provisions of the relevant accounting guidance. That guidance requires the disclosure of both basic net loss per share, which is based on the weighted average number of shares outstanding, and diluted loss per share, which is based on the weighted average number of shares and dilutive potential shares outstanding. The number of shares of common stock subject to outstanding options, preferred shares on an as converted basis and shares issuable upon exercise of warrants excluded from the calculation of loss per share as their inclusion would be anti-dilutive are as follows: December 31, 2014 December 31, 2013 Common Stock subject to outstanding options 58 56 Series A-1 Preferred Stock 6,252 7,368 Series B Preferred Stock 282,750 256,241 Series C Preferred Stock 221,104 200,354 Series D-1 Preferred Stock 257,773 151,766 Series D-2 Preferred Stock 114,400 95,682 Warrants outstanding 171 62 Foreign currency translation: The Company considers the functional currency of the Joint Venture, CICC, to be the local currency of China, which is the Renminbi (“RMB”) and, accordingly, gains and losses from the translation of the local foreign currency financial statements are included as a component of accumulated other comprehensive loss in the accompanying consolidated balance sheets. Foreign currency assets and liabilities are translated into U.S. dollars at the end-of-period exchange rates except for long-term assets and liabilities, which are translated at historical exchange rates. Revenue and expenses are translated at the average exchange rates in effect during each period except for those expenses related to consolidated balance sheet amounts which are translated at historical exchange rates. Net foreign currency transaction gains and losses are included in interest and other income, net in the accompanying consolidated statements of operations. Foreign currency transaction gains and losses in 2014 and 2013 were insignificant. Income taxes: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their financial statement reported amounts and for tax loss and credit carry-forwards. A valuation allowance is provided against deferred tax assets when it is determined to be more likely than not that the deferred tax asset will not be realized. There have been no unrecognized tax benefits and, accordingly, there has been no effect on the Company’s financial condition or results of operations. The Company files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. The Company is no longer subject to U.S. federal tax examinations for years before 2006, and state tax examinations for years before 2005. Management does not believe there will be any material changes in the Company’s unrecognized tax positions over the next 12 months. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Recently issued accounting pronouncement: Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

Concentrations (10K)

Concentrations (10K)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure	2. Concentrations The following table summarizes accounts receivable and revenue concentrations: Accounts Receivable As of September 30, Total Revenue for the three months ended September 30, Total Revenue for the nine months ended September 30, 2015 2014 2015 2014 2015 2014 Customer #1 38 % 46 % — 17 % 12 % 11 % Customer #2 24 % — 17 % — — — Customer #3 — — 10 % 12 % — 10 % Customer #4 — 12 % — — — — Customer #5 — 19 % — — — — Customer #6 — — — 10 % 16 % — Customer #7 — — — — 17 % 14 % Total concentration 62 % 77 % 27 % 39 % 45 % 35 %	2. Concentrations: The following table summarizes accounts receivable and revenue concentrations: Accounts Receivable As of December 31, Total Revenue for the year ended December 31, 2014 2013 2014 2013 Customer #1 44 % 47 % — 15 % Customer #2 — 15 % — 10 % Customer #3 19 % 19 % 12 % 16 % Customer #4 — — — 10 % Customer #5 — — — 12 % Customer #6 — — 12 % — Customer #7 — — 11 % — Customer #8 10 % — — — Total concentration 73 % 81 % 35 % 63 % The following table summarizes sales concentrations: December 31, 2014 December 31, 2013 Sales within the United States 99 % 98 % Sales outside of the United States 1 % 2 % Total 100 % 100 %

Property, plant and equipment (

Property, plant and equipment (10K)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, plant and equipment	3. Property and equipment: Property and equipment, net at December 31, consists of the following: 2014 2013 Machinery and equipment $ 1,235 $ 1,231 Office furniture and fixtures 435 435 Leasehold improvements 90 90 Purchased software 323 323 2,083 2,079 Less accumulated depreciation and amortization (2,072 ) (2,062 ) $ 11 $ 17

Intangible Assets (10K)

Intangible Assets (10K)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	3. Intangible assets The Company performs an intangible asset impairment analysis on its technology at least annually or whenever circumstances or events indicate such assets might be impaired. The Company would recognize an impairment charge in the event the net book value of such assets exceeded the future undiscounted cash flows attributable to such assets. Management completed an analysis of the Company’s intangible assets as of December 31, 2014. Based on that analysis, the Company concluded that no impairment of the carrying value of the intangible assets existed. The Company believes that no events or circumstances changed during the three and nine months ended September 30, 2015 that would impact this conclusion. Amortization of intangible asset costs was $87 and $260 for the three and nine-month periods ended September 30, 2015 and $90 and $270 for the three- and nine-month periods ended September 30, 2014. The following table summarizes the amortizable intangible assets: September 30, 2015 December 31, 2014 Carrying Amount Accumulated Amortization Net Value Carrying Amount Accumulated Amortization Net Value $6,745 $(6,072) $673 $6,745 $(5,812) $933	4. Intangible Assets: Intangible assets, net consists of the following at December 31: Weighted Average Amortization Period (Years) 2014 2013 Technology 3 6,745 6,745 Less accumulated amortization (5,812 ) (5,455 ) $ 933 $ 1,290 The nature of the underlying technology of our intangible assets can be referred to as “transaction-enabling,” “digital authentication” and “business process work flow.” This technology includes various forms of electronic signature methods, such as handwritten, biometric, click-to-sign and others, as well as technologies related to signature verification, authentication, cryptography and the logging of audit trails to prove signers’ intent. Our technologies enable the appending of secure, legal and regulatory compliant electronic signatures coupled with an enhanced user experience at a fraction of the time and cost required by traditional, paper-based processes for signature capture. The Company does not foresee any effects of obsolescence or significant competitive pressure on its current or future products, anticipates increasing demand for products utilizing its technology, and believes that the current markets for its products based on technology will remain constant or will grow over the remaining useful lives assigned to its intangible assets because of business environments encouraging the use of electronic signatures.

Chinese Joint Venture (Non-Cont

Chinese Joint Venture (Non-Controlling Interest) (10K)	12 Months Ended
	Dec. 31, 2014
Noncontrolling Interest [Abstract]
Noncontrolling Interest Disclosure	5. Chinese Joint Venture (Non-Controlling Interest): The Company currently owns 90% of a joint venture (the “Joint Venture”) with the Jiangsu Hongtu Electronics Group, a provincial agency of the People’s Republic of China. The Joint Venture’s business license expires October 18, 2043. There were no significant operations in 2014 or 2013. The Joint Venture had no revenue for the years ended December 31, 2014 and 2013, respectively. It had no long-lived assets as of December 31, 2014 and 2013.

Other accrued liabilities (10K)

Other accrued liabilities (10K)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Other accrued liabilities disclosure	6. Other accrued liabilities: The Company records liabilities based on reasonable estimates for expenses, or payables that are known or estimated including deposits, taxes, rents and services. The estimates are for current liabilities that should be extinguished within one year. The Company had the following other accrued liabilities at December 31: 2014 2013 Accrued professional services $ 8 $ 8 Rents 44 35 Management fees 280 180 Other 6 9 Total $ 338 $ 232

Short-term notes payable (10K)

Short-term notes payable (10K)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Short-term notes payable [Abstract]
Short-term notes payable	4. Short-term note payable On September 29, 2015, the Company issued a demand note for an aggregate amount of $250 to an affiliate of the Company. This note bears interest at the rate of 10% per annum and both the principal and interest accrued are payable on demand.	7. Debt: Short-term notes payable: In April 2013, the Company borrowed $250 in the form of a demand note from Phoenix Banner Holdings LLC, with an interest rate of 10% per annum. The demand note plus $2 of accrued interest was paid in May 2013. From August 2013 through December 2013, the Company secured $1,150 in 10% demand notes from related parties and others that was used for working capital and general corporate purposes. In November, the Board of Directors approved the issuance of warrants in addition to the interest on these demand notes. The Company issued 17 warrants, 12 of which were issued for the notes secured prior to November 6, 2013, and a total of 6 warrants were issued for demand notes secured on November 26, and December 13, 2013. The Company ascribed a value of $406, recorded as interest expense, to the warrants issued prior to November 6, 2013, and ascribed a value of $111, recorded as a debt discount to the warrants issued with notes secured after November 6, 2013. The Company recorded $44 in debt discount amortization expense and $67 in loss on extinguishment upon conversion of the notes in 2013. The warrants have a three year life from the date of grant and an exercise price of $37.50. Detail on these demand notes and warrants is as follows: Phoenix Banner Holdings LLC Michael W. Engmann Kendu Partners Company JAG Multi Investments Philip Sassower Date Note Amount Warrants Note Amount Warrants Note Amount Warrants Note Amount Warrants Note Amount Warrants 8/2/2013 $ 250 9/3/2013 $ 250 9/27/2013 $ 250 11/1/2013 $ 125 2 11/6/2013 3 3 3 12/13/2013 $ 150 4 12/17/2013 $ 125 2 Total $ 250 3 $ 400 7 $ 250 3 $ 125 2 $ 125 2 The warrants were valued using the Black Sholes Merton pricing model with the following assumptions: Date Expected Term Volatility Risk free interest rate Dividend yield 11/6/2013 Three years 202.9% 0.58% $0.00 11/26/2013 Three years 200.8% 0.55% $0.00 12/3/2013 Three years 198.8% 0.68% $0.00 12/17/2013 Three years 198.0% 0.68% $0.00 On December 31, 2013, the Company’s note holders converted the notes discussed above into 786 shares of Series D-1 Preferred Stock and 393 shares of Series D-2 preferred Stock. In November 2013, in addition to the above, the Company borrowed, in the form of demand notes, $60 from an employee of the Company. The notes plus accrued interest of $1 were repaid at December 31, 2013, from the proceeds of the financing. Line of Credit: On May 6, 2014, the Company entered into a Credit Agreement with Venture Champion Asia Limited, an affiliate of ICG Global Limited (the “Lender”). Under the terms of the Credit Agreement, for a period of 18 months, the Company was permitted to borrow up to $2,000 in unsecured indebtedness from the Lender. Each draw would have been subject to a 15% original issue discount, so that borrowing the full $2,000 would have resulted in an aggregate of $2,352 in debt with fifty percent (50%) warrant coverage and also could have been converted at the Lender’s option into shares of the Company’s Common Stock at an initial conversion price of $34.375 per share. In connection with the Company’s entry into the Credit Agreement, the Company issued to the Lender 9 warrants to purchase 9 shares of Common Stock. In addition, the Company issued to a third party 1 warrant for assisting in the closing of the Credit Agreement. The warrants had a three-year life and an exercise price of $34.375 per share. The Company ascribed a value of $258 using the Black Scholes Merton Pricing Model. The warrants valuation was charged to interest expense during the three month period ended June 30, 2014 as the Company concluded it did not have the intent nor the need to draw funds under the line during the term of the agreement. On February 23, 2015, the Company and the Lender mutually agreed to terminate the Credit Agreement. At the time of the termination of the Credit Agreement, no amount was owed by the Company under the Credit Agreement, and contemporaneously with the termination of the Credit Agreement, the above mentioned warrants were likewise terminated.

Derivative Liability (10K)

Derivative Liability (10K)	12 Months Ended
	Dec. 31, 2014
Derivative liability [Abstract]
Derivative liability	8. Derivative liabilities: The Company has determined that a contract that would otherwise meet the definition of a derivative but is both (a) indexed to the Company’s own stock and (b) classified in stockholders’ equity in the statement of financial position would not be considered a derivative financial instrument. The Company applies a two-step model in determining whether a financial instrument or an embedded feature is indexed to an issuer’s own stock and thus able to qualify for the scope exception. The Company issued certain warrants in connection with financing transactions from 2010 through 2012 that require liability classification because of certain provisions that may result in an adjustment to the number of shares issued upon settlement and an adjustment to their exercise price. The Company classifies these warrants on its balance sheet as a derivative liability which is fair valued at each reporting period subsequent to the initial issuance. The Company used a simulated probability valuation model to value these warrants. Determining the appropriate fair-value model and calculating the fair value of warrants requires considerable judgment. Any change in the estimates (specifically, probabilities) used may cause the value to be higher or lower than that reported. The assumptions used in the model required significant judgment by management and include the following: volatility, expected term, risk-free interest rate, dividends, warrant holders’ expected rate of return, reset provisions based on expected future financings, projected stock prices, and probability of exercise. The estimated volatility of the Company’s common stock at the date of issuance, and at each subsequent reporting period, is based on historical volatility. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. Dividends are estimated at 0% based on the Company’s history of no common stock dividends. The Company issued the following warrants related to the bridge financings in April and November 2012. Included in the April 2012 warrants were warrants issued as finder’s fees. The November warrants issued included warrants issued to related parties as administrative fees and warrants issued as finder’s fees. The warrants have a three year life from the date of issue with a zero dividend yield and were valued using a simulated probability valuation model. Additional information with respect to these warrants is presented in the table below. Issue Date Reason for issuance Number of warrants issued Exercise price Risk free interest rate Expected volatility Derivative liability value on date of issue 4/23/2012 Bridge financing warrants 4 $ 62.50 1.78 % 205.3 % $ 50 4/23/2012 Finder’s fee warrants 0.2792 $ 62.50 1.78 % 205.3 % $ — 11/15/2012 Administrative fee warrants 2.4 $ 62.50 1.78 % 202.2 % $ 8 11/15/2012 Finder’s fee warrants 0.2352 $ 62.50 1.78 % 202.2 % $ — The fair value of the outstanding derivative liabilities at December 31, 2014, and December 31, 2013, was $18 and $25, respectively. Changes in the fair value of the level 3 derivative liability for the year ended December 31, 2014, are as follows: Derivative Liability Balance at January 1, 2013 $ 25 Gain on derivative liability (7 ) Balance at December 31, 2014 $ 18 Assets and liabilities measured at fair value as of December 31, 2014 are as follows: Value at December 31, 2014 Quoted prices in active markets Significant other observable inputs Significant unobservable inputs (Level 1) (Level 2) (Level 3) Derivative liability $ 18 $ — $ — $ 18

Stockholders' Equity (10K)

Stockholders' Equity (10K)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Stockholders' Equity [Abstract]
Stockholders' Equity	6. Equity Stock-based compensation expense is based on the estimated grant date fair value of the portion of stock-based payment awards that are ultimately expected to vest during the period. The grant date fair value of stock-based awards to employees and directors is calculated using the Black-Scholes-Merton valuation model. Forfeitures of stock-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated average forfeiture rate for the three months ended September 30, 2015 and 2014, was approximately 7.89% and 9.75%, respectively, based on historical data. Valuation and Expense Information: The weighted-average fair value of stock-based compensation is based on the Black-Scholes-Merton valuation model. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized using the accrual method over the vesting period of the options. The fair value calculations are based on the following assumptions: Nine Months Ended September 30, 2015 Nine Months Ended September 30, 2014 Risk free interest rate 0.04% − 3.28% 0.04% − 3.73% Expected life (years) 3.26 – 6.33 2.82 – 7.00 Expected volatility 120.74% – 198.38% 93.63% – 198.38% Expected dividends None None There were no stock options granted during the three month period ended September 30, 2015. The Company granted 29 stock options during the nine months ended September 30, 2015 at a weighted average exercise price of $28.00 per share. There were no stock options exercised during the three- and nine-months ended September 30, 2015. There were no stock options granted during the three months ended September 30, 2014. The Company granted 2 stock options during the nine months ended September 30, 2014 at a weighted average exercise price of $34.125 per share. There were no stock options exercised during the three- and nine-months ended September 30, 2014. The following table summarizes the allocation of stock-based compensation expense related to stock option grants for the three- and nine-month periods ended September 30, 2015 and 2014. Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Research and development $ 35 $ 16 $ 148 $ 64 Sales and marketing 26 17 112 54 General and administrative 47 29 192 112 Director options 8 3 35 12 Stock-based compensation expense $ 116 $ 65 $ 487 $ 242 A summary of option activity under the Company’s plans as of September 30, 2015 and 2014 is as follows: 2015 2014 Options Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at January 1, 58 $ 50.00 $ — 56 $ 62.50 $ — Granted 29 $ 25.00 $ — 2 $ 37.50 $ — Forfeited or expired (2 ) $ 37.50 $ — (1 ) $ 62.50 $ — Outstanding at September 30 85 $ 50.00 4.39 $ — 57 $ 62.50 4.30 $ — Vested and expected to vest at September 30 83 $ 37.50 3.21 $ — 51 $ 62.50 4.30 $ — Exercisable at September 30 56 $ 50.00 3.53 $ — 44 $ 62.50 3.98 $ — The following table summarizes significant ranges of outstanding and exercisable options as of September 30, 2015: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Per Share Number Outstanding Weighted Average Exercise Price Per Share $ 12.50 – $25.00 2 6.23 $ 25.00 1 $ 25.00 $ 25.00 – $37.50 43 5.21 $ 25.00 18 $ 25.00 $ 37.50 – $75.00 25 4.06 $ 62.50 22 $ 62.50 $ 75.00 – $250.00 15 2.32 $ 87.50 15 $ 87.50 85 4.39 $ 50.00 56 $ 50.00 The following table summarizes the Company’s non-vested option shares as of September 30, 2015: Non-vested Option Shares Shares Weighted Average Grant-Date Fair Value Non-vested at January 1, 2015 12 $ 50.00 Granted 29 $ 25.00 Forfeited (1 ) $ 25.00 Vested (11 ) $ 37.50 Non-vested at September 30, 2015 29 $ 25.00 As of September 30, 2015, there was $363 of total unrecognized compensation expense related to non-vested stock-based compensation arrangements granted under the plans. The unrecognized compensation expense is expected to be realized over a weighted average period of 3.2 years. Preferred Stock Information with respect to the class of Preferred Stock at September 30, 2015 is as follows: Class of Preferred Stock Annual Dividend Annual Dividend Payable, in Cash or In Kind Liquidation Preference Conversion Price Total Preferred Shares Outstanding Common Shares to be issued if Fully Converted Series A-1 8 % Quarterly in Arrears $ 1.00 $ 0.1400 929 5 Series B 10 % Quarterly in Arrears $ 1.50 $ 0.0433 13,191 244 Series C 10 % Quarterly in Arrears $ 1.50 $ 0.0225 5,356 190 Series D-1 10 % Quarterly in Arrears $ 1.00 $ 0.0225 7,878 280 Series D-2 10 % Quarterly in Arrears $ 1.00 $ 0.0500 6,223 100 Information with respect to in-kind dividends issued on the Company’s Preferred Stock for the three and nine-month periods ended September 30, 2015 and September 30, 2014 is as follows: Dividends Beneficial Conversion Feature Related to Dividends Three Months Ended September 30, Nine Months Ended September 30, Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 2015 2014 2015 2014 Series A-1 $ 18 $ 22 $ 53 $ 63 $ — $ — $ — $ — Series B 324 294 939 852 — — — — Series C 132 119 382 345 — 64 13 114 Series D-1 192 128 516 329 — 107 16 151 Series D-2 153 145 445 400 — — — — Total $ 819 $ 708 $ 2,335 $ 1,989 $ — $ 171 $ 29 $ 265 Series D Preferred Stock On February 7, 2014, the Company sold for $733 in cash, net of a $47 administrative fee paid in cash to SG Phoenix and a nonrelated third party, 520 shares of Series D-1 Preferred Stock and 260 shares of Series D-2 Preferred Stock. The investors received one hundred percent (100%) warrant coverage. These warrants are have an exercise price of $28.125 per share, immediately exercisable and expire December 31, 2016. The warrants are exercisable in whole or in part and contain a cashless exercise provision. On March 6, 2014, the Company sold for $406 in cash, net of $4 in administrative fees paid in cash to an unrelated third party, 273 shares of Series D-1 Preferred Stock and 137 shares of Series D-2 Preferred Stock. The investors received one hundred percent (100%) warrant coverage. These warrants have an exercise price of $34.375 per share, are immediately exercisable and expire December 31, 2016. The warrants are exercisable in whole or in part and contain a cashless exercise provision. SG Phoenix received warrants to purchase 2.4 shares of common stock, and two unrelated parties received warrants to purchase an aggregate of 1.3 shares of common stock in payment of administrative and related fees associated with the financings, in addition to the cash payments discussed above. These warrants have an exercise price of $34.375 per share, are immediately exercisable and expire three (3) years from the date of issuance. The warrants are exercisable in whole or in part and contain a cashless exercise provision. On March 24, 2015, the Company sold for $1,200 in cash, net of $33 in administrative fees paid in cash to SG Phoenix, 1,233 shares of Series D-1 Preferred Stock. The investors received 22 warrants, immediately exercisable into common stock of the Company at an exercise price of $28.125 per share. The warrants expire March 23, 2018. The Company ascribed a relative fair value of $366 to the warrants using the Black-Scholes-Merton pricing model and are classified as Additional Paid in Capital on the balance sheet. See the warrant table below for more detail. The warrants are exercisable in whole or in part and contain a cashless exercise provision. On July 23, 2015, the Company sold for $325 in cash, net of $4 in administrative fees paid in cash to SG Phoenix, 329 Shares of Series D-1 Preferred Stock. The investors received 11 warrants, immediately exercisable into common stock of the Company at $15.625 per share. The warrants expire July 22, 2018. The Company ascribed a relative fair value of $91 to the warrants using the Black-Scholes-Merton pricing model and are classified as Additional Paid in Capital on the balance sheet. See the warrant table below for more detail. The warrants are exercisable in whole or in part and contain a cashless exercise provision. Warrants On February 23, 2015, the Company and Venture Champion Asia Limited, an affiliate of IGC Global Limited, mutually agreed to terminate the $2,000 Credit Agreement signed in May 2014. At the time of the termination of the Credit Agreement, no amount was owed by the Company under the Credit Agreement, and contemporaneously with the termination of the Credit Agreement, the 9 warrants were likewise terminated. A summary of the warrant activity is as follows: September 30, 2015 September 30, 2014 Warrants Weighted Average Exercise Price Per Share Warrants Weighted Average Exercise Price Per Share Outstanding at beginning of period 171 $ 35.500 62 $ 36.125 Issued 32 24.125 100 34.375 Expired/Cancelled (13 ) 62.50 (22 ) 28.125 Outstanding at end of period 190 $ 33.00 139 $ 35.75 Exercisable at end of period 190 $ 33.00 139 $ 35.75 A summary of the status of the warrants outstanding and exercisable as of September 30, 2015 is as follows: Number of Warrants Weighted Average Remaining Life (Years) Weighted Average Exercise Price Per Share Warrants 22 2.52 $ 28.125 Warrants 155 1.26 $ 34.375 Warrants 3 0.13 $ 62.50 Warrants 10 2.83 $ 15.625 190 1.48 $ 33.00	9. Stockholders’ equity: Common stock options: At December 31, 2014, the Company has three stock-based employee compensation plans, the 1999 Option Plan, the 2009 Stock Compensation Plan, and the 2011 Stock Compensation Plan. The 1999 Option Plan expired in April 2009 (options outstanding under that plan are not affected by its expiration). The Company may also grant options to employees, directors and consultants outside of the active 2009 and 2011 plans under individual plans. Information with respect to the Stock Compensation Plans at December 31, 2014 is as follows: 1999 Option Plan 2009 Stock Compensation Plan 2011 Stock Compensation Plan Individual Plans Shares authorized for issuance 4,000 7,000 150,000 — Option vesting period Quarterly over Quarterly over Immediate/Quarterly Quarterly over Date adopted by stockholders June 2009 — November 2011 — Option term 7 Years 7 Years 7 Years 7 Years Options outstanding 0.02 0.34 57 0.1 Options exercisable 0.02 0.34 45 0.1 Weighted average exercise price $250.00 $131.25 $57.50 $187.50 Valuation and Expense Information: The weighted-average fair value of stock-based compensation is based on the Black Scholes Merton valuation model. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized over the vesting period of the options. The fair value calculations are based on the following assumptions: Year Ended December 31, 2014 Year Ended December 31, 2013 Risk free interest rate 0.04% - 3.73% 0.40% - 4.92% Expected life (years) 3.26 - 7.00 2.82 - 7.00 Expected volatility 91.99% - 198.38% 91.99% - 198.38% Expected dividends None None Estimated average forfeiture rate 10% 10% The following table summarizes the allocation of stock-based compensation expense for the years ended December 31, 2014 and 2013. During 2014, the Company granted 3.6 options at a weighted average grant date fair value of $25.00 per share. There were no stock options exercised during the years ended December 31, 2014 and 2013. Year Ended December 31, 2014 Year Ended December 31, 2013 Research and development $ 77 $ 262 Sales and marketing 72 100 General and administrative 134 410 Director options 15 47 Stock-based compensation expense included in operating expenses $ 298 $ 819 As of December 31, 2014, there was $236 of total unrecognized compensation cost related to non-vested share-based compensation arrangements. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.0 years. The cash flows from tax benefits for deductions in excess of the compensation costs recognized for share-based payment awards would be classified as financing cash flows. Due to the Company’s loss position, there were no such tax benefits during the year ended December 31, 2014. The summary activity for the Company’s 2009 and 2011 Stock Compensation Plans, the 1999 Option Plan and Individual Plans is as follows: December 31, 2014 December 31, 2013 Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Life Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Life Outstanding at beginning of period 56 $ 62.50 36 $ 62.50 Granted 4 $ 25.00 $ 27 21 $ 50.00 — Forfeited/ Cancelled (2 ) $ 137.50 (1 ) $ 137.50 Outstanding at period end 58 $ 50.00 — 4.18 56 $ 62.50 — 5.02 Options vested and exercisable at period end 46 $ 62.50 $ 7 3.86 35 $ 62.50 — 4.61 Weighted average grant-date fair value of options granted during the period $ 50.00 $ 50.00 The following table summarizes significant ranges of outstanding and exercisable options as of December 31, 2014: Options Outstanding Options Exercisable Range of Exercise Prices Options Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Outstanding Weighted Average Exercise Price $0.00 – $625.00 58 4.18 $ 50.00 46 $ 62.50 A summary of the status of the Company’s non-vested shares as of December 31, 2014 is as follows: Non-vested Shares Shares Weighted Average Grant-Date Fair Value Non-vested at January 1, 2013 21 $ 50.00 Granted 4 $ 50.00 Forfeited (1 ) $ 37.50 Vested (12 ) $ 50.00 Non-vested at December 31, 2014 12 $ 50.00 An employee or consultant desiring to exercise or convert his or her stock options must provide a signed notice of exercise to the Chief Financial Officer. Once the exercise is approved an issue order is sent to the Company’s transfer agent and by certificate or through other means of conveyance, the shares are delivered to the employee or consultant, generally within three business days. The Company expects to make additional option grants in future years. The options issued to employees and directors will be subject to the same provisions outlined above, which may have a material impact on the Company’s financial statements. As of December 31, 2014, 58 shares of common stock were reserved for issuance upon exercise of outstanding options. Treasury Stock: The Company received 5 shares of its Common Stock having a fair value under the cost method of $325 in January 2012, in settlement of a 16b suit brought by a shareholder against Phoenix Venture Fund, LLC (“Phoenix”). At December 31, 2014, the total value of treasury stock was $325. The Company has no plans to repurchase shares of Common Stock in the future. Preferred Shares: The Company has five series of Preferred Stock: Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D-1 Preferred Stock and Series D-2 Preferred Stock. Generally, the Company’s Preferred Stock votes together on an as converted basis with the holders of Common Stock. In addition, the Company’s Preferred Stock enjoys certain protective provisions, a liquidation preference and anti-dilution protection that are similar to one another. The Company has amended its Amended and Restated Certificate of Incorporation to increase the number of authorized shares of its Series D-1 and Series D-2 Preferred Stock. The Company solicited its stockholders and its stockholders approved an amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Series D-1 Preferred Stock from 6,000 to 10,000, and of Series D-2. Preferred Stock from 9,000 to 10,000 (the “Charter Amendment”). The Charter Amendment allows the Company to have additional shares of stock available for possible future capital raising activities as approved by the Board of Directors. The Company has amended and restated the Certificates of Designation for the Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock to, among other things, subordinate the Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock, in terms of dividend rights, liquidation preferences and other rights, to the Series D Preferred Stock. Holders of at least a majority of the shares of the Company’s Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock have approved the amendment and restatement of the Certificate of Designation applicable to such holders. Information with respect to the classes of Preferred Stock at December 31, 2014 is as follows: Class of Preferred Stock Issue Date Annual Dividend Annual Dividend Payable, in Cash or In Kind Liquidation Preference Conversion Price Total Preferred Shares Outstanding Common Shares to be issued if Fully Converted Series A-1 May 2008 8 % Quarterly in Arrears $ 1.00 $ 0.1400 875 5 Series B August 2010 10 % Quarterly in Arrears $ 1.50 $ 0.0433 12,251 226 Series C December/ 10 % Quarterly in Arrears $ 1.50 $ 0.0225 4,975 177 Series D-1 November 2012/ 10 % Quarterly in Arrears $ 1.00 $ 0.0225 5,800 206 Series D-2 November 2012/ 10 % Quarterly in Arrears $ 1.00 $ 0.0500 5,720 92 Total 706 Information with respect to dividends issued on the Company’s Preferred stock for the years ended December 31, 2014 and 2013 is as follows: December 31, December 31, 2014 2013 2014 2013 Dividends Beneficial Conversion Feature Related to dividends Series A-1 $ 82 $ 78 $ — $ — Series B 1,149 1,044 — — Series C 468 433 152 191 Series D-1 472 131 195 59 Series D-2 541 402 — — Total $ 2,712 $ 2,088 $ 347 $ 250 Series A-1 Preferred Stock The shares of Series A-1 Preferred Stock are convertible any time and are subordinate to the Series B, Series C and Series D Preferred Stock. In November 2014, a total of 238 shares of Series A-1 Preferred Stock was converted and the Company issued 1 share of Common Stock. Series B Preferred Stock The shares of Series B Preferred Stock are convertible at any time and are subordinate to the Series C and Series D Preferred Stock. Series C Preferred Stock The shares of Series C Preferred Stock are convertible into Common Stock at any time and are subordinate to the Series D Preferred Stock. In January 2012, the Company received 5 shares of Common Stock from Phoenix in settlement of a 16b claim brought by a Company stockholder against Phoenix, certain affiliates and the Company, as a nominal defendant. The Common Stock was valued at $325. In settlement of an indemnification claim brought by Phoenix in March 2012, resulting from the settlement of the 16b claim in January 2012, the Company issued to Phoenix 278 shares of Series C Preferred Stock valued at $417. The Company booked a $417 accretion amount for the beneficial conversion feature on the 278 shares of Series C Preferred Stock. In November 2013, a shareholder converted 100 shares of Series C Preferred Stock, and the Company issued 4 shares of common stock. In August 2014, a total of 0.04 share of Series C Preferred Stock was converted and the Company issued 4 shares of Common Stock. Series D Preferred Stock The material terms of the Series D-1 and Series D-2 Preferred Stock, other than the initial conversion price, are essentially the same. The shares of Series D Preferred Stock are convertible at any time and rank senior to the Company’s outstanding shares of Series A-1, Series B and Series C Preferred Stock, and of Common Stock with respect to dividend rights and liquidation preferences. In May 2013, the Company completed a private placement of 230 units of Series D Preferred Stock consisting of one (1) share of Series D-1 Preferred Stock and four (4) shares of Series D-2 Preferred Stock. The private placement provided $1,150 in proceeds to the Company. On December 31, 2013, the Company converted approximately $1,179 of short-term debt plus accrued interest into 786 shares of Series D-1 Preferred Stock and 393 shares of Series D-2 Preferred Stock. The investors received one hundred percent (100%) warrant coverage. These warrants were immediately exercisable and expire three (3) years from the date of issuance. See the warrant table below for more detail. The warrants are exercisable in whole or in part and contain a cashless exercise provision. On December 31, 2013, the Company sold for $870 in cash, net of a $40 administrative fee paid to SG Phoenix, 607 Shares of Series D-1 preferred Stock and 303 shares of Series D-2 Preferred Stock. The investors received hundred percent (100%) warrant coverage. These warrants are immediately exercisable and expire three (3) years from the date of issuance. See the warrant table below for more detail. The warrants are exercisable in whole or in part and contain a cashless exercise provision. The Company recorded a beneficial conversion feature related to the shares of Series D Preferred Stock issued in the 2013 closings of $411 based on the accounting conversion price of the shares of Series D Preferred Stock issued. In connection with the December 31, 2013 offering, the Company adjusted the number of shares of Series D-1 Preferred Stock and Series D-2 Preferred Stock issued to investors in the May 2013 offering described above, in order to give such investors shares of Series D-1 Preferred Stock and Series D-2 Preferred Stock in the same ratio as offered to Investors in the December 31, 2013 offering. This resulted in an exchange of 537 shares of Series D-2 Preferred into Series D-1 Preferred. The Company also issued warrants to purchase Common Stock in the same manner as offered to investors in the December 31, 2013 offering. On February 7, 2014, the Company sold for $733 in cash, net of a $47 administrative fee paid in cash to SG Phoenix and a nonrelated third party, 520 shares of Series D-1 Preferred Stock and 260 shares of Series D-2 Preferred Stock. The investors received one hundred percent (100%) warrant coverage. These warrants are immediately exercisable at $34.375 per share and expire December 31, 2016. See the warrant table below for more detail. The warrants are exercisable in whole or in part into shares of the Company’s Common Stock and contain a cashless exercise provision. On March 6, 2014, the Company sold for $406 in cash, net of a $4 in administrative fee paid in cash to an unrelated third party, 273 Shares of Series D-1 Preferred Stock and 137 shares of Series D-2 Preferred Stock. The investors received one hundred percent (100%) warrant coverage. These warrants are immediately exercisable at $34.375 per share and expire December 31, 2016. See the warrant table below for more detail. The warrants are exercisable in whole or in part into shares of the Company’s Common Stock and contain a cashless exercise provision. On August 5, 2014, the Company sold for $1,070 in cash, net of $50 in administrative fees paid in cash to SG Phoenix, 1,120 Shares of Series D-1 Preferred Stock. SG Phoenix received warrants to purchase 2 shares of Common stock, and two unrelated parties received warrants to purchase an aggregate of 1 share of Common Stock in payment of administrative and finder’s fees associated with the financings, in addition to the cash payments discussed above. These warrants are immediately exercisable and expire three (3) years from the date of issuance. The warrants are exercisable in whole or in part and contain a cashless exercise provision. Preferred Stock Voting and Other Rights Generally, the Company’s Preferred Stock votes together on an as converted basis with the holders of Common Stock. In addition, the Company’s Preferred Stock enjoys certain protective provisions, a liquidation preference and anti-dilution protection that are similar to one another. Warrants: Summary of Warrant exercises in 2014 and 2013: December 31,2014 December 31, 2013 Warrants Common Shares Issued Cash received Warrants Common Shares Issued Cash received — — $ — 1 1 $ 29 — — $ — 9 2 $ — Total — — $ — 10 3 $ 29 Summary of warrants issued in 2014 and 2013: December 31, 2014 December 31, 2013 Related Party Other Total Related Party Other Total Warrants issued in connection with Notes — — — 16 2 18 Warrants issued with purchase of Series D Preferred 5 12 17 8 8 16 Warrants issued in the December Series D Preferred exchange 2 6 8 Warrants issued with line of credit — 9 9 — — — Contingent Warrants issued 27 70 97 — — — Total 32 91 123 26 16 42 A summary of the outstanding warrants is as follows: December 31, 2014 December 31, 2013 Warrants Weighted Average Exercise Price Warrants Weighted Average Exercise Price Outstanding at beginning of period 62 $ 36.125 121 $ 33.625 Issued 123 $ 34.375 42 $ 33.375 Exercised — — (10 ) $ 28.125 Expired (14 ) $ 28.125 (91 ) $ 28.750 Outstanding at end of period 171 $ 35.50 62 $ 36.125 Exercisable at end of period 171 $ 35.50 62 $ 36.125 A summary of the status of the warrants outstanding as of December 31, 2014 is as follows: Number of Warrants Outstanding and Exercisable Weighted Average Remaining Life Weighted Average Exercise Price per share 7 1.95 $ 34.375 164 0.52 $ 62.500 171 1.89 $ 35.500 Contingent warrants: Investors that received warrants in connection with the December 31, 2013 Series D Preferred Stock offering, received 97 additional warrants during 2014 due to the Company not achieving certain revenue targets during the first three quarters of 2014. The Company ascribed a value at December 31, 2013 of $1,618 to the contingent warrants using a Black Sholes Merton pricing model. The cost of the contingent warrants was recognized at December 31, 2013 due to the assessment by the Company of the likelihood of achieving the revenue targets in 2014. At December 31, 2014, 213,521 shares of common stock were reserved for issuance upon exercise of outstanding warrants.

Commitments and Contingencies (

Commitments and Contingencies (10K)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies disclosure	10. Commitments and Contingencies: Lease commitments: The Company currently leases its principal facilities in Redwood Shores, California, pursuant to a sublease that expires in 2016. In addition to monthly rent, the facilities are subject to additional rental payments for utilities and other costs above the base amount. Facilities rent expense was approximately $289 and $275 in 2014 and 2013, respectively. Contractual obligations Total 2015 2016 Thereafter Operating lease commitments $ 543 $ 293 $ 250 —

Income Taxes (10K)

Income Taxes (10K)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income tax disclosure	11. Income taxes: As of December 31, 2014, the Company had federal net operating loss carry-forwards available to reduce taxable income of approximately $61,735. The net operating loss carry-forwards will begin to expire in 2017 if unused. The Company also has state net operating loss carry-forwards available to reduce taxable income of approximately $36,411. The net state operating loss carry-forwards will begin to expire in 2025 if unused. Deferred tax assets and liabilities at December 31 consist of the following: 2014 2013 Deferred tax assets: Net operating loss carry-forwards $ 23,114 $ 27,266 Credit carry-forwards — 137 Accruals and reserves 141 Deferred revenue 382 224 Intangibles 273 1,046 Other, net — 373 Fixed Assets 894 — Gross tax assets 24,804 29,046 Valuation allowance (24,804 ) (29,046 ) Net deferred tax assets $ — $ — The Company’s provision for income taxes differs from the amount computed by applying the statutory U.S. federal income tax rate to loss before taxes as follows for the years ended December 31, 2014 and December 31, 2013: 2014 2013 Income tax benefit at the federal statutory rate $ (1,364 ) $ (2,668 ) State income tax benefit (233 ) (458 ) Credits — — Prior year true up to return 5,758 1,416 Permanent items and other 81 1,391 Change in valuation allowance (4,242 ) 319 Income tax expense $ — $ — A full valuation allowance has been established for the Company’s net deferred tax assets since the realization of such assets through the generation of future taxable income is uncertain. Under the Tax Reform Act of 1986, the amounts of, and the benefit from, net operating losses and tax credit carry-forwards may be impaired or limited in certain circumstances. These circumstances include, but are not limited to, a cumulative stock ownership change of greater than 50%, as defined, over a three-year period. During 1997, the Company experienced stock ownership changes which could limit the utilization of its net operating loss and research and investment tax credit carry-forwards in future periods. In addition, a study of recent transactions has not been performed to determine whether any further limitations might apply.

Subsequent event (10K)

Subsequent event (10K)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Subsequent Event [Abstract]
Subsequent event	7. Subsequent Events Unsecured Convertible Promissory Notes On November 25, 2015, the Company issued to accredited investors unsecured convertible promissory notes in the aggregate principal amount of $1,000,000 in consideration of gross cash proceeds of $750,000 plus the exchange of a $250,000 demand note previously issued by the Company in an initial closing under the terms and conditions of a note purchase agreement dated as of November 25, 2015. On December 15, 2015, the Company issued unsecured convertible promissory notes in the aggregate principal amount of $268,000 to accredited investors in a subsequent closing under the terms and conditions of the note purchase agreement. The principal amount of the unsecured convertible promissory notes issued in connection with the Company’s unsecured debt financing in November and December 2015 bear interest at a rate of 24% per annum, are due after nine months on August 25, 2016 and are convertible into shares of our common stock at the holder’s option (i) prior to maturity, in the event the Company consummates an SEC registered public offering of shares of common stock, at a conversion price that is 30% less than the price to the public of the common stock in the public offering, or (ii) up to 60 days after maturity, at a conversion price based upon a Company pre-money valuation of $5,000,000, as determined by taking into account the outstanding shares of common stock and preferred stock, on an as-converted basis, on the maturity date of the note; provided, that following such conversion, each holder that converted such note will also receive cash payments, payable from 1.5% for each $100,000 of notes converted of the revenue actually received by the Company under that certain Amended and Restated Master License Agreement dated as of January 15, 2015 by and between the Company and Cegedim SA, to be paid quarterly on a pro rata basis, with any and all other holders who converted their notes; provided, further, however, that the total amount of cash payments that the holder will be entitled to receive will not exceed three times the aggregate principal amount of the holder’s note. Change of Name On December 11, 2015, the Company changed its name from Communication Intelligence Corp. to iSign Solutions Inc. In addition, on December 14, 2015, the Company changed the trading symbol for its common stock from “CICI” to “ISGN”. Common Stock Offering, Proposed Reverse Stock Split, Reduction in Conversion Prices and Conversion of Preferred Stock On December 17, 2015, the Company filed a Registration Statement on Form S-1 with the Securities and Exchange Commission with respect to a firm commitment public offering of $10 million in shares of common stock, excluding the underwriter’s over-allotment option. On January 20, 2016, the Company held a special meeting of stockholders to consider and vote upon proposals to, among other matters, amend its corporate charter and certificates of designation to provide for (i) a reverse stock split of outstanding common stock in a range of not less than 1-for-750 and not more than 1-for-1,250 and (ii) the automatic conversion of each share of preferred stock into shares of common stock upon the closing of a firm-commitment underwritten public offering of shares of our common stock at a price per share of not less than $4.00 which provides at least $8 million in gross proceeds to the Company and a decrease in the conversion price of each series of preferred stock. Each of the proposals, other than the proposal to decrease the Company's authorized shares of common stock and preferred stock, was approved by the required holders.	12. Subsequent events: Termination of credit agreement On February 23, 2015, the Company and the Lender mutually agreed to terminate the Credit Agreement. At the time of the termination of the Credit Agreement, no amount was owed by the Company under the Credit Agreement, and contemporaneously with the termination of the Credit Agreement, the warrants were likewise terminated. Series D Financing On March 24, 2015, the Company entered into subscription agreements (the “Subscription Agreements”) with certain investors (each, an “Investor,” and, collectively, the “Investors”). Under the terms of the Subscription Agreements, the Investors purchased an aggregate of 1,233 Units (each a “Unit,” and, collectively, the “Units”) at a purchase price of $1.00 per Unit for an aggregate purchase price of approximately $1,233. Each Unit consists of one (1) share of the Company’s Series D-1 Preferred Stock and one (1) warrant to purchase shares of the Company’s Common Stock. The shares of Series D-1 Preferred Stock are convertible into shares of Common Stock at an initial conversion price of $0.0225 per share (subject to adjustment). The warrants issued to the Investors entitle the Investors to purchase up to an aggregate of approximately 22 shares of Common Stock. These warrants are exercisable for a period of three years from the date of issue and have an exercise price of $28.125 per share. Unsecured Convertible Promissory Notes On November 25, 2015, the Company issued to accredited investors unsecured convertible promissory notes in the aggregate principal amount of $1,000,000 in consideration of gross cash proceeds of $750,000 plus the exchange of a $250,000 demand note previously issued by the Company in an initial closing under the terms and conditions of a note purchase agreement dated as of November 25, 2015. On December 15, 2015, the Company issued unsecured convertible promissory notes in the aggregate principal amount of $268,000 to accredited investors in a subsequent closing under the terms and conditions of the note purchase agreement. The principal amount of the unsecured convertible promissory notes issued in connection with the Company’s unsecured debt financing in November and December 2015 bear interest at a rate of 24% per annum, are due after nine months on August 25, 2016 and are convertible into shares of our common stock at the holder’s option (i) prior to maturity, in the event the Company consummates an SEC registered public offering of shares of common stock, at a conversion price that is 30% less than the price to the public of the common stock in the public offering, or (ii) up to 60 days after maturity, at a conversion price based upon a Company pre-money valuation of $5,000,000, as determined by taking into account the outstanding shares of common stock and preferred stock, on an as-converted basis, on the maturity date of the note; provided, that following such conversion, each holder that converted such note will also receive cash payments, payable from 1.5% for each $100,000 of notes converted of the revenue actually received by the Company under that certain Amended and Restated Master License Agreement dated as of January 15, 2015 by and between the Company and Cegedim SA, to be paid quarterly on a pro rata basis, with any and all other holders who converted their notes; provided, further, however, that the total amount of cash payments that the holder will be entitled to receive will not exceed three times the aggregate principal amount of the holder’s note. Change of Name On December 11, 2015, the Company changed its name from Communication Intelligence Corp. to iSign Solutions Inc. In addition, on December 14, 2015, the Company changed the trading symbol for its common stock from “CICI” to “ISGN”. Common Stock Offering, Proposed Reverse Stock Split, Reduction in Conversion Prices and Conversion of Preferred Stock On December 17, 2015, the Company filed a Registration Statement on Form S-1 with the Securities and Exchange Commission with respect to a firm commitment public offering of $10 million in shares of common stock, excluding the underwriter’s over-allotment option. On January 20, 2016, the Company held a special meeting of stockholders to consider and vote upon proposals to, among other matters, amend its corporate charter and certificates of designation to provide for (i) a reverse stock split of outstanding common stock in a range of not less than 1-for-750 and not more than 1-for-1,250 and (ii) the automatic conversion of each share of preferred stock into shares of common stock upon the closing of a firm-commitment underwritten public offering of shares of our common stock at a price per share of not less than $4.00 which provides at least $8 million in gross proceeds to the Company and the decrease in conversion price of each series of preferred stock. Each of the proposals, other than the proposal to decrease the Company's authorized shares of common stock and preferred stock, was approved by the required holders.

Nature of business, basis of 26

Nature of business, basis of presentation and summary of significant accounting policies (10Q)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of business, basis of presentation and summary of significant accounting policies	1. Nature of business and summary of significant accounting policies Nature of Business iSign Solutions Inc., formerly known as Communication Intelligence Corporation, and its subsidiary (the “Company” or “iSign”) is a leading provider of digital transaction management (DTM) software enabling fully digital (paperless) business processes. The Company’s software solutions encompass a wide array of functionality and services, including electronic signatures, biometric authentication and simple-to-complex workflow management. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. The Company’s platform can be deployed both on-premise and as a cloud-based service, with the ability to easily transition between deployment models. To date, the Company primarily has delivered its solutions to channel partners and end-user customers in the financial services industry. The Company’s products include SignatureOne® Ceremony™ Server, the iSign® suite of products and services, including iSign® Enterprise and iSign® Console™, and Sign-it® programs. Basis of Presentation The financial information contained herein should be read in conjunction with the Company's consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2014. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company’s results of operations and cash flows for the periods presented. The Company’s interim results are not necessarily indicative of the results to be expected for the entire year. Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at September 30, 2015, the Company’s accumulated deficit was $126,082. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of September 30, 2015, the Company’s cash balance was $358. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accounting Changes and Recent Accounting Pronouncements Accounting Standards Issued But Not Yet Adopted Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies are not expected to have a material impact on the Company’s financial position, results of operations and cash flows.	1. Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies: The Company: iSign Solutions Inc., formerly known as Communication Intelligence Corporation (the “Company” or “iSign”), is a leading supplier of digital transaction management (DTM) software enabling the paperless, secure and cost-effective management of document-based transactions. iSign’s solutions encompass a wide array of functionality and services, including electronic signatures, biometric authentication and simple-to-complex workflow management. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. The Company’s products and services result in legally binding transactions that are compliant with applicable laws and regulations and that can provide a higher level of security than paper-based processes. The Company has been a leading supplier of enterprise software solutions within the financial services and insurance industries and has delivered significant expense reduction by enabling complete document and workflow automation and the resulting reduction in mailing, scanning, filing and other costs related to the use of paper. The Company’s research and development activities have given rise to numerous technologies and products. The Company’s core DTM technologies include various forms of electronic signatures, such as handwritten biometric, click-to-sign and others, as well as signature verification, cryptography and the logging of audit trails to show signers’ intent. These technologies can enable secure, legal and regulatory compliant electronic transactions that can enhance customer experience at a fraction of the time and cost required by traditional, paper-based processes. The Company’s products include SignatureOne®Ceremony™Server, Sign-it® and the iSign® family of products and services. Going concern and management plans: The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Except for 2004, the Company has incurred significant losses since its inception and, at December 31, 2014, the Company’s accumulated deficit was $123,199. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of December 31, 2014, the Company’s cash balance was $775. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company’s business, results of operations and ability to operate as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis of consolidation: The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America, and include the accounts of iSign Solutions Inc. and its 90%-owned Joint Venture in the People’s Republic of China. All inter-company accounts and transactions have been eliminated. All amounts shown in the accompanying consolidated financial statements are in thousands of dollars except per share amounts. Reclassification: Certain amounts in the consolidated financial statements for 2013 have been reclassified to conform to the 2014 presentation. These reclassifications have no effect on net income, earnings per share, or cash flows as previously reported. Use of estimates: The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates. Fair value measures: Fair value is the price that would be received to sell an asset, or paid to transfer a liability, in the principal or most advantageous market for the asset or liability in an ordinary transaction between market participants on the measurement date. Our policy on fair value measures requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The policy prioritizes the inputs into three levels that may be used to measure fair value: Level 1: Applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2: Applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3: Applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s assets and liabilities measured at fair value, whether recurring or non-recurring, at December 31, 2014 and December 31, 2013, and the fair value calculation input hierarchy level that we have determined applies to each asset and liability category. Fair Value of Financial Instruments: The Company carries financial instruments on the consolidated balance sheet at the fair value of the instruments as of the consolidated balance sheet date. At the end of each period, management assesses the fair value of each instrument and adjusts the carrying value to reflect its assessment. At December 31, 2014 and December 31, 2013, the carrying values of accounts receivable and accounts payable approximated their fair values. Treasury Stock: Shares of common stock returned to, or repurchased by, the Company are recorded at cost and are included as a separate component of stockholders’ equity (deficit). Under the cost method, the gross cost of the shares reacquired is charged to a contra equity account entitled treasury stock. The equity accounts that were credited for the original share issuance (common stock, additional paid-in capital, etc.) remain intact. When the treasury shares are reissued, proceeds in excess of cost are credited to additional paid-in capital. Any deficiency is charged to accumulated deficit (unless additional paid-in capital from previous treasury share transactions exists, in which case the deficiency is charged to that account, with any excess charged to accumulated deficit). Derivatives: The Company, from time to time, enters into transactions which contain conversion privileges, the settlement of which may entitle the holder or the Company to settle the obligation(s) by issuance of Company securities. The Company applies a two-step model in determining whether a financial instrument or an embedded feature is indexed to an issuer’s own stock and thus able to qualify for the scope exception. The fair value of each derivative is estimated each reporting period. Cash and cash equivalents: The Company considers all highly liquid investments with maturities at the date of purchase of three months or less to be cash equivalents. The Company’s cash and cash equivalents, at December 31, consisted of the following: 2014 2013 Cash in bank $ 775 $ 945 Money market funds — — Cash and cash equivalents $ 775 $ 945 Concentrations of credit risk: Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company maintains its cash and cash equivalents with various financial institutions. This diversification of risk is consistent with Company policy to maintain liquidity, and mitigate risk of loss as to principal. To date, accounts receivable have been derived principally from revenue earned from end users, manufacturers, and distributors of computer products in North America. The Company performs periodic credit evaluations of its customers, and does not require collateral. The Company maintains reserves for potential credit losses; historically, such losses have been within management’s expectations. The allowance for doubtful accounts is based on the Company’s assessment of the collectability of specific customer accounts and an assessment of international, political and economic risk as well as the aging of the accounts receivable. If there is a change in actual defaults from the Company’s historical experience, the Company’s estimates of recoverability of amounts due could be affected and the Company will adjust the allowance accordingly. Deferred financing costs: Deferred financing costs include costs paid in cash, such as professional fees and commissions. The costs are amortized to interest expense over the life of the notes or upon early payment using the effective interest method. There were $0 and $44 in cost amortized to interest expense for the years ended December 31, 2014 and 2013, respectively. Property and equipment, net: Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, ranging from three to five years. Leasehold improvements are amortized over their estimated useful lives, not to exceed the term of the related lease. The cost of additions and improvements is capitalized, while maintenance and repairs are charged to expense as incurred. Depreciation expense was $10 and $16 for the years ended December 31, 2014 and 2013, respectively. Intangible Assets: The Company’s core technologies can be referred to as “transaction-enabling,” “digital authentication” and “business process work flow.” These technologies include various forms of electronic signature methods, such as handwritten, biometric, click-to-sign and others, as well as technologies related to signature verification, authentication, cryptography and the logging of audit trails to prove signers’ intent. Our technologies enable the appending of secure, legal and regulatory compliant electronic signatures coupled with an enhanced user experience at a fraction of the time and cost required by traditional, paper-based processes for signature capture. The Company’s enterprise-class SignatureOne® and iSign® suite of electronic signature solutions enable businesses to implement paperless, electronic signature-driven business processes. The aggregate of the software functionality enabling the digitization of end-to-end work flow processes is sometimes referred to as “Digital Transaction Management” (“DTM”). Many applications provide electronic forms and allow users to fill-in information, but most of these applications still require users to print out a paper copy for the application of a handwritten, ink signature. Solutions powered by the Company’s products allow legally binding electronic signatures to be added to digitized documents, eliminating the need for paper to memorialize the completion, approval or authentication of the transaction. This allows users to reduce transaction times and processing costs. Intangible assets are stated at cost less accumulated amortization and reflect a portion of the value of the technologies described above. Amortization is computed using the straight-line method over the estimated lives of the related assets. Amortization expense was $357 and $365 for the years ended December 31, 2014 and 2013, respectively. The estimated remaining weighted average useful lives of the intangible assets are 3 years. Future intangible asset amortization is as follows: Year Ended December 31, 2015 $ 342 2016 323 2017 268 Total $ 933 Long-lived assets: The Company evaluates the recoverability of its long-lived assets, including intangible assets, at least annually or whenever circumstances or events indicate such assets might be impaired. The Company would recognize an impairment charge in the event the net book value of such assets exceeded the future undiscounted cash flows attributable to such assets. No such impairment charges have been recorded during the two years ended December 31, 2014 and 2013, respectively. Share-based payment: Share-based compensation expense is based on the estimated grant date fair value of the portion of share-based payment awards that are ultimately expected to vest during the period. The grant date fair value of share-based awards to employees and directors is calculated using the Black Scholes Merton valuation model. Forfeitures of share-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates and it is assumed no dividends will be declared. The estimated fair value of share-based compensation awards to employees is amortized over the vesting period of the options. Revenue recognition: The Company recognizes revenue from sales of software products upon shipment, provided that persuasive evidence of an arrangement exists, collection is determined to be probable, all non-recurring engineering work necessary to enable the Company’s product to function within the customer’s application has been completed and the Company’s product has been delivered according to specifications. Revenue from service subscriptions is recognized as costs are incurred or over the service period, whichever is longer. Software license agreements may contain multiple elements, including upgrades and enhancements, products deliverable on a when and if available basis and post contract support. Revenue from software license agreements is recognized upon delivery of the software, provided that persuasive evidence of an arrangement exists, collection is determined to be probable, all nonrecurring engineering work necessary to enable the Company’s products to function within the customer’s application has been completed, and the Company has delivered its product according to specifications. For arrangements with multiple deliverables, the Company allocates consideration at the inception of an arrangement to all of its deliverables based on their relative selling prices which is determined using vendor specific objective evidence. Maintenance revenue is recorded for post-contract support and upgrades or enhancements, which is paid for in addition to license fees, and is recognized as costs are incurred or over the support period whichever is longer. For undelivered elements where vendor specific objective evidence does not exist, revenue is deferred and subsequently recognized when delivery has occurred and when vendor specific evidence has been determined. Research and development: Research and development costs are charged to expense as incurred. Marketing: The Company expenses advertising (marketing) costs as incurred. These expenses are outbound marketing expenses associated with participation in industry events, related sales collateral and email campaigns aimed at generating customer participation in webinars. The expense for the years ended December 31, 2014 and 2013 was $46 and $15, respectively. Net loss per share: The Company calculates net loss per share under the provisions of the relevant accounting guidance. That guidance requires the disclosure of both basic net loss per share, which is based on the weighted average number of shares outstanding, and diluted loss per share, which is based on the weighted average number of shares and dilutive potential shares outstanding. The number of shares of common stock subject to outstanding options, preferred shares on an as converted basis and shares issuable upon exercise of warrants excluded from the calculation of loss per share as their inclusion would be anti-dilutive are as follows: December 31, 2014 December 31, 2013 Common Stock subject to outstanding options 58 56 Series A-1 Preferred Stock 6,252 7,368 Series B Preferred Stock 282,750 256,241 Series C Preferred Stock 221,104 200,354 Series D-1 Preferred Stock 257,773 151,766 Series D-2 Preferred Stock 114,400 95,682 Warrants outstanding 171 62 Foreign currency translation: The Company considers the functional currency of the Joint Venture, CICC, to be the local currency of China, which is the Renminbi (“RMB”) and, accordingly, gains and losses from the translation of the local foreign currency financial statements are included as a component of accumulated other comprehensive loss in the accompanying consolidated balance sheets. Foreign currency assets and liabilities are translated into U.S. dollars at the end-of-period exchange rates except for long-term assets and liabilities, which are translated at historical exchange rates. Revenue and expenses are translated at the average exchange rates in effect during each period except for those expenses related to consolidated balance sheet amounts which are translated at historical exchange rates. Net foreign currency transaction gains and losses are included in interest and other income, net in the accompanying consolidated statements of operations. Foreign currency transaction gains and losses in 2014 and 2013 were insignificant. Income taxes: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their financial statement reported amounts and for tax loss and credit carry-forwards. A valuation allowance is provided against deferred tax assets when it is determined to be more likely than not that the deferred tax asset will not be realized. There have been no unrecognized tax benefits and, accordingly, there has been no effect on the Company’s financial condition or results of operations. The Company files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. The Company is no longer subject to U.S. federal tax examinations for years before 2006, and state tax examinations for years before 2005. Management does not believe there will be any material changes in the Company’s unrecognized tax positions over the next 12 months. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Recently issued accounting pronouncement: Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

Concentrations (10Q)

Concentrations (10Q)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure	2. Concentrations The following table summarizes accounts receivable and revenue concentrations: Accounts Receivable As of September 30, Total Revenue for the three months ended September 30, Total Revenue for the nine months ended September 30, 2015 2014 2015 2014 2015 2014 Customer #1 38 % 46 % — 17 % 12 % 11 % Customer #2 24 % — 17 % — — — Customer #3 — — 10 % 12 % — 10 % Customer #4 — 12 % — — — — Customer #5 — 19 % — — — — Customer #6 — — — 10 % 16 % — Customer #7 — — — — 17 % 14 % Total concentration 62 % 77 % 27 % 39 % 45 % 35 %	2. Concentrations: The following table summarizes accounts receivable and revenue concentrations: Accounts Receivable As of December 31, Total Revenue for the year ended December 31, 2014 2013 2014 2013 Customer #1 44 % 47 % — 15 % Customer #2 — 15 % — 10 % Customer #3 19 % 19 % 12 % 16 % Customer #4 — — — 10 % Customer #5 — — — 12 % Customer #6 — — 12 % — Customer #7 — — 11 % — Customer #8 10 % — — — Total concentration 73 % 81 % 35 % 63 % The following table summarizes sales concentrations: December 31, 2014 December 31, 2013 Sales within the United States 99 % 98 % Sales outside of the United States 1 % 2 % Total 100 % 100 %

Intangible Assets (10Q)

Intangible Assets (10Q)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	3. Intangible assets The Company performs an intangible asset impairment analysis on its technology at least annually or whenever circumstances or events indicate such assets might be impaired. The Company would recognize an impairment charge in the event the net book value of such assets exceeded the future undiscounted cash flows attributable to such assets. Management completed an analysis of the Company’s intangible assets as of December 31, 2014. Based on that analysis, the Company concluded that no impairment of the carrying value of the intangible assets existed. The Company believes that no events or circumstances changed during the three and nine months ended September 30, 2015 that would impact this conclusion. Amortization of intangible asset costs was $87 and $260 for the three and nine-month periods ended September 30, 2015 and $90 and $270 for the three- and nine-month periods ended September 30, 2014. The following table summarizes the amortizable intangible assets: September 30, 2015 December 31, 2014 Carrying Amount Accumulated Amortization Net Value Carrying Amount Accumulated Amortization Net Value $6,745 $(6,072) $673 $6,745 $(5,812) $933	4. Intangible Assets: Intangible assets, net consists of the following at December 31: Weighted Average Amortization Period (Years) 2014 2013 Technology 3 6,745 6,745 Less accumulated amortization (5,812 ) (5,455 ) $ 933 $ 1,290 The nature of the underlying technology of our intangible assets can be referred to as “transaction-enabling,” “digital authentication” and “business process work flow.” This technology includes various forms of electronic signature methods, such as handwritten, biometric, click-to-sign and others, as well as technologies related to signature verification, authentication, cryptography and the logging of audit trails to prove signers’ intent. Our technologies enable the appending of secure, legal and regulatory compliant electronic signatures coupled with an enhanced user experience at a fraction of the time and cost required by traditional, paper-based processes for signature capture. The Company does not foresee any effects of obsolescence or significant competitive pressure on its current or future products, anticipates increasing demand for products utilizing its technology, and believes that the current markets for its products based on technology will remain constant or will grow over the remaining useful lives assigned to its intangible assets because of business environments encouraging the use of electronic signatures.

Short-term note payable (10Q)

Short-term note payable (10Q)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Short-term notes payable [Abstract]
Short-term notes payable	4. Short-term note payable On September 29, 2015, the Company issued a demand note for an aggregate amount of $250 to an affiliate of the Company. This note bears interest at the rate of 10% per annum and both the principal and interest accrued are payable on demand.	7. Debt: Short-term notes payable: In April 2013, the Company borrowed $250 in the form of a demand note from Phoenix Banner Holdings LLC, with an interest rate of 10% per annum. The demand note plus $2 of accrued interest was paid in May 2013. From August 2013 through December 2013, the Company secured $1,150 in 10% demand notes from related parties and others that was used for working capital and general corporate purposes. In November, the Board of Directors approved the issuance of warrants in addition to the interest on these demand notes. The Company issued 17 warrants, 12 of which were issued for the notes secured prior to November 6, 2013, and a total of 6 warrants were issued for demand notes secured on November 26, and December 13, 2013. The Company ascribed a value of $406, recorded as interest expense, to the warrants issued prior to November 6, 2013, and ascribed a value of $111, recorded as a debt discount to the warrants issued with notes secured after November 6, 2013. The Company recorded $44 in debt discount amortization expense and $67 in loss on extinguishment upon conversion of the notes in 2013. The warrants have a three year life from the date of grant and an exercise price of $37.50. Detail on these demand notes and warrants is as follows: Phoenix Banner Holdings LLC Michael W. Engmann Kendu Partners Company JAG Multi Investments Philip Sassower Date Note Amount Warrants Note Amount Warrants Note Amount Warrants Note Amount Warrants Note Amount Warrants 8/2/2013 $ 250 9/3/2013 $ 250 9/27/2013 $ 250 11/1/2013 $ 125 2 11/6/2013 3 3 3 12/13/2013 $ 150 4 12/17/2013 $ 125 2 Total $ 250 3 $ 400 7 $ 250 3 $ 125 2 $ 125 2 The warrants were valued using the Black Sholes Merton pricing model with the following assumptions: Date Expected Term Volatility Risk free interest rate Dividend yield 11/6/2013 Three years 202.9% 0.58% $0.00 11/26/2013 Three years 200.8% 0.55% $0.00 12/3/2013 Three years 198.8% 0.68% $0.00 12/17/2013 Three years 198.0% 0.68% $0.00 On December 31, 2013, the Company’s note holders converted the notes discussed above into 786 shares of Series D-1 Preferred Stock and 393 shares of Series D-2 preferred Stock. In November 2013, in addition to the above, the Company borrowed, in the form of demand notes, $60 from an employee of the Company. The notes plus accrued interest of $1 were repaid at December 31, 2013, from the proceeds of the financing. Line of Credit: On May 6, 2014, the Company entered into a Credit Agreement with Venture Champion Asia Limited, an affiliate of ICG Global Limited (the “Lender”). Under the terms of the Credit Agreement, for a period of 18 months, the Company was permitted to borrow up to $2,000 in unsecured indebtedness from the Lender. Each draw would have been subject to a 15% original issue discount, so that borrowing the full $2,000 would have resulted in an aggregate of $2,352 in debt with fifty percent (50%) warrant coverage and also could have been converted at the Lender’s option into shares of the Company’s Common Stock at an initial conversion price of $34.375 per share. In connection with the Company’s entry into the Credit Agreement, the Company issued to the Lender 9 warrants to purchase 9 shares of Common Stock. In addition, the Company issued to a third party 1 warrant for assisting in the closing of the Credit Agreement. The warrants had a three-year life and an exercise price of $34.375 per share. The Company ascribed a value of $258 using the Black Scholes Merton Pricing Model. The warrants valuation was charged to interest expense during the three month period ended June 30, 2014 as the Company concluded it did not have the intent nor the need to draw funds under the line during the term of the agreement. On February 23, 2015, the Company and the Lender mutually agreed to terminate the Credit Agreement. At the time of the termination of the Credit Agreement, no amount was owed by the Company under the Credit Agreement, and contemporaneously with the termination of the Credit Agreement, the above mentioned warrants were likewise terminated.

Net loss per share (10Q)

Net loss per share (10Q)	9 Months Ended
	Sep. 30, 2015
Net loss per share [Abstract]
Net loss per share	5. Net loss per share The Company calculates basic net loss per share based on the weighted average number of shares outstanding, and when applicable, diluted income per share, which is based on the weighted average number of shares and potential dilutive shares outstanding. The following table lists shares and warrants that were excluded from the calculation of dilutive earnings per share as the exercise of such options and warrants and the conversion of such preferred shares would be anti-dilutive: For the Nine Months Ended September 30, 2015 September 30, 2014 Stock options 85 57 Warrants 190 137 Preferred shares as if converted Series A-1 Preferred Stock 6,633 7,818 Series B Preferred Stock 304,430 275,888 Series C Preferred Stock 238,056 215,668 Series D-1 Preferred Stock 350,127 251,435 Series D-2 Preferred Stock 124,470 112,737

Equity (10Q)

Equity (10Q)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Stockholders' Equity [Abstract]
Stockholders' Equity	6. Equity Stock-based compensation expense is based on the estimated grant date fair value of the portion of stock-based payment awards that are ultimately expected to vest during the period. The grant date fair value of stock-based awards to employees and directors is calculated using the Black-Scholes-Merton valuation model. Forfeitures of stock-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated average forfeiture rate for the three months ended September 30, 2015 and 2014, was approximately 7.89% and 9.75%, respectively, based on historical data. Valuation and Expense Information: The weighted-average fair value of stock-based compensation is based on the Black-Scholes-Merton valuation model. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized using the accrual method over the vesting period of the options. The fair value calculations are based on the following assumptions: Nine Months Ended September 30, 2015 Nine Months Ended September 30, 2014 Risk free interest rate 0.04% − 3.28% 0.04% − 3.73% Expected life (years) 3.26 – 6.33 2.82 – 7.00 Expected volatility 120.74% – 198.38% 93.63% – 198.38% Expected dividends None None There were no stock options granted during the three month period ended September 30, 2015. The Company granted 29 stock options during the nine months ended September 30, 2015 at a weighted average exercise price of $28.00 per share. There were no stock options exercised during the three- and nine-months ended September 30, 2015. There were no stock options granted during the three months ended September 30, 2014. The Company granted 2 stock options during the nine months ended September 30, 2014 at a weighted average exercise price of $34.125 per share. There were no stock options exercised during the three- and nine-months ended September 30, 2014. The following table summarizes the allocation of stock-based compensation expense related to stock option grants for the three- and nine-month periods ended September 30, 2015 and 2014. Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Research and development $ 35 $ 16 $ 148 $ 64 Sales and marketing 26 17 112 54 General and administrative 47 29 192 112 Director options 8 3 35 12 Stock-based compensation expense $ 116 $ 65 $ 487 $ 242 A summary of option activity under the Company’s plans as of September 30, 2015 and 2014 is as follows: 2015 2014 Options Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at January 1, 58 $ 50.00 $ — 56 $ 62.50 $ — Granted 29 $ 25.00 $ — 2 $ 37.50 $ — Forfeited or expired (2 ) $ 37.50 $ — (1 ) $ 62.50 $ — Outstanding at September 30 85 $ 50.00 4.39 $ — 57 $ 62.50 4.30 $ — Vested and expected to vest at September 30 83 $ 37.50 3.21 $ — 51 $ 62.50 4.30 $ — Exercisable at September 30 56 $ 50.00 3.53 $ — 44 $ 62.50 3.98 $ — The following table summarizes significant ranges of outstanding and exercisable options as of September 30, 2015: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Per Share Number Outstanding Weighted Average Exercise Price Per Share $ 12.50 – $25.00 2 6.23 $ 25.00 1 $ 25.00 $ 25.00 – $37.50 43 5.21 $ 25.00 18 $ 25.00 $ 37.50 – $75.00 25 4.06 $ 62.50 22 $ 62.50 $ 75.00 – $250.00 15 2.32 $ 87.50 15 $ 87.50 85 4.39 $ 50.00 56 $ 50.00 The following table summarizes the Company’s non-vested option shares as of September 30, 2015: Non-vested Option Shares Shares Weighted Average Grant-Date Fair Value Non-vested at January 1, 2015 12 $ 50.00 Granted 29 $ 25.00 Forfeited (1 ) $ 25.00 Vested (11 ) $ 37.50 Non-vested at September 30, 2015 29 $ 25.00 As of September 30, 2015, there was $363 of total unrecognized compensation expense related to non-vested stock-based compensation arrangements granted under the plans. The unrecognized compensation expense is expected to be realized over a weighted average period of 3.2 years. Preferred Stock Information with respect to the class of Preferred Stock at September 30, 2015 is as follows: Class of Preferred Stock Annual Dividend Annual Dividend Payable, in Cash or In Kind Liquidation Preference Conversion Price Total Preferred Shares Outstanding Common Shares to be issued if Fully Converted Series A-1 8 % Quarterly in Arrears $ 1.00 $ 0.1400 929 5 Series B 10 % Quarterly in Arrears $ 1.50 $ 0.0433 13,191 244 Series C 10 % Quarterly in Arrears $ 1.50 $ 0.0225 5,356 190 Series D-1 10 % Quarterly in Arrears $ 1.00 $ 0.0225 7,878 280 Series D-2 10 % Quarterly in Arrears $ 1.00 $ 0.0500 6,223 100 Information with respect to in-kind dividends issued on the Company’s Preferred Stock for the three and nine-month periods ended September 30, 2015 and September 30, 2014 is as follows: Dividends Beneficial Conversion Feature Related to Dividends Three Months Ended September 30, Nine Months Ended September 30, Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 2015 2014 2015 2014 Series A-1 $ 18 $ 22 $ 53 $ 63 $ — $ — $ — $ — Series B 324 294 939 852 — — — — Series C 132 119 382 345 — 64 13 114 Series D-1 192 128 516 329 — 107 16 151 Series D-2 153 145 445 400 — — — — Total $ 819 $ 708 $ 2,335 $ 1,989 $ — $ 171 $ 29 $ 265 Series D Preferred Stock On February 7, 2014, the Company sold for $733 in cash, net of a $47 administrative fee paid in cash to SG Phoenix and a nonrelated third party, 520 shares of Series D-1 Preferred Stock and 260 shares of Series D-2 Preferred Stock. The investors received one hundred percent (100%) warrant coverage. These warrants are have an exercise price of $28.125 per share, immediately exercisable and expire December 31, 2016. The warrants are exercisable in whole or in part and contain a cashless exercise provision. On March 6, 2014, the Company sold for $406 in cash, net of $4 in administrative fees paid in cash to an unrelated third party, 273 shares of Series D-1 Preferred Stock and 137 shares of Series D-2 Preferred Stock. The investors received one hundred percent (100%) warrant coverage. These warrants have an exercise price of $34.375 per share, are immediately exercisable and expire December 31, 2016. The warrants are exercisable in whole or in part and contain a cashless exercise provision. SG Phoenix received warrants to purchase 2.4 shares of common stock, and two unrelated parties received warrants to purchase an aggregate of 1.3 shares of common stock in payment of administrative and related fees associated with the financings, in addition to the cash payments discussed above. These warrants have an exercise price of $34.375 per share, are immediately exercisable and expire three (3) years from the date of issuance. The warrants are exercisable in whole or in part and contain a cashless exercise provision. On March 24, 2015, the Company sold for $1,200 in cash, net of $33 in administrative fees paid in cash to SG Phoenix, 1,233 shares of Series D-1 Preferred Stock. The investors received 22 warrants, immediately exercisable into common stock of the Company at an exercise price of $28.125 per share. The warrants expire March 23, 2018. The Company ascribed a relative fair value of $366 to the warrants using the Black-Scholes-Merton pricing model and are classified as Additional Paid in Capital on the balance sheet. See the warrant table below for more detail. The warrants are exercisable in whole or in part and contain a cashless exercise provision. On July 23, 2015, the Company sold for $325 in cash, net of $4 in administrative fees paid in cash to SG Phoenix, 329 Shares of Series D-1 Preferred Stock. The investors received 11 warrants, immediately exercisable into common stock of the Company at $15.625 per share. The warrants expire July 22, 2018. The Company ascribed a relative fair value of $91 to the warrants using the Black-Scholes-Merton pricing model and are classified as Additional Paid in Capital on the balance sheet. See the warrant table below for more detail. The warrants are exercisable in whole or in part and contain a cashless exercise provision. Warrants On February 23, 2015, the Company and Venture Champion Asia Limited, an affiliate of IGC Global Limited, mutually agreed to terminate the $2,000 Credit Agreement signed in May 2014. At the time of the termination of the Credit Agreement, no amount was owed by the Company under the Credit Agreement, and contemporaneously with the termination of the Credit Agreement, the 9 warrants were likewise terminated. A summary of the warrant activity is as follows: September 30, 2015 September 30, 2014 Warrants Weighted Average Exercise Price Per Share Warrants Weighted Average Exercise Price Per Share Outstanding at beginning of period 171 $ 35.500 62 $ 36.125 Issued 32 24.125 100 34.375 Expired/Cancelled (13 ) 62.50 (22 ) 28.125 Outstanding at end of period 190 $ 33.00 139 $ 35.75 Exercisable at end of period 190 $ 33.00 139 $ 35.75 A summary of the status of the warrants outstanding and exercisable as of September 30, 2015 is as follows: Number of Warrants Weighted Average Remaining Life (Years) Weighted Average Exercise Price Per Share Warrants 22 2.52 $ 28.125 Warrants 155 1.26 $ 34.375 Warrants 3 0.13 $ 62.50 Warrants 10 2.83 $ 15.625 190 1.48 $ 33.00	9. Stockholders’ equity: Common stock options: At December 31, 2014, the Company has three stock-based employee compensation plans, the 1999 Option Plan, the 2009 Stock Compensation Plan, and the 2011 Stock Compensation Plan. The 1999 Option Plan expired in April 2009 (options outstanding under that plan are not affected by its expiration). The Company may also grant options to employees, directors and consultants outside of the active 2009 and 2011 plans under individual plans. Information with respect to the Stock Compensation Plans at December 31, 2014 is as follows: 1999 Option Plan 2009 Stock Compensation Plan 2011 Stock Compensation Plan Individual Plans Shares authorized for issuance 4,000 7,000 150,000 — Option vesting period Quarterly over Quarterly over Immediate/Quarterly Quarterly over Date adopted by stockholders June 2009 — November 2011 — Option term 7 Years 7 Years 7 Years 7 Years Options outstanding 0.02 0.34 57 0.1 Options exercisable 0.02 0.34 45 0.1 Weighted average exercise price $250.00 $131.25 $57.50 $187.50 Valuation and Expense Information: The weighted-average fair value of stock-based compensation is based on the Black Scholes Merton valuation model. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized over the vesting period of the options. The fair value calculations are based on the following assumptions: Year Ended December 31, 2014 Year Ended December 31, 2013 Risk free interest rate 0.04% - 3.73% 0.40% - 4.92% Expected life (years) 3.26 - 7.00 2.82 - 7.00 Expected volatility 91.99% - 198.38% 91.99% - 198.38% Expected dividends None None Estimated average forfeiture rate 10% 10% The following table summarizes the allocation of stock-based compensation expense for the years ended December 31, 2014 and 2013. During 2014, the Company granted 3.6 options at a weighted average grant date fair value of $25.00 per share. There were no stock options exercised during the years ended December 31, 2014 and 2013. Year Ended December 31, 2014 Year Ended December 31, 2013 Research and development $ 77 $ 262 Sales and marketing 72 100 General and administrative 134 410 Director options 15 47 Stock-based compensation expense included in operating expenses $ 298 $ 819 As of December 31, 2014, there was $236 of total unrecognized compensation cost related to non-vested share-based compensation arrangements. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.0 years. The cash flows from tax benefits for deductions in excess of the compensation costs recognized for share-based payment awards would be classified as financing cash flows. Due to the Company’s loss position, there were no such tax benefits during the year ended December 31, 2014. The summary activity for the Company’s 2009 and 2011 Stock Compensation Plans, the 1999 Option Plan and Individual Plans is as follows: December 31, 2014 December 31, 2013 Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Life Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Life Outstanding at beginning of period 56 $ 62.50 36 $ 62.50 Granted 4 $ 25.00 $ 27 21 $ 50.00 — Forfeited/ Cancelled (2 ) $ 137.50 (1 ) $ 137.50 Outstanding at period end 58 $ 50.00 — 4.18 56 $ 62.50 — 5.02 Options vested and exercisable at period end 46 $ 62.50 $ 7 3.86 35 $ 62.50 — 4.61 Weighted average grant-date fair value of options granted during the period $ 50.00 $ 50.00 The following table summarizes significant ranges of outstanding and exercisable options as of December 31, 2014: Options Outstanding Options Exercisable Range of Exercise Prices Options Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Outstanding Weighted Average Exercise Price $0.00 – $625.00 58 4.18 $ 50.00 46 $ 62.50 A summary of the status of the Company’s non-vested shares as of December 31, 2014 is as follows: Non-vested Shares Shares Weighted Average Grant-Date Fair Value Non-vested at January 1, 2013 21 $ 50.00 Granted 4 $ 50.00 Forfeited (1 ) $ 37.50 Vested (12 ) $ 50.00 Non-vested at December 31, 2014 12 $ 50.00 An employee or consultant desiring to exercise or convert his or her stock options must provide a signed notice of exercise to the Chief Financial Officer. Once the exercise is approved an issue order is sent to the Company’s transfer agent and by certificate or through other means of conveyance, the shares are delivered to the employee or consultant, generally within three business days. The Company expects to make additional option grants in future years. The options issued to employees and directors will be subject to the same provisions outlined above, which may have a material impact on the Company’s financial statements. As of December 31, 2014, 58 shares of common stock were reserved for issuance upon exercise of outstanding options. Treasury Stock: The Company received 5 shares of its Common Stock having a fair value under the cost method of $325 in January 2012, in settlement of a 16b suit brought by a shareholder against Phoenix Venture Fund, LLC (“Phoenix”). At December 31, 2014, the total value of treasury stock was $325. The Company has no plans to repurchase shares of Common Stock in the future. Preferred Shares: The Company has five series of Preferred Stock: Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D-1 Preferred Stock and Series D-2 Preferred Stock. Generally, the Company’s Preferred Stock votes together on an as converted basis with the holders of Common Stock. In addition, the Company’s Preferred Stock enjoys certain protective provisions, a liquidation preference and anti-dilution protection that are similar to one another. The Company has amended its Amended and Restated Certificate of Incorporation to increase the number of authorized shares of its Series D-1 and Series D-2 Preferred Stock. The Company solicited its stockholders and its stockholders approved an amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Series D-1 Preferred Stock from 6,000 to 10,000, and of Series D-2. Preferred Stock from 9,000 to 10,000 (the “Charter Amendment”). The Charter Amendment allows the Company to have additional shares of stock available for possible future capital raising activities as approved by the Board of Directors. The Company has amended and restated the Certificates of Designation for the Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock to, among other things, subordinate the Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock, in terms of dividend rights, liquidation preferences and other rights, to the Series D Preferred Stock. Holders of at least a majority of the shares of the Company’s Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock have approved the amendment and restatement of the Certificate of Designation applicable to such holders. Information with respect to the classes of Preferred Stock at December 31, 2014 is as follows: Class of Preferred Stock Issue Date Annual Dividend Annual Dividend Payable, in Cash or In Kind Liquidation Preference Conversion Price Total Preferred Shares Outstanding Common Shares to be issued if Fully Converted Series A-1 May 2008 8 % Quarterly in Arrears $ 1.00 $ 0.1400 875 5 Series B August 2010 10 % Quarterly in Arrears $ 1.50 $ 0.0433 12,251 226 Series C December/ 10 % Quarterly in Arrears $ 1.50 $ 0.0225 4,975 177 Series D-1 November 2012/ 10 % Quarterly in Arrears $ 1.00 $ 0.0225 5,800 206 Series D-2 November 2012/ 10 % Quarterly in Arrears $ 1.00 $ 0.0500 5,720 92 Total 706 Information with respect to dividends issued on the Company’s Preferred stock for the years ended December 31, 2014 and 2013 is as follows: December 31, December 31, 2014 2013 2014 2013 Dividends Beneficial Conversion Feature Related to dividends Series A-1 $ 82 $ 78 $ — $ — Series B 1,149 1,044 — — Series C 468 433 152 191 Series D-1 472 131 195 59 Series D-2 541 402 — — Total $ 2,712 $ 2,088 $ 347 $ 250 Series A-1 Preferred Stock The shares of Series A-1 Preferred Stock are convertible any time and are subordinate to the Series B, Series C and Series D Preferred Stock. In November 2014, a total of 238 shares of Series A-1 Preferred Stock was converted and the Company issued 1 share of Common Stock. Series B Preferred Stock The shares of Series B Preferred Stock are convertible at any time and are subordinate to the Series C and Series D Preferred Stock. Series C Preferred Stock The shares of Series C Preferred Stock are convertible into Common Stock at any time and are subordinate to the Series D Preferred Stock. In January 2012, the Company received 5 shares of Common Stock from Phoenix in settlement of a 16b claim brought by a Company stockholder against Phoenix, certain affiliates and the Company, as a nominal defendant. The Common Stock was valued at $325. In settlement of an indemnification claim brought by Phoenix in March 2012, resulting from the settlement of the 16b claim in January 2012, the Company issued to Phoenix 278 shares of Series C Preferred Stock valued at $417. The Company booked a $417 accretion amount for the beneficial conversion feature on the 278 shares of Series C Preferred Stock. In November 2013, a shareholder converted 100 shares of Series C Preferred Stock, and the Company issued 4 shares of common stock. In August 2014, a total of 0.04 share of Series C Preferred Stock was converted and the Company issued 4 shares of Common Stock. Series D Preferred Stock The material terms of the Series D-1 and Series D-2 Preferred Stock, other than the initial conversion price, are essentially the same. The shares of Series D Preferred Stock are convertible at any time and rank senior to the Company’s outstanding shares of Series A-1, Series B and Series C Preferred Stock, and of Common Stock with respect to dividend rights and liquidation preferences. In May 2013, the Company completed a private placement of 230 units of Series D Preferred Stock consisting of one (1) share of Series D-1 Preferred Stock and four (4) shares of Series D-2 Preferred Stock. The private placement provided $1,150 in proceeds to the Company. On December 31, 2013, the Company converted approximately $1,179 of short-term debt plus accrued interest into 786 shares of Series D-1 Preferred Stock and 393 shares of Series D-2 Preferred Stock. The investors received one hundred percent (100%) warrant coverage. These warrants were immediately exercisable and expire three (3) years from the date of issuance. See the warrant table below for more detail. The warrants are exercisable in whole or in part and contain a cashless exercise provision. On December 31, 2013, the Company sold for $870 in cash, net of a $40 administrative fee paid to SG Phoenix, 607 Shares of Series D-1 preferred Stock and 303 shares of Series D-2 Preferred Stock. The investors received hundred percent (100%) warrant coverage. These warrants are immediately exercisable and expire three (3) years from the date of issuance. See the warrant table below for more detail. The warrants are exercisable in whole or in part and contain a cashless exercise provision. The Company recorded a beneficial conversion feature related to the shares of Series D Preferred Stock issued in the 2013 closings of $411 based on the accounting conversion price of the shares of Series D Preferred Stock issued. In connection with the December 31, 2013 offering, the Company adjusted the number of shares of Series D-1 Preferred Stock and Series D-2 Preferred Stock issued to investors in the May 2013 offering described above, in order to give such investors shares of Series D-1 Preferred Stock and Series D-2 Preferred Stock in the same ratio as offered to Investors in the December 31, 2013 offering. This resulted in an exchange of 537 shares of Series D-2 Preferred into Series D-1 Preferred. The Company also issued warrants to purchase Common Stock in the same manner as offered to investors in the December 31, 2013 offering. On February 7, 2014, the Company sold for $733 in cash, net of a $47 administrative fee paid in cash to SG Phoenix and a nonrelated third party, 520 shares of Series D-1 Preferred Stock and 260 shares of Series D-2 Preferred Stock. The investors received one hundred percent (100%) warrant coverage. These warrants are immediately exercisable at $34.375 per share and expire December 31, 2016. See the warrant table below for more detail. The warrants are exercisable in whole or in part into shares of the Company’s Common Stock and contain a cashless exercise provision. On March 6, 2014, the Company sold for $406 in cash, net of a $4 in administrative fee paid in cash to an unrelated third party, 273 Shares of Series D-1 Preferred Stock and 137 shares of Series D-2 Preferred Stock. The investors received one hundred percent (100%) warrant coverage. These warrants are immediately exercisable at $34.375 per share and expire December 31, 2016. See the warrant table below for more detail. The warrants are exercisable in whole or in part into shares of the Company’s Common Stock and contain a cashless exercise provision. On August 5, 2014, the Company sold for $1,070 in cash, net of $50 in administrative fees paid in cash to SG Phoenix, 1,120 Shares of Series D-1 Preferred Stock. SG Phoenix received warrants to purchase 2 shares of Common stock, and two unrelated parties received warrants to purchase an aggregate of 1 share of Common Stock in payment of administrative and finder’s fees associated with the financings, in addition to the cash payments discussed above. These warrants are immediately exercisable and expire three (3) years from the date of issuance. The warrants are exercisable in whole or in part and contain a cashless exercise provision. Preferred Stock Voting and Other Rights Generally, the Company’s Preferred Stock votes together on an as converted basis with the holders of Common Stock. In addition, the Company’s Preferred Stock enjoys certain protective provisions, a liquidation preference and anti-dilution protection that are similar to one another. Warrants: Summary of Warrant exercises in 2014 and 2013: December 31,2014 December 31, 2013 Warrants Common Shares Issued Cash received Warrants Common Shares Issued Cash received — — $ — 1 1 $ 29 — — $ — 9 2 $ — Total — — $ — 10 3 $ 29 Summary of warrants issued in 2014 and 2013: December 31, 2014 December 31, 2013 Related Party Other Total Related Party Other Total Warrants issued in connection with Notes — — — 16 2 18 Warrants issued with purchase of Series D Preferred 5 12 17 8 8 16 Warrants issued in the December Series D Preferred exchange 2 6 8 Warrants issued with line of credit — 9 9 — — — Contingent Warrants issued 27 70 97 — — — Total 32 91 123 26 16 42 A summary of the outstanding warrants is as follows: December 31, 2014 December 31, 2013 Warrants Weighted Average Exercise Price Warrants Weighted Average Exercise Price Outstanding at beginning of period 62 $ 36.125 121 $ 33.625 Issued 123 $ 34.375 42 $ 33.375 Exercised — — (10 ) $ 28.125 Expired (14 ) $ 28.125 (91 ) $ 28.750 Outstanding at end of period 171 $ 35.50 62 $ 36.125 Exercisable at end of period 171 $ 35.50 62 $ 36.125 A summary of the status of the warrants outstanding as of December 31, 2014 is as follows: Number of Warrants Outstanding and Exercisable Weighted Average Remaining Life Weighted Average Exercise Price per share 7 1.95 $ 34.375 164 0.52 $ 62.500 171 1.89 $ 35.500 Contingent warrants: Investors that received warrants in connection with the December 31, 2013 Series D Preferred Stock offering, received 97 additional warrants during 2014 due to the Company not achieving certain revenue targets during the first three quarters of 2014. The Company ascribed a value at December 31, 2013 of $1,618 to the contingent warrants using a Black Sholes Merton pricing model. The cost of the contingent warrants was recognized at December 31, 2013 due to the assessment by the Company of the likelihood of achieving the revenue targets in 2014. At December 31, 2014, 213,521 shares of common stock were reserved for issuance upon exercise of outstanding warrants.

Subsequent events (10Q)

Subsequent events (10Q)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Subsequent Event [Abstract]
Subsequent events	7. Subsequent Events Unsecured Convertible Promissory Notes On November 25, 2015, the Company issued to accredited investors unsecured convertible promissory notes in the aggregate principal amount of $1,000,000 in consideration of gross cash proceeds of $750,000 plus the exchange of a $250,000 demand note previously issued by the Company in an initial closing under the terms and conditions of a note purchase agreement dated as of November 25, 2015. On December 15, 2015, the Company issued unsecured convertible promissory notes in the aggregate principal amount of $268,000 to accredited investors in a subsequent closing under the terms and conditions of the note purchase agreement. The principal amount of the unsecured convertible promissory notes issued in connection with the Company’s unsecured debt financing in November and December 2015 bear interest at a rate of 24% per annum, are due after nine months on August 25, 2016 and are convertible into shares of our common stock at the holder’s option (i) prior to maturity, in the event the Company consummates an SEC registered public offering of shares of common stock, at a conversion price that is 30% less than the price to the public of the common stock in the public offering, or (ii) up to 60 days after maturity, at a conversion price based upon a Company pre-money valuation of $5,000,000, as determined by taking into account the outstanding shares of common stock and preferred stock, on an as-converted basis, on the maturity date of the note; provided, that following such conversion, each holder that converted such note will also receive cash payments, payable from 1.5% for each $100,000 of notes converted of the revenue actually received by the Company under that certain Amended and Restated Master License Agreement dated as of January 15, 2015 by and between the Company and Cegedim SA, to be paid quarterly on a pro rata basis, with any and all other holders who converted their notes; provided, further, however, that the total amount of cash payments that the holder will be entitled to receive will not exceed three times the aggregate principal amount of the holder’s note. Change of Name On December 11, 2015, the Company changed its name from Communication Intelligence Corp. to iSign Solutions Inc. In addition, on December 14, 2015, the Company changed the trading symbol for its common stock from “CICI” to “ISGN”. Common Stock Offering, Proposed Reverse Stock Split, Reduction in Conversion Prices and Conversion of Preferred Stock On December 17, 2015, the Company filed a Registration Statement on Form S-1 with the Securities and Exchange Commission with respect to a firm commitment public offering of $10 million in shares of common stock, excluding the underwriter’s over-allotment option. On January 20, 2016, the Company held a special meeting of stockholders to consider and vote upon proposals to, among other matters, amend its corporate charter and certificates of designation to provide for (i) a reverse stock split of outstanding common stock in a range of not less than 1-for-750 and not more than 1-for-1,250 and (ii) the automatic conversion of each share of preferred stock into shares of common stock upon the closing of a firm-commitment underwritten public offering of shares of our common stock at a price per share of not less than $4.00 which provides at least $8 million in gross proceeds to the Company and a decrease in the conversion price of each series of preferred stock. Each of the proposals, other than the proposal to decrease the Company's authorized shares of common stock and preferred stock, was approved by the required holders.	12. Subsequent events: Termination of credit agreement On February 23, 2015, the Company and the Lender mutually agreed to terminate the Credit Agreement. At the time of the termination of the Credit Agreement, no amount was owed by the Company under the Credit Agreement, and contemporaneously with the termination of the Credit Agreement, the warrants were likewise terminated. Series D Financing On March 24, 2015, the Company entered into subscription agreements (the “Subscription Agreements”) with certain investors (each, an “Investor,” and, collectively, the “Investors”). Under the terms of the Subscription Agreements, the Investors purchased an aggregate of 1,233 Units (each a “Unit,” and, collectively, the “Units”) at a purchase price of $1.00 per Unit for an aggregate purchase price of approximately $1,233. Each Unit consists of one (1) share of the Company’s Series D-1 Preferred Stock and one (1) warrant to purchase shares of the Company’s Common Stock. The shares of Series D-1 Preferred Stock are convertible into shares of Common Stock at an initial conversion price of $0.0225 per share (subject to adjustment). The warrants issued to the Investors entitle the Investors to purchase up to an aggregate of approximately 22 shares of Common Stock. These warrants are exercisable for a period of three years from the date of issue and have an exercise price of $28.125 per share. Unsecured Convertible Promissory Notes On November 25, 2015, the Company issued to accredited investors unsecured convertible promissory notes in the aggregate principal amount of $1,000,000 in consideration of gross cash proceeds of $750,000 plus the exchange of a $250,000 demand note previously issued by the Company in an initial closing under the terms and conditions of a note purchase agreement dated as of November 25, 2015. On December 15, 2015, the Company issued unsecured convertible promissory notes in the aggregate principal amount of $268,000 to accredited investors in a subsequent closing under the terms and conditions of the note purchase agreement. The principal amount of the unsecured convertible promissory notes issued in connection with the Company’s unsecured debt financing in November and December 2015 bear interest at a rate of 24% per annum, are due after nine months on August 25, 2016 and are convertible into shares of our common stock at the holder’s option (i) prior to maturity, in the event the Company consummates an SEC registered public offering of shares of common stock, at a conversion price that is 30% less than the price to the public of the common stock in the public offering, or (ii) up to 60 days after maturity, at a conversion price based upon a Company pre-money valuation of $5,000,000, as determined by taking into account the outstanding shares of common stock and preferred stock, on an as-converted basis, on the maturity date of the note; provided, that following such conversion, each holder that converted such note will also receive cash payments, payable from 1.5% for each $100,000 of notes converted of the revenue actually received by the Company under that certain Amended and Restated Master License Agreement dated as of January 15, 2015 by and between the Company and Cegedim SA, to be paid quarterly on a pro rata basis, with any and all other holders who converted their notes; provided, further, however, that the total amount of cash payments that the holder will be entitled to receive will not exceed three times the aggregate principal amount of the holder’s note. Change of Name On December 11, 2015, the Company changed its name from Communication Intelligence Corp. to iSign Solutions Inc. In addition, on December 14, 2015, the Company changed the trading symbol for its common stock from “CICI” to “ISGN”. Common Stock Offering, Proposed Reverse Stock Split, Reduction in Conversion Prices and Conversion of Preferred Stock On December 17, 2015, the Company filed a Registration Statement on Form S-1 with the Securities and Exchange Commission with respect to a firm commitment public offering of $10 million in shares of common stock, excluding the underwriter’s over-allotment option. On January 20, 2016, the Company held a special meeting of stockholders to consider and vote upon proposals to, among other matters, amend its corporate charter and certificates of designation to provide for (i) a reverse stock split of outstanding common stock in a range of not less than 1-for-750 and not more than 1-for-1,250 and (ii) the automatic conversion of each share of preferred stock into shares of common stock upon the closing of a firm-commitment underwritten public offering of shares of our common stock at a price per share of not less than $4.00 which provides at least $8 million in gross proceeds to the Company and the decrease in conversion price of each series of preferred stock. Each of the proposals, other than the proposal to decrease the Company's authorized shares of common stock and preferred stock, was approved by the required holders.

Nature of business, basis of 33

Nature of business, basis of presentation and summary of significant accounting policies (10K) (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Summary of Significant Accounting Policies
Going concern and management plans	Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at September 30, 2015, the Company’s accumulated deficit was $126,082. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of September 30, 2015, the Company’s cash balance was $358. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.	Going concern and management plans: The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Except for 2004, the Company has incurred significant losses since its inception and, at December 31, 2014, the Company’s accumulated deficit was $123,199. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of December 31, 2014, the Company’s cash balance was $775. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company’s business, results of operations and ability to operate as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis of consolidation		Basis of consolidation: The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America, and include the accounts of iSign Solutions Inc. and its 90%-owned Joint Venture in the People’s Republic of China. All inter-company accounts and transactions have been eliminated. All amounts shown in the accompanying consolidated financial statements are in thousands of dollars except per share amounts.
Reclassifications		Reclassification: Certain amounts in the consolidated financial statements for 2013 have been reclassified to conform to the 2014 presentation. These reclassifications have no effect on net income, earnings per share, or cash flows as previously reported.
Use of estimates		Use of estimates: The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates.
Fair value measurement		Fair value measures: Fair value is the price that would be received to sell an asset, or paid to transfer a liability, in the principal or most advantageous market for the asset or liability in an ordinary transaction between market participants on the measurement date. Our policy on fair value measures requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The policy prioritizes the inputs into three levels that may be used to measure fair value: Level 1: Applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2: Applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3: Applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s assets and liabilities measured at fair value, whether recurring or non-recurring, at December 31, 2014 and December 31, 2013, and the fair value calculation input hierarchy level that we have determined applies to each asset and liability category.
Fair Value of Financial Instruments		Fair Value of Financial Instruments: The Company carries financial instruments on the consolidated balance sheet at the fair value of the instruments as of the consolidated balance sheet date. At the end of each period, management assesses the fair value of each instrument and adjusts the carrying value to reflect its assessment. At December 31, 2014 and December 31, 2013, the carrying values of accounts receivable and accounts payable approximated their fair values.
Treasury stock		Treasury Stock: Shares of common stock returned to, or repurchased by, the Company are recorded at cost and are included as a separate component of stockholders’ equity (deficit). Under the cost method, the gross cost of the shares reacquired is charged to a contra equity account entitled treasury stock. The equity accounts that were credited for the original share issuance (common stock, additional paid-in capital, etc.) remain intact. When the treasury shares are reissued, proceeds in excess of cost are credited to additional paid-in capital. Any deficiency is charged to accumulated deficit (unless additional paid-in capital from previous treasury share transactions exists, in which case the deficiency is charged to that account, with any excess charged to accumulated deficit).
Derivatives policy		Derivatives: The Company, from time to time, enters into transactions which contain conversion privileges, the settlement of which may entitle the holder or the Company to settle the obligation(s) by issuance of Company securities. The Company applies a two-step model in determining whether a financial instrument or an embedded feature is indexed to an issuer’s own stock and thus able to qualify for the scope exception. The fair value of each derivative is estimated each reporting period.
Cash and cash equivalents		Cash and cash equivalents: The Company considers all highly liquid investments with maturities at the date of purchase of three months or less to be cash equivalents. The Company’s cash and cash equivalents, at December 31, consisted of the following: 2014 2013 Cash in bank $ 775 $ 945 Money market funds — — Cash and cash equivalents $ 775 $ 945
Concentration of credit risk		Concentrations of credit risk: Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company maintains its cash and cash equivalents with various financial institutions. This diversification of risk is consistent with Company policy to maintain liquidity, and mitigate risk of loss as to principal. To date, accounts receivable have been derived principally from revenue earned from end users, manufacturers, and distributors of computer products in North America. The Company performs periodic credit evaluations of its customers, and does not require collateral. The Company maintains reserves for potential credit losses; historically, such losses have been within management’s expectations. The allowance for doubtful accounts is based on the Company’s assessment of the collectability of specific customer accounts and an assessment of international, political and economic risk as well as the aging of the accounts receivable. If there is a change in actual defaults from the Company’s historical experience, the Company’s estimates of recoverability of amounts due could be affected and the Company will adjust the allowance accordingly.
Deferred financing costs		Deferred financing costs: Deferred financing costs include costs paid in cash, such as professional fees and commissions. The costs are amortized to interest expense over the life of the notes or upon early payment using the effective interest method. There were $0 and $44 in cost amortized to interest expense for the years ended December 31, 2014 and 2013, respectively.
Property, plant and equipment, net		Property and equipment, net: Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, ranging from three to five years. Leasehold improvements are amortized over their estimated useful lives, not to exceed the term of the related lease. The cost of additions and improvements is capitalized, while maintenance and repairs are charged to expense as incurred. Depreciation expense was $10 and $16 for the years ended December 31, 2014 and 2013, respectively.
Intangible Assets		Intangible Assets: The Company’s core technologies can be referred to as “transaction-enabling,” “digital authentication” and “business process work flow.” These technologies include various forms of electronic signature methods, such as handwritten, biometric, click-to-sign and others, as well as technologies related to signature verification, authentication, cryptography and the logging of audit trails to prove signers’ intent. Our technologies enable the appending of secure, legal and regulatory compliant electronic signatures coupled with an enhanced user experience at a fraction of the time and cost required by traditional, paper-based processes for signature capture. The Company’s enterprise-class SignatureOne® and iSign® suite of electronic signature solutions enable businesses to implement paperless, electronic signature-driven business processes. The aggregate of the software functionality enabling the digitization of end-to-end work flow processes is sometimes referred to as “Digital Transaction Management” (“DTM”). Many applications provide electronic forms and allow users to fill-in information, but most of these applications still require users to print out a paper copy for the application of a handwritten, ink signature. Solutions powered by the Company’s products allow legally binding electronic signatures to be added to digitized documents, eliminating the need for paper to memorialize the completion, approval or authentication of the transaction. This allows users to reduce transaction times and processing costs. Intangible assets are stated at cost less accumulated amortization and reflect a portion of the value of the technologies described above. Amortization is computed using the straight-line method over the estimated lives of the related assets. Amortization expense was $357 and $365 for the years ended December 31, 2014 and 2013, respectively. The estimated remaining weighted average useful lives of the intangible assets are 3 years. Future intangible asset amortization is as follows: Year Ended December 31, 2015 $ 342 2016 323 2017 268 Total $ 933
Long-lived assets		Long-lived assets: The Company evaluates the recoverability of its long-lived assets, including intangible assets, at least annually or whenever circumstances or events indicate such assets might be impaired. The Company would recognize an impairment charge in the event the net book value of such assets exceeded the future undiscounted cash flows attributable to such assets. No such impairment charges have been recorded during the two years ended December 31, 2014 and 2013, respectively.
Share-based payment		Share-based payment: Share-based compensation expense is based on the estimated grant date fair value of the portion of share-based payment awards that are ultimately expected to vest during the period. The grant date fair value of share-based awards to employees and directors is calculated using the Black Scholes Merton valuation model. Forfeitures of share-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates and it is assumed no dividends will be declared. The estimated fair value of share-based compensation awards to employees is amortized over the vesting period of the options.
Revenue Recognition, Software		Revenue recognition: The Company recognizes revenue from sales of software products upon shipment, provided that persuasive evidence of an arrangement exists, collection is determined to be probable, all non-recurring engineering work necessary to enable the Company’s product to function within the customer’s application has been completed and the Company’s product has been delivered according to specifications. Revenue from service subscriptions is recognized as costs are incurred or over the service period, whichever is longer. Software license agreements may contain multiple elements, including upgrades and enhancements, products deliverable on a when and if available basis and post contract support. Revenue from software license agreements is recognized upon delivery of the software, provided that persuasive evidence of an arrangement exists, collection is determined to be probable, all nonrecurring engineering work necessary to enable the Company’s products to function within the customer’s application has been completed, and the Company has delivered its product according to specifications.
Revenue Recognition, Multiple-deliverable Arrangements		For arrangements with multiple deliverables, the Company allocates consideration at the inception of an arrangement to all of its deliverables based on their relative selling prices which is determined using vendor specific objective evidence. Maintenance revenue is recorded for post-contract support and upgrades or enhancements, which is paid for in addition to license fees, and is recognized as costs are incurred or over the support period whichever is longer. For undelivered elements where vendor specific objective evidence does not exist, revenue is deferred and subsequently recognized when delivery has occurred and when vendor specific evidence has been determined.
Research and development		Research and development: Research and development costs are charged to expense as incurred.
Marketing		Marketing: The Company expenses advertising (marketing) costs as incurred. These expenses are outbound marketing expenses associated with participation in industry events, related sales collateral and email campaigns aimed at generating customer participation in webinars. The expense for the years ended December 31, 2014 and 2013 was $46 and $15, respectively.
Net loss per share		Net loss per share: The Company calculates net loss per share under the provisions of the relevant accounting guidance. That guidance requires the disclosure of both basic net loss per share, which is based on the weighted average number of shares outstanding, and diluted loss per share, which is based on the weighted average number of shares and dilutive potential shares outstanding. The number of shares of common stock subject to outstanding options, preferred shares on an as converted basis and shares issuable upon exercise of warrants excluded from the calculation of loss per share as their inclusion would be anti-dilutive are as follows: December 31, 2014 December 31, 2013 Common Stock subject to outstanding options 58 56 Series A-1 Preferred Stock 6,252 7,368 Series B Preferred Stock 282,750 256,241 Series C Preferred Stock 221,104 200,354 Series D-1 Preferred Stock 257,773 151,766 Series D-2 Preferred Stock 114,400 95,682 Warrants outstanding 171 62
Foreign currency translation		Foreign currency translation: The Company considers the functional currency of the Joint Venture, CICC, to be the local currency of China, which is the Renminbi (“RMB”) and, accordingly, gains and losses from the translation of the local foreign currency financial statements are included as a component of accumulated other comprehensive loss in the accompanying consolidated balance sheets. Foreign currency assets and liabilities are translated into U.S. dollars at the end-of-period exchange rates except for long-term assets and liabilities, which are translated at historical exchange rates. Revenue and expenses are translated at the average exchange rates in effect during each period except for those expenses related to consolidated balance sheet amounts which are translated at historical exchange rates. Net foreign currency transaction gains and losses are included in interest and other income, net in the accompanying consolidated statements of operations. Foreign currency transaction gains and losses in 2014 and 2013 were insignificant.
Income taxes		Income taxes: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their financial statement reported amounts and for tax loss and credit carry-forwards. A valuation allowance is provided against deferred tax assets when it is determined to be more likely than not that the deferred tax asset will not be realized. There have been no unrecognized tax benefits and, accordingly, there has been no effect on the Company’s financial condition or results of operations. The Company files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. The Company is no longer subject to U.S. federal tax examinations for years before 2006, and state tax examinations for years before 2005. Management does not believe there will be any material changes in the Company’s unrecognized tax positions over the next 12 months. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.
Recently issued accounting pronouncement	Accounting Changes and Recent Accounting Pronouncements Accounting Standards Issued But Not Yet Adopted Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies are not expected to have a material impact on the Company’s financial position, results of operations and cash flows.	Recently issued accounting pronouncement: Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

Nature of business, basis of 34

Nature of business, basis of presentation and summary of significant accounting policies (10Q) (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Summary of Significant Accounting Policies
Basis of presentation	Basis of Presentation The financial information contained herein should be read in conjunction with the Company's consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2014. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company’s results of operations and cash flows for the periods presented. The Company’s interim results are not necessarily indicative of the results to be expected for the entire year.
Going concern and management plans	Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at September 30, 2015, the Company’s accumulated deficit was $126,082. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of September 30, 2015, the Company’s cash balance was $358. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.	Going concern and management plans: The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Except for 2004, the Company has incurred significant losses since its inception and, at December 31, 2014, the Company’s accumulated deficit was $123,199. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of December 31, 2014, the Company’s cash balance was $775. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company’s business, results of operations and ability to operate as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Recently issued accounting pronouncement	Accounting Changes and Recent Accounting Pronouncements Accounting Standards Issued But Not Yet Adopted Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies are not expected to have a material impact on the Company’s financial position, results of operations and cash flows.	Recently issued accounting pronouncement: Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

Nature of business, basis of 35

Nature of business, basis of presentation and summary of significant accounting policies (10K) (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of cash and cash equivalents		The Company’s cash and cash equivalents, at December 31, consisted of the following: 2014 2013 Cash in bank $ 775 $ 945 Money market funds — — Cash and cash equivalents $ 775 $ 945
Schedule of amortization for intangible assets		Future intangible asset amortization is as follows: Year Ended December 31, 2015 $ 342 2016 323 2017 268 Total $ 933
Schedule of Antidilutive Securities Excluded from Calculation of Earnings Per Share	The following table lists shares and warrants that were excluded from the calculation of dilutive earnings per share as the exercise of such options and warrants and the conversion of such preferred shares would be anti-dilutive: For the Nine Months Ended September 30, 2015 September 30, 2014 Stock options 85 57 Warrants 190 137 Preferred shares as if converted Series A-1 Preferred Stock 6,633 7,818 Series B Preferred Stock 304,430 275,888 Series C Preferred Stock 238,056 215,668 Series D-1 Preferred Stock 350,127 251,435 Series D-2 Preferred Stock 124,470 112,737	The number of shares of common stock subject to outstanding options, preferred shares on an as converted basis and shares issuable upon exercise of warrants excluded from the calculation of loss per share as their inclusion would be anti-dilutive are as follows: December 31, 2014 December 31, 2013 Common Stock subject to outstanding options 58 56 Series A-1 Preferred Stock 6,252 7,368 Series B Preferred Stock 282,750 256,241 Series C Preferred Stock 221,104 200,354 Series D-1 Preferred Stock 257,773 151,766 Series D-2 Preferred Stock 114,400 95,682 Warrants outstanding 171 62

Concentration (10K) (Tables)

Concentration (10K) (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Risks and Uncertainties [Abstract]
Schedule of accounts receivable and revenue concentration	The following table summarizes accounts receivable and revenue concentrations: Accounts Receivable As of September 30, Total Revenue for the three months ended September 30, Total Revenue for the nine months ended September 30, 2015 2014 2015 2014 2015 2014 Customer #1 38 % 46 % — 17 % 12 % 11 % Customer #2 24 % — 17 % — — — Customer #3 — — 10 % 12 % — 10 % Customer #4 — 12 % — — — — Customer #5 — 19 % — — — — Customer #6 — — — 10 % 16 % — Customer #7 — — — — 17 % 14 % Total concentration 62 % 77 % 27 % 39 % 45 % 35 %	The following table summarizes accounts receivable and revenue concentrations: Accounts Receivable As of December 31, Total Revenue for the year ended December 31, 2014 2013 2014 2013 Customer #1 44 % 47 % — 15 % Customer #2 — 15 % — 10 % Customer #3 19 % 19 % 12 % 16 % Customer #4 — — — 10 % Customer #5 — — — 12 % Customer #6 — — 12 % — Customer #7 — — 11 % — Customer #8 10 % — — — Total concentration 73 % 81 % 35 % 63 %
Schedule of sales concentrations by geographical areas		The following table summarizes sales concentrations: December 31, 2014 December 31, 2013 Sales within the United States 99 % 98 % Sales outside of the United States 1 % 2 % Total 100 % 100 %

Property, plant and equipment37

Property, plant and equipment (10K) (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment	Property and equipment, net at December 31, consists of the following: 2014 2013 Machinery and equipment $ 1,235 $ 1,231 Office furniture and fixtures 435 435 Leasehold improvements 90 90 Purchased software 323 323 2,083 2,079 Less accumulated depreciation and amortization (2,072 ) (2,062 ) $ 11 $ 17

Intangible Assets (10K) (Tables

Intangible Assets (10K) (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets	The following table summarizes the amortizable intangible assets: September 30, 2015 December 31, 2014 Carrying Amount Accumulated Amortization Net Value Carrying Amount Accumulated Amortization Net Value $6,745 $(6,072) $673 $6,745 $(5,812) $933	Intangible assets, net consists of the following at December 31: Weighted Average Amortization Period (Years) 2014 2013 Technology 3 6,745 6,745 Less accumulated amortization (5,812 ) (5,455 ) $ 933 $ 1,290

Other accrued liabilities (1039

Other accrued liabilities (10K) (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of other accrued liabilities	The Company had the following other accrued liabilities at December 31: 2014 2013 Accrued professional services $ 8 $ 8 Rents 44 35 Management fees 280 180 Other 6 9 Total $ 338 $ 232

Short-term notes payable (10K)

Short-term notes payable (10K) (Tables)	12 Months Ended
	Dec. 31, 2014
Short-term notes payable [Abstract]
Summary of demand notes and warrants	Detail on these demand notes and warrants is as follows: Phoenix Banner Holdings LLC Michael W. Engmann Kendu Partners Company JAG Multi Investments Philip Sassower Date Note Amount Warrants Note Amount Warrants Note Amount Warrants Note Amount Warrants Note Amount Warrants 8/2/2013 $ 250 9/3/2013 $ 250 9/27/2013 $ 250 11/1/2013 $ 125 2 11/6/2013 3 3 3 12/13/2013 $ 150 4 12/17/2013 $ 125 2 Total $ 250 3 $ 400 7 $ 250 3 $ 125 2 $ 125 2
Key assumptions used to calculate fair value of warrants	The warrants were valued using the Black Sholes Merton pricing model with the following assumptions: Date Expected Term Volatility Risk free interest rate Dividend yield 11/6/2013 Three years 202.9% 0.58% $0.00 11/26/2013 Three years 200.8% 0.55% $0.00 12/3/2013 Three years 198.8% 0.68% $0.00 12/17/2013 Three years 198.0% 0.68% $0.00

Derivative Liability (10K) (Tab

Derivative Liability (10K) (Tables)	12 Months Ended
	Dec. 31, 2014
Derivative liability [Abstract]
Summary Of Bridge Financing Warrants	The warrants have a three year life from the date of issue with a zero dividend yield and were valued using a simulated probability valuation model. Additional information with respect to these warrants is presented in the table below. Issue Date Reason for issuance Number of warrants issued Exercise price Risk free interest rate Expected volatility Derivative liability value on date of issue 4/23/2012 Bridge financing warrants 4 $ 62.50 1.78 % 205.3 % $ 50 4/23/2012 Finder’s fee warrants 0.2792 $ 62.50 1.78 % 205.3 % $ — 11/15/2012 Administrative fee warrants 2.4 $ 62.50 1.78 % 202.2 % $ 8 11/15/2012 Finder’s fee warrants 0.2352 $ 62.50 1.78 % 202.2 % $ —
Changes in the market value of the Level 3 derivative liability	Changes in the fair value of the level 3 derivative liability for the year ended December 31, 2014, are as follows: Derivative Liability Balance at January 1, 2013 $ 25 Gain on derivative liability (7 ) Balance at December 31, 2014 $ 18
Liabilities measured at fair value	Assets and liabilities measured at fair value as of December 31, 2014 are as follows: Value at December 31, 2014 Quoted prices in active markets Significant other observable inputs Significant unobservable inputs (Level 1) (Level 2) (Level 3) Derivative liability $ 18 $ — $ — $ 18

Stockholders' Equity (10K) (Tab

Stockholders' Equity (10K) (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Stockholders' Equity [Abstract]
Stock Compensation Plans Information Summary		Information with respect to the Stock Compensation Plans at December 31, 2014 is as follows: 1999 Option Plan 2009 Stock Compensation Plan 2011 Stock Compensation Plan Individual Plans Shares authorized for issuance 4,000 7,000 150,000 — Option vesting period Quarterly over Quarterly over Immediate/Quarterly Quarterly over Date adopted by stockholders June 2009 — November 2011 — Option term 7 Years 7 Years 7 Years 7 Years Options outstanding 0.02 0.34 57 0.1 Options exercisable 0.02 0.34 45 0.1 Weighted average exercise price $250.00 $131.25 $57.50 $187.50
Key assumptions for fair value calculation, stock options	The fair value calculations are based on the following assumptions: Nine Months Ended September 30, 2015 Nine Months Ended September 30, 2014 Risk free interest rate 0.04% − 3.28% 0.04% − 3.73% Expected life (years) 3.26 – 6.33 2.82 – 7.00 Expected volatility 120.74% – 198.38% 93.63% – 198.38% Expected dividends None None	The fair value calculations are based on the following assumptions: Year Ended December 31, 2014 Year Ended December 31, 2013 Risk free interest rate 0.04% - 3.73% 0.40% - 4.92% Expected life (years) 3.26 - 7.00 2.82 - 7.00 Expected volatility 91.99% - 198.38% 91.99% - 198.38% Expected dividends None None Estimated average forfeiture rate 10% 10%
Allocation of stock-based compensation expense related to stock option grants	The following table summarizes the allocation of stock-based compensation expense related to stock option grants for the three- and nine-month periods ended September 30, 2015 and 2014. Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Research and development $ 35 $ 16 $ 148 $ 64 Sales and marketing 26 17 112 54 General and administrative 47 29 192 112 Director options 8 3 35 12 Stock-based compensation expense $ 116 $ 65 $ 487 $ 242	There were no stock options exercised during the years ended December 31, 2014 and 2013. Year Ended December 31, 2014 Year Ended December 31, 2013 Research and development $ 77 $ 262 Sales and marketing 72 100 General and administrative 134 410 Director options 15 47 Stock-based compensation expense included in operating expenses $ 298 $ 819
Summary of option activity	A summary of option activity under the Company’s plans as of September 30, 2015 and 2014 is as follows: 2015 2014 Options Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at January 1, 58 $ 50.00 $ — 56 $ 62.50 $ — Granted 29 $ 25.00 $ — 2 $ 37.50 $ — Forfeited or expired (2 ) $ 37.50 $ — (1 ) $ 62.50 $ — Outstanding at September 30 85 $ 50.00 4.39 $ — 57 $ 62.50 4.30 $ — Vested and expected to vest at September 30 83 $ 37.50 3.21 $ — 51 $ 62.50 4.30 $ — Exercisable at September 30 56 $ 50.00 3.53 $ — 44 $ 62.50 3.98 $ —	The summary activity for the Company’s 2009 and 2011 Stock Compensation Plans, the 1999 Option Plan and Individual Plans is as follows: December 31, 2014 December 31, 2013 Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Life Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Life Outstanding at beginning of period 56 $ 62.50 36 $ 62.50 Granted 4 $ 25.00 $ 27 21 $ 50.00 — Forfeited/ Cancelled (2 ) $ 137.50 (1 ) $ 137.50 Outstanding at period end 58 $ 50.00 — 4.18 56 $ 62.50 — 5.02 Options vested and exercisable at period end 46 $ 62.50 $ 7 3.86 35 $ 62.50 — 4.61 Weighted average grant-date fair value of options granted during the period $ 50.00 $ 50.00
Summary of the significant ranges of outstanding and exercisable options	The following table summarizes significant ranges of outstanding and exercisable options as of September 30, 2015: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Per Share Number Outstanding Weighted Average Exercise Price Per Share $ 12.50 – $25.00 2 6.23 $ 25.00 1 $ 25.00 $ 25.00 – $37.50 43 5.21 $ 25.00 18 $ 25.00 $ 37.50 – $75.00 25 4.06 $ 62.50 22 $ 62.50 $ 75.00 – $250.00 15 2.32 $ 87.50 15 $ 87.50 85 4.39 $ 50.00 56 $ 50.00	The following table summarizes significant ranges of outstanding and exercisable options as of December 31, 2014: Options Outstanding Options Exercisable Range of Exercise Prices Options Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Outstanding Weighted Average Exercise Price $0.00 – $625.00 58 4.18 $ 50.00 46 $ 62.50
Summary of the status of the Company's non-vested shares	The following table summarizes the Company’s non-vested option shares as of September 30, 2015: Non-vested Option Shares Shares Weighted Average Grant-Date Fair Value Non-vested at January 1, 2015 12 $ 50.00 Granted 29 $ 25.00 Forfeited (1 ) $ 25.00 Vested (11 ) $ 37.50 Non-vested at September 30, 2015 29 $ 25.00	A summary of the status of the Company’s non-vested shares as of December 31, 2014 is as follows: Non-vested Shares Shares Weighted Average Grant-Date Fair Value Non-vested at January 1, 2013 21 $ 50.00 Granted 4 $ 50.00 Forfeited (1 ) $ 37.50 Vested (12 ) $ 50.00 Non-vested at December 31, 2014 12 $ 50.00
Information with respect to the classes of Preferred Stock	Information with respect to the class of Preferred Stock at September 30, 2015 is as follows: Class of Preferred Stock Annual Dividend Annual Dividend Payable, in Cash or In Kind Liquidation Preference Conversion Price Total Preferred Shares Outstanding Common Shares to be issued if Fully Converted Series A-1 8 % Quarterly in Arrears $ 1.00 $ 0.1400 929 5 Series B 10 % Quarterly in Arrears $ 1.50 $ 0.0433 13,191 244 Series C 10 % Quarterly in Arrears $ 1.50 $ 0.0225 5,356 190 Series D-1 10 % Quarterly in Arrears $ 1.00 $ 0.0225 7,878 280 Series D-2 10 % Quarterly in Arrears $ 1.00 $ 0.0500 6,223 100	Information with respect to the classes of Preferred Stock at December 31, 2014 is as follows: Class of Preferred Stock Issue Date Annual Dividend Annual Dividend Payable, in Cash or In Kind Liquidation Preference Conversion Price Total Preferred Shares Outstanding Common Shares to be issued if Fully Converted Series A-1 May 2008 8 % Quarterly in Arrears $ 1.00 $ 0.1400 875 5 Series B August 2010 10 % Quarterly in Arrears $ 1.50 $ 0.0433 12,251 226 Series C December/ 10 % Quarterly in Arrears $ 1.50 $ 0.0225 4,975 177 Series D-1 November 2012/ 10 % Quarterly in Arrears $ 1.00 $ 0.0225 5,800 206 Series D-2 November 2012/ 10 % Quarterly in Arrears $ 1.00 $ 0.0500 5,720 92 Total 706
Information with respect to dividends issued on the Company's preferred stock	Information with respect to in-kind dividends issued on the Company’s Preferred Stock for the three and nine-month periods ended September 30, 2015 and September 30, 2014 is as follows: Dividends Beneficial Conversion Feature Related to Dividends Three Months Ended September 30, Nine Months Ended September 30, Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 2015 2014 2015 2014 Series A-1 $ 18 $ 22 $ 53 $ 63 $ — $ — $ — $ — Series B 324 294 939 852 — — — — Series C 132 119 382 345 — 64 13 114 Series D-1 192 128 516 329 — 107 16 151 Series D-2 153 145 445 400 — — — — Total $ 819 $ 708 $ 2,335 $ 1,989 $ — $ 171 $ 29 $ 265	Information with respect to dividends issued on the Company’s Preferred stock for the years ended December 31, 2014 and 2013 is as follows: December 31, December 31, 2014 2013 2014 2013 Dividends Beneficial Conversion Feature Related to dividends Series A-1 $ 82 $ 78 $ — $ — Series B 1,149 1,044 — — Series C 468 433 152 191 Series D-1 472 131 195 59 Series D-2 541 402 — — Total $ 2,712 $ 2,088 $ 347 $ 250
Summary of warrants excercises	A summary of the warrant activity is as follows: September 30, 2015 September 30, 2014 Warrants Weighted Average Exercise Price Per Share Warrants Weighted Average Exercise Price Per Share Outstanding at beginning of period 171 $ 35.500 62 $ 36.125 Issued 32 24.125 100 34.375 Expired/Cancelled (13 ) 62.50 (22 ) 28.125 Outstanding at end of period 190 $ 33.00 139 $ 35.75 Exercisable at end of period 190 $ 33.00 139 $ 35.75	Summary of Warrant exercises in 2014 and 2013: December 31,2014 December 31, 2013 Warrants Common Shares Issued Cash received Warrants Common Shares Issued Cash received — — $ — 1 1 $ 29 — — $ — 9 2 $ — Total — — $ — 10 3 $ 29
Summary of warrants issued to related party and other		Summary of warrants issued in 2014 and 2013: December 31, 2014 December 31, 2013 Related Party Other Total Related Party Other Total Warrants issued in connection with Notes — — — 16 2 18 Warrants issued with purchase of Series D Preferred 5 12 17 8 8 16 Warrants issued in the December Series D Preferred exchange 2 6 8 Warrants issued with line of credit — 9 9 — — — Contingent Warrants issued 27 70 97 — — — Total 32 91 123 26 16 42
Summary of the warrants issued	A summary of the warrant activity is as follows: September 30, 2015 September 30, 2014 Warrants Weighted Average Exercise Price Per Share Warrants Weighted Average Exercise Price Per Share Outstanding at beginning of period 171 $ 35.500 62 $ 36.125 Issued 32 24.125 100 34.375 Expired/Cancelled (13 ) 62.50 (22 ) 28.125 Outstanding at end of period 190 $ 33.00 139 $ 35.75 Exercisable at end of period 190 $ 33.00 139 $ 35.75	A summary of the outstanding warrants is as follows: December 31, 2014 December 31, 2013 Warrants Weighted Average Exercise Price Warrants Weighted Average Exercise Price Outstanding at beginning of period 62 $ 36.125 121 $ 33.625 Issued 123 $ 34.375 42 $ 33.375 Exercised — — (10 ) $ 28.125 Expired (14 ) $ 28.125 (91 ) $ 28.750 Outstanding at end of period 171 $ 35.50 62 $ 36.125 Exercisable at end of period 171 $ 35.50 62 $ 36.125
Status of the warrants outstanding	A summary of the status of the warrants outstanding and exercisable as of September 30, 2015 is as follows: Number of Warrants Weighted Average Remaining Life (Years) Weighted Average Exercise Price Per Share Warrants 22 2.52 $ 28.125 Warrants 155 1.26 $ 34.375 Warrants 3 0.13 $ 62.50 Warrants 10 2.83 $ 15.625 190 1.48 $ 33.00	A summary of the status of the warrants outstanding as of December 31, 2014 is as follows: Number of Warrants Outstanding and Exercisable Weighted Average Remaining Life Weighted Average Exercise Price per share 7 1.95 $ 34.375 164 0.52 $ 62.500 171 1.89 $ 35.500

Commitments and Contingencies43

Commitments and Contingencies (10K) (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Contractual obligations, material commitments	Contractual obligations Total 2015 2016 Thereafter Operating lease commitments $ 543 $ 293 $ 250 —

Income Taxes (10K) (Tables)

Income Taxes (10K) (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of deferred tax assets and liabilities	Deferred tax assets and liabilities at December 31 consist of the following: 2014 2013 Deferred tax assets: Net operating loss carry-forwards $ 23,114 $ 27,266 Credit carry-forwards — 137 Accruals and reserves 141 Deferred revenue 382 224 Intangibles 273 1,046 Other, net — 373 Fixed Assets 894 — Gross tax assets 24,804 29,046 Valuation allowance (24,804 ) (29,046 ) Net deferred tax assets $ — $ —
Schedule of components of income tax expense (benefit)	The Company’s provision for income taxes differs from the amount computed by applying the statutory U.S. federal income tax rate to loss before taxes as follows for the years ended December 31, 2014 and December 31, 2013: 2014 2013 Income tax benefit at the federal statutory rate $ (1,364 ) $ (2,668 ) State income tax benefit (233 ) (458 ) Credits — — Prior year true up to return 5,758 1,416 Permanent items and other 81 1,391 Change in valuation allowance (4,242 ) 319 Income tax expense $ — $ —

Concentration (10Q) (Tables)

Concentration (10Q) (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Risks and Uncertainties [Abstract]
Schedule of accounts receivable and revenue concentration	The following table summarizes accounts receivable and revenue concentrations: Accounts Receivable As of September 30, Total Revenue for the three months ended September 30, Total Revenue for the nine months ended September 30, 2015 2014 2015 2014 2015 2014 Customer #1 38 % 46 % — 17 % 12 % 11 % Customer #2 24 % — 17 % — — — Customer #3 — — 10 % 12 % — 10 % Customer #4 — 12 % — — — — Customer #5 — 19 % — — — — Customer #6 — — — 10 % 16 % — Customer #7 — — — — 17 % 14 % Total concentration 62 % 77 % 27 % 39 % 45 % 35 %	The following table summarizes accounts receivable and revenue concentrations: Accounts Receivable As of December 31, Total Revenue for the year ended December 31, 2014 2013 2014 2013 Customer #1 44 % 47 % — 15 % Customer #2 — 15 % — 10 % Customer #3 19 % 19 % 12 % 16 % Customer #4 — — — 10 % Customer #5 — — — 12 % Customer #6 — — 12 % — Customer #7 — — 11 % — Customer #8 10 % — — — Total concentration 73 % 81 % 35 % 63 %

Intangible Assets (10Q) (Tables

Intangible Assets (10Q) (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets	The following table summarizes the amortizable intangible assets: September 30, 2015 December 31, 2014 Carrying Amount Accumulated Amortization Net Value Carrying Amount Accumulated Amortization Net Value $6,745 $(6,072) $673 $6,745 $(5,812) $933	Intangible assets, net consists of the following at December 31: Weighted Average Amortization Period (Years) 2014 2013 Technology 3 6,745 6,745 Less accumulated amortization (5,812 ) (5,455 ) $ 933 $ 1,290

Net loss per share (10Q) (Table

Net loss per share (10Q) (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Net loss per share [Abstract]
Schedule of Antidilutive Securities Excluded from Calculation of Earnings Per Share	The following table lists shares and warrants that were excluded from the calculation of dilutive earnings per share as the exercise of such options and warrants and the conversion of such preferred shares would be anti-dilutive: For the Nine Months Ended September 30, 2015 September 30, 2014 Stock options 85 57 Warrants 190 137 Preferred shares as if converted Series A-1 Preferred Stock 6,633 7,818 Series B Preferred Stock 304,430 275,888 Series C Preferred Stock 238,056 215,668 Series D-1 Preferred Stock 350,127 251,435 Series D-2 Preferred Stock 124,470 112,737	The number of shares of common stock subject to outstanding options, preferred shares on an as converted basis and shares issuable upon exercise of warrants excluded from the calculation of loss per share as their inclusion would be anti-dilutive are as follows: December 31, 2014 December 31, 2013 Common Stock subject to outstanding options 58 56 Series A-1 Preferred Stock 6,252 7,368 Series B Preferred Stock 282,750 256,241 Series C Preferred Stock 221,104 200,354 Series D-1 Preferred Stock 257,773 151,766 Series D-2 Preferred Stock 114,400 95,682 Warrants outstanding 171 62

Equity (10Q) (Tables)

Equity (10Q) (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Stockholders' Equity [Abstract]
Key assumptions for fair value calculation, stock options	The fair value calculations are based on the following assumptions: Nine Months Ended September 30, 2015 Nine Months Ended September 30, 2014 Risk free interest rate 0.04% − 3.28% 0.04% − 3.73% Expected life (years) 3.26 – 6.33 2.82 – 7.00 Expected volatility 120.74% – 198.38% 93.63% – 198.38% Expected dividends None None	The fair value calculations are based on the following assumptions: Year Ended December 31, 2014 Year Ended December 31, 2013 Risk free interest rate 0.04% - 3.73% 0.40% - 4.92% Expected life (years) 3.26 - 7.00 2.82 - 7.00 Expected volatility 91.99% - 198.38% 91.99% - 198.38% Expected dividends None None Estimated average forfeiture rate 10% 10%
Allocation of stock-based compensation expense related to stock option grants	The following table summarizes the allocation of stock-based compensation expense related to stock option grants for the three- and nine-month periods ended September 30, 2015 and 2014. Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Research and development $ 35 $ 16 $ 148 $ 64 Sales and marketing 26 17 112 54 General and administrative 47 29 192 112 Director options 8 3 35 12 Stock-based compensation expense $ 116 $ 65 $ 487 $ 242	There were no stock options exercised during the years ended December 31, 2014 and 2013. Year Ended December 31, 2014 Year Ended December 31, 2013 Research and development $ 77 $ 262 Sales and marketing 72 100 General and administrative 134 410 Director options 15 47 Stock-based compensation expense included in operating expenses $ 298 $ 819
Summary of option activity	A summary of option activity under the Company’s plans as of September 30, 2015 and 2014 is as follows: 2015 2014 Options Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at January 1, 58 $ 50.00 $ — 56 $ 62.50 $ — Granted 29 $ 25.00 $ — 2 $ 37.50 $ — Forfeited or expired (2 ) $ 37.50 $ — (1 ) $ 62.50 $ — Outstanding at September 30 85 $ 50.00 4.39 $ — 57 $ 62.50 4.30 $ — Vested and expected to vest at September 30 83 $ 37.50 3.21 $ — 51 $ 62.50 4.30 $ — Exercisable at September 30 56 $ 50.00 3.53 $ — 44 $ 62.50 3.98 $ —	The summary activity for the Company’s 2009 and 2011 Stock Compensation Plans, the 1999 Option Plan and Individual Plans is as follows: December 31, 2014 December 31, 2013 Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Life Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Life Outstanding at beginning of period 56 $ 62.50 36 $ 62.50 Granted 4 $ 25.00 $ 27 21 $ 50.00 — Forfeited/ Cancelled (2 ) $ 137.50 (1 ) $ 137.50 Outstanding at period end 58 $ 50.00 — 4.18 56 $ 62.50 — 5.02 Options vested and exercisable at period end 46 $ 62.50 $ 7 3.86 35 $ 62.50 — 4.61 Weighted average grant-date fair value of options granted during the period $ 50.00 $ 50.00
Summary of the significant ranges of outstanding and exercisable options	The following table summarizes significant ranges of outstanding and exercisable options as of September 30, 2015: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Per Share Number Outstanding Weighted Average Exercise Price Per Share $ 12.50 – $25.00 2 6.23 $ 25.00 1 $ 25.00 $ 25.00 – $37.50 43 5.21 $ 25.00 18 $ 25.00 $ 37.50 – $75.00 25 4.06 $ 62.50 22 $ 62.50 $ 75.00 – $250.00 15 2.32 $ 87.50 15 $ 87.50 85 4.39 $ 50.00 56 $ 50.00	The following table summarizes significant ranges of outstanding and exercisable options as of December 31, 2014: Options Outstanding Options Exercisable Range of Exercise Prices Options Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Outstanding Weighted Average Exercise Price $0.00 – $625.00 58 4.18 $ 50.00 46 $ 62.50
Summary of the status of the Company's non-vested shares	The following table summarizes the Company’s non-vested option shares as of September 30, 2015: Non-vested Option Shares Shares Weighted Average Grant-Date Fair Value Non-vested at January 1, 2015 12 $ 50.00 Granted 29 $ 25.00 Forfeited (1 ) $ 25.00 Vested (11 ) $ 37.50 Non-vested at September 30, 2015 29 $ 25.00	A summary of the status of the Company’s non-vested shares as of December 31, 2014 is as follows: Non-vested Shares Shares Weighted Average Grant-Date Fair Value Non-vested at January 1, 2013 21 $ 50.00 Granted 4 $ 50.00 Forfeited (1 ) $ 37.50 Vested (12 ) $ 50.00 Non-vested at December 31, 2014 12 $ 50.00
Information with respect to the classes of Preferred Stock	Information with respect to the class of Preferred Stock at September 30, 2015 is as follows: Class of Preferred Stock Annual Dividend Annual Dividend Payable, in Cash or In Kind Liquidation Preference Conversion Price Total Preferred Shares Outstanding Common Shares to be issued if Fully Converted Series A-1 8 % Quarterly in Arrears $ 1.00 $ 0.1400 929 5 Series B 10 % Quarterly in Arrears $ 1.50 $ 0.0433 13,191 244 Series C 10 % Quarterly in Arrears $ 1.50 $ 0.0225 5,356 190 Series D-1 10 % Quarterly in Arrears $ 1.00 $ 0.0225 7,878 280 Series D-2 10 % Quarterly in Arrears $ 1.00 $ 0.0500 6,223 100	Information with respect to the classes of Preferred Stock at December 31, 2014 is as follows: Class of Preferred Stock Issue Date Annual Dividend Annual Dividend Payable, in Cash or In Kind Liquidation Preference Conversion Price Total Preferred Shares Outstanding Common Shares to be issued if Fully Converted Series A-1 May 2008 8 % Quarterly in Arrears $ 1.00 $ 0.1400 875 5 Series B August 2010 10 % Quarterly in Arrears $ 1.50 $ 0.0433 12,251 226 Series C December/ 10 % Quarterly in Arrears $ 1.50 $ 0.0225 4,975 177 Series D-1 November 2012/ 10 % Quarterly in Arrears $ 1.00 $ 0.0225 5,800 206 Series D-2 November 2012/ 10 % Quarterly in Arrears $ 1.00 $ 0.0500 5,720 92 Total 706
Information with respect to dividends issued on the Company's preferred stock	Information with respect to in-kind dividends issued on the Company’s Preferred Stock for the three and nine-month periods ended September 30, 2015 and September 30, 2014 is as follows: Dividends Beneficial Conversion Feature Related to Dividends Three Months Ended September 30, Nine Months Ended September 30, Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 2015 2014 2015 2014 Series A-1 $ 18 $ 22 $ 53 $ 63 $ — $ — $ — $ — Series B 324 294 939 852 — — — — Series C 132 119 382 345 — 64 13 114 Series D-1 192 128 516 329 — 107 16 151 Series D-2 153 145 445 400 — — — — Total $ 819 $ 708 $ 2,335 $ 1,989 $ — $ 171 $ 29 $ 265	Information with respect to dividends issued on the Company’s Preferred stock for the years ended December 31, 2014 and 2013 is as follows: December 31, December 31, 2014 2013 2014 2013 Dividends Beneficial Conversion Feature Related to dividends Series A-1 $ 82 $ 78 $ — $ — Series B 1,149 1,044 — — Series C 468 433 152 191 Series D-1 472 131 195 59 Series D-2 541 402 — — Total $ 2,712 $ 2,088 $ 347 $ 250
Summary of the warrants issued	A summary of the warrant activity is as follows: September 30, 2015 September 30, 2014 Warrants Weighted Average Exercise Price Per Share Warrants Weighted Average Exercise Price Per Share Outstanding at beginning of period 171 $ 35.500 62 $ 36.125 Issued 32 24.125 100 34.375 Expired/Cancelled (13 ) 62.50 (22 ) 28.125 Outstanding at end of period 190 $ 33.00 139 $ 35.75 Exercisable at end of period 190 $ 33.00 139 $ 35.75	A summary of the outstanding warrants is as follows: December 31, 2014 December 31, 2013 Warrants Weighted Average Exercise Price Warrants Weighted Average Exercise Price Outstanding at beginning of period 62 $ 36.125 121 $ 33.625 Issued 123 $ 34.375 42 $ 33.375 Exercised — — (10 ) $ 28.125 Expired (14 ) $ 28.125 (91 ) $ 28.750 Outstanding at end of period 171 $ 35.50 62 $ 36.125 Exercisable at end of period 171 $ 35.50 62 $ 36.125
Status of the warrants outstanding	A summary of the status of the warrants outstanding and exercisable as of September 30, 2015 is as follows: Number of Warrants Weighted Average Remaining Life (Years) Weighted Average Exercise Price Per Share Warrants 22 2.52 $ 28.125 Warrants 155 1.26 $ 34.375 Warrants 3 0.13 $ 62.50 Warrants 10 2.83 $ 15.625 190 1.48 $ 33.00	A summary of the status of the warrants outstanding as of December 31, 2014 is as follows: Number of Warrants Outstanding and Exercisable Weighted Average Remaining Life Weighted Average Exercise Price per share 7 1.95 $ 34.375 164 0.52 $ 62.500 171 1.89 $ 35.500

Nature of business, basis of 49

Nature of business, basis of presentation and summary of significant accounting policies (10K) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash and Cash Equivalents, at Carrying Value [Abstract]
Cash in bank		$ 775		$ 945
Money market funds
Cash and cash equivalents	$ 358	$ 775	$ 641	$ 945	$ 486

Nature of business, basis of 50

Nature of business, basis of presentation and summary of significant accounting policies (10K) (Details 1) $ in Thousands	12 Months Ended
	Dec. 31, 2014USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2,015	$ 342
2,016	323
2,017	268
Total	$ 933

Nature of business, basis of 51

Nature of business, basis of presentation and summary of significant accounting policies (10K) (Details 2) - shares shares in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	6,633	7,818	6,252	7,368
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	304,430	275,888	282,750	256,241
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	238,056	215,668	221,104	200,354
Series D One Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	350,127	251,435	257,773	151,766
Series D Two Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	124,470	112,737	114,400	95,682
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	85	57	58	56
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	190	137	171	62

Nature of business, basis of 52

Nature of business, basis of presentation and summary of significant accounting policies (10K) (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and Cash Equivalents, at Carrying Value	$ 358	$ 641	$ 358	$ 641	$ 775	$ 945	$ 486
Accumulated deficit	(126,082)		(126,082)		(123,199)	(119,184)
Amortization of debt discount and deferred financing costs						44
Depreciation expense					10	15
Patent amortization expense	$ 87	$ 90	$ 260	$ 270	357	365
Marketing expense					$ 46	$ 15
Estimated remaining weighted average useful lives of patents					P3Y
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life					3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life					5 years

Concentrations (10K) (Details)

Concentrations (10K) (Details)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			62.00%	77.00%	73.00%	81.00%
Accounts Receivable [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			38.00%	46.00%	44.00%	47.00%
Accounts Receivable [Member] | Customer Two [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			24.00%			15.00%
Accounts Receivable [Member] | Customer Three [Member]
Concentration Risk [Line Items]
Concentration risk, percentage					19.00%	19.00%
Accounts Receivable [Member] | Customer Four [Member]
Concentration Risk [Line Items]
Concentration risk, percentage				12.00%
Accounts Receivable [Member] | Customer Five [Member]
Concentration Risk [Line Items]
Concentration risk, percentage				19.00%
Accounts Receivable [Member] | Customer Eight [Member]
Concentration Risk [Line Items]
Concentration risk, percentage					10.00%
Sales Revenue, Services, Net [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	27.00%	39.00%	45.00%	35.00%	35.00%	63.00%
Sales Revenue, Services, Net [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		17.00%	12.00%	11.00%		15.00%
Sales Revenue, Services, Net [Member] | Customer Two [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	17.00%					10.00%
Sales Revenue, Services, Net [Member] | Customer Three [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%	12.00%		10.00%	12.00%	16.00%
Sales Revenue, Services, Net [Member] | Customer Four [Member]
Concentration Risk [Line Items]
Concentration risk, percentage						10.00%
Sales Revenue, Services, Net [Member] | Customer Five [Member]
Concentration Risk [Line Items]
Concentration risk, percentage						12.00%
Sales Revenue, Services, Net [Member] | Customer Six [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		10.00%	16.00%		12.00%
Sales Revenue, Services, Net [Member] | Customer Seven [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			17.00%	14.00%	11.00%

Concentrations (10K) (Details 1

Concentrations (10K) (Details 1)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Concentration Risk [Line Items]
Concentration risk, percentage of total sales	100.00%	100.00%
Domestic Destination [Member] | Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage of total sales	99.00%	98.00%
Export Sales [Member] | Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage of total sales	1.00%	2.00%

Property, plant and equipment55

Property, plant and equipment (10K) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross		$ 2,083	$ 2,079
Less accumulated depreciation and amortization		(2,072)	(2,062)
Property, Plant and Equipment, Net	$ 17	11	17
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross		1,235	1,231
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross		435	435
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross		90	90
Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross		$ 323	$ 323

Intangible Assets (10K) (Detail

Intangible Assets (10K) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Amortizable intangible assets
Finite-lived intangible assets, gross	$ 6,745	$ 6,745
Finite-Lived intangible assets, accumulated amortization	(6,072)	(5,812)	$ (5,455)
Finite-lived intangible assets, net	$ 673	933	1,290
Technology [Member]
Amortizable intangible assets
Finite-lived intangible assets, gross		$ 6,745	$ 6,745

Chinese Joint Venture (Non-Co57

Chinese Joint Venture (Non-Controlling Interest) (10K) (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Noncontrolling Interest [Line Items]
Revenues	$ 351	$ 285	$ 1,164	$ 1,059	$ 1,515	$ 1,418
Joint Venture with Jiangsu Hongtu Electronics Group [Member]
Noncontrolling Interest [Line Items]
Ownership percentage					90.00%	90.00%
Revenues					$ 0	$ 0
Long-lived assets					$ 0	$ 0

Other accrued liabilities (1058

Other accrued liabilities (10K) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Accrued Liabilities, Current [Abstract]
Accrued professional services		$ 8	$ 8
Rents		44	35
Management fees		280	180
Other		6	9
Total	$ 477	$ 338	$ 232

Short-term notes payable (10K59

Short-term notes payable (10K) (Details) - Demand Notes [Member] - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2013	Dec. 17, 2013	Dec. 13, 2013	Nov. 06, 2013	Nov. 01, 2013	Sep. 27, 2013	Sep. 03, 2013	Apr. 18, 2013
Short-term Debt [Line Items]
Note Amount	$ 1,150
Phoenix Banne Holding LLC [Member]
Short-term Debt [Line Items]
Note Amount								$ 250
Michael W Engmann [Member]
Short-term Debt [Line Items]
Note Amount			$ 150			$ 250
Warrants			4	3
Kendu Partners Company [Member]
Short-term Debt [Line Items]
Note Amount							$ 250
Warrants				3
Jag Multi Investments [Member]
Short-term Debt [Line Items]
Note Amount					$ 125
Warrants					2
Philip Sassower [Member]
Short-term Debt [Line Items]
Note Amount		$ 125
Warrants		2

Short-term notes payable (10K60

Short-term notes payable (10K) (Details 1) - $ / shares	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Volatility	205.30%	205.30%
Risk-free interest rate	1.78%	1.78%
Dividend yield	$ 0	$ 0
Demand Notes Warrants Group One [Member]
Class of Warrant or Right [Line Items]
Issue date	Nov. 6, 2013
Expected term	3 years
Volatility	202.90%
Risk-free interest rate	0.58%
Dividend yield	$ 0
Demand Notes Warrants Group Two [Member]
Class of Warrant or Right [Line Items]
Issue date	Nov. 26, 2013
Expected term	3 years
Volatility	200.80%
Risk-free interest rate	0.55%
Dividend yield	$ 0
Demand Notes Warrants Group Three [Member]
Class of Warrant or Right [Line Items]
Issue date	Dec. 3, 2013
Expected term	3 years
Volatility	198.80%
Risk-free interest rate	0.68%
Dividend yield	$ 0
Demand Notes Warrants Group Four [Member]
Class of Warrant or Right [Line Items]
Issue date	Dec. 17, 2013
Expected term	3 years
Volatility	198.00%
Risk-free interest rate	0.68%
Dividend yield	$ 0

Short-term notes payable (10K61

Short-term notes payable (10K) (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended			9 Months Ended	12 Months Ended
	Feb. 28, 2015	May. 31, 2013	Nov. 30, 2012	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2014	Nov. 20, 2013	Apr. 18, 2013	Dec. 31, 2012
Short-term notes payable [Abstract]
Amortization of debt discount and deferred financing costs						$ 44
Loss on extinguishment of debt						67
Short-term Debt [Line Items]
Interest Paid				$ 3	$ 1	$ 1
Debt Instrument, Interest Rate, Stated Percentage				10.00%
Warrants Weighted Average Exercise Price				$ 33	$ 35.500	$ 36.125	$ 35.75			$ 33.625
Number of common shares callable by warrants						3
Venture Champion Asia Limited [Member]
Short-term Debt [Line Items]
Line of cerdit, initiation day	May 6, 2014				May 6, 2014
Line of credit facility, description					Credit Agreement
Line of credit facility, unsecured indebtedness, current amount	$ 2,000				$ 2,000
Line of credit facility, unsecured indebtedness, maximum amount					$ 2,352
Line of credit facility period					18 months
Conversion price					$ 34.375
Original issue discount, percentage					15.00%
Number of common shares callable by warrants					9
Warrant coverage, maximum percentage					50.00%
Credit agreement termination date	Feb. 23, 2015				Feb. 23, 2015
Demand Notes Warrants [Member]
Short-term Debt [Line Items]
Class Of Warrant Or Right Number Of Warrants Or Rights Issued						17
Warrants Weighted Average Exercise Price						$ 37.50
Fair value assumptions for warrants pricing, expected term						3 years
Interest Expense [Member] | Demand Notes Warrants [Member]
Short-term Debt [Line Items]
Class Of Warrant Or Right Number Of Warrants Or Rights Issued						12
Fair value of warrants issued, initial						$ 406
Debt Discount [Member] | Demand Notes Warrants [Member]
Short-term Debt [Line Items]
Class Of Warrant Or Right Number Of Warrants Or Rights Issued						7,084
Fair value of warrants issued, initial						$ 111
Series D One Preferred Stock [Member]
Short-term Debt [Line Items]
Conversion price				0.0225	$ 0.0225
Series D Two Preferred Stock [Member]
Short-term Debt [Line Items]
Conversion price				$ 0.0500	0.0500
Credit Agreement Warrant [Member] | Venture Champion Asia Limited [Member]
Short-term Debt [Line Items]
Warrants Weighted Average Exercise Price					$ 34.375
Fair value assumptions for warrants pricing, expected term					3 years
Number of common shares callable by warrants	9				1
Fair value of warrants booked as interest expense at period end					$ 258
Demand Notes [Member]
Short-term Debt [Line Items]
Short-term Debt						$ 1,150
Debt Instrument, Interest Rate, Stated Percentage						10.00%
Demand Notes [Member] | Phoenix Banne Holding LLC [Member]
Short-term Debt [Line Items]
Short-term Debt									$ 250
Repayments of Notes Payable		$ 250
Interest Paid		$ 2
Debt Instrument, Interest Rate, Stated Percentage									10.00%
Demand Notes [Member] | Company Employee [Member]
Short-term Debt [Line Items]
Short-term Debt								$ 60
Repayments of Notes Payable			$ 60
Interest Paid			$ 1

Derivative liability (10K) (Det

Derivative liability (10K) (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Class of Warrant or Right [Line Items]
Number of warrants issued	32,000	100,000	123,000	42,000
Exercise price	$ 33	$ 35.75	$ 35.500	$ 36.125	$ 33.625
Risk-free interest rate			1.78%	1.78%
Volatility			205.30%	205.30%
Fair value of the derivative liability			$ 18	$ 25
Bridge Financing Warrants [Member] | April Two Thousand Twelve Note And Warrant Purchase Agreement [Member]
Class of Warrant or Right [Line Items]
Issue date			Apr. 23, 2012
Reason for Issuance			Bridge financing warrants
Number of warrants issued			4,000
Exercise price			$ 62.50
Risk-free interest rate			1.78%
Volatility			205.30%
Fair value of the derivative liability			$ 50
Finders Fee Warrants [Member] | April Two Thousand Twelve Note And Warrant Purchase Agreement [Member]
Class of Warrant or Right [Line Items]
Issue date			Apr. 23, 2012
Reason for Issuance			Finder's fee warrants
Number of warrants issued			279.2
Exercise price			$ 62.50
Risk-free interest rate			1.78%
Volatility			205.30%
Fair value of the derivative liability			$ 0
Finders Fee Warrants [Member] | November 2012 Note And Warrant Purchase Agreement [Member]
Class of Warrant or Right [Line Items]
Issue date			Nov. 15, 2012
Reason for Issuance			Finder's fee warrants
Number of warrants issued			235.2
Exercise price			$ 62.50
Risk-free interest rate			1.78%
Volatility			202.20%
Fair value of the derivative liability			$ 0
Administrative Fee Warrants [Member] | November 2012 Note And Warrant Purchase Agreement [Member]
Class of Warrant or Right [Line Items]
Issue date			Nov. 15, 2012
Reason for Issuance			Administrative fee warrants
Number of warrants issued			2,400
Exercise price			$ 62.50
Risk-free interest rate			1.78%
Volatility			202.20%
Fair value of the derivative liability			$ 8

Derivative liability (10K) (D63

Derivative liability (10K) (Details 1) $ in Thousands	12 Months Ended
	Dec. 31, 2014USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period	$ 25
Gain on derivative liability	(7)
Balance at end of period	$ 18

Derivative liability (10K) (D64

Derivative liability (10K) (Details 2) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Liabilities measured at fair value
Derivative liability	$ 18	$ 25
Fair Value, Inputs, Level 1 [Member]
Liabilities measured at fair value
Derivative liability
Fair Value, Inputs, Level 2 [Member]
Liabilities measured at fair value
Derivative liability
Fair Value, Inputs, Level 3 [Member]
Liabilities measured at fair value
Derivative liability	$ 18

Derivative Liability (10K) (D65

Derivative Liability (10K) (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Derivative Liability, Fair Value, Net [Abstract]
Fair value of the derivative liability	$ 18	$ 25

Stockholders' Equity (10K) (Det

Stockholders' Equity (10K) (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option term	4 years 4 months 20 days
Options outstanding	85,000	58,000	57,000	56,000	36,000
Excercisable stock options	56,000	46,000	44,000	35,000
Weighted average exercise price	$ 50	$ 50	$ 62.50	$ 62.50	$ 62.50
1999 Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance		4,000,000
Option vesting period		Quarterly over 3 years
Date adopted by stockholders		June 1, 2009
Option term		7 years
Options outstanding		20
Excercisable stock options		20
Weighted average exercise price		$ 250
2009 Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance		7,000,000
Option vesting period		Quarterly over 3 years
Option term		7 years
Options outstanding		340
Excercisable stock options		340
Weighted average exercise price		$ 131.25
2011 Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance		150,000,000
Option vesting period		Immediate/Quarterly over 3 years
Date adopted by stockholders		November 1, 2011
Option term		7 years
Options outstanding		57,000
Excercisable stock options		45,000
Weighted average exercise price		$ 57.50
Individual Stock Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option vesting period		Quarterly over 3 years
Option term		7 years
Options outstanding		100
Excercisable stock options		100
Weighted average exercise price		$ 187.50

Stockholders' Equity (10K) (D67

Stockholders' Equity (10K) (Details1) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]
Risk-free interest rate, minimum			0.04%	0.04%	0.04%	0.40%
Risk-free interest rate, maximum			3.28%	3.73%	3.73%	4.92%
Expected volatility, minimum			120.74%	93.63%	91.99%	91.99%
Expected volatility, maximum			198.38%	198.38%	198.38%	198.38%
Expected dividend yield			$ 0	$ 0	$ 0	$ 0
Estimated average forfeiture rate	7.89%	9.75%			10.00%	10.00%
Minimum [Member]
Fair value assumptions, stock options
Expected life			3 years 3 months 4 days	2 years 9 months 25 days	3 years 3 months 4 days	2 years 9 months 25 days
Maximum [Member]
Fair value assumptions, stock options
Expected life			6 years 3 months 29 days	7 years	7 years	7 years

Stockholders' Equity (10K) (D68

Stockholders' Equity (10K) (Details 2) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 116	$ 65	$ 487	$ 242	$ 298	$ 819
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	35	16	148	64	77	262
Selling and Marketing Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	26	17	112	54	72	100
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	47	29	192	112	134	410
Director Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 8	$ 3	$ 35	$ 12	$ 15	$ 47

Stockholders' Equity (10K) (D69

Stockholders' Equity (10K) (Details 3) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Summary of stock options outstanding
Stock Options Outstanding, Beginning Balance			58,000	56,000	56,000	36,000
Stock Options, Granted			29,000	2,000	3,600	21,000
Stock Options, Exercised
Stock Options, Forfeited, or expired			(2,000)	(1,000)	(2,000)	(1,000)
Stock Options Outstanding, Ending Balance	85,000	57,000	85,000	57,000	58,000	56,000
Stock Options, Vested and expected to vest at ending balance	83,000	51,000	83,000	51,000
Options exercisable	56,000	44,000	56,000	44,000	46,000	35,000
Weighted Average Exercise Price, Beginning Period			$ 50	$ 62.50	$ 62.50	$ 62.50
Weighted Average Exercise Price, Granted			25	37.50	25	50
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited, or expired			37.50	62.50	137.50	137.50
Weighted Average Exercise Price, Ending Period	$ 50	$ 62.50	50	62.50	50	62.50
Weighted Average Exercise Price, Vested and expected to vest at ending balance	37.50	62.50	37.50	62.50
Weighted Average Exercise Price, Exercisable at ending balance	$ 50	$ 62.50	$ 50	$ 62.50	$ 62.50	$ 62.50	$ 62.50
Weighted Average Remaining Contractual Term, ending balance			4 years 4 months 20 days	4 years 3 months 18 days	4 years 2 months 5 days	5 years 7 days
Weighted Average Remaining Contractual Term, vested and expected to vest at ending balance			3 years 2 months 16 days	4 years 3 months 18 days
Weighted Average Remaining Contractual Term, excercisable at ending balance			3 years 6 months 11 days	3 years 11 months 23 days	3 years 10 months 10 days	4 years 7 months 10 days
Aggregate Intrinsic Value, Beginning Balance
Aggregate Intrinsic Value, Granted					$ 27
Aggregate Intrinsic Value, Exercised
Aggregate Intrinsic Value, Forfeited or expired
Aggregate Intrinsic Value, Ending Balance
Aggregate Intrinsic Value, Vested and expected to vest at ending balance
Aggregate Intrinsic Value, Exercisable at ending balance					$ 7
Weighted average grant date fair value of options granted during period					$ 25	$ 50

Stockholders' Equity (10K) (D70

Stockholders' Equity (10K) (Details 4) - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Number of Outstanding Options	85
Outstanding Options, Weighted Average Remaining Contractual Term	4 years 4 months 20 days
Outstanding Options, Weighted Average Exercise Price	$ 28		$ 34.125
Exercise Price Range, Number of Exercisable Options	56
Exercisable Options, Weighted Average Exercise Price	$ 50
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, Lower Range Limit	12.50	$ 0
Exercise Price Range, Upper Range Limit	$ 25	$ 625
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Number of Outstanding Options	2	58
Outstanding Options, Weighted Average Remaining Contractual Term	6 years 2 months 23 days	4 years 2 months 5 days
Outstanding Options, Weighted Average Exercise Price	$ 25	$ 50
Exercise Price Range, Number of Exercisable Options	1	46
Exercisable Options, Weighted Average Exercise Price	$ 25	$ 62.50

Stockholders' Equity (10K) (D71

Stockholders' Equity (10K) (Details 5) - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Equity Instruments, Options, Nonvested Shares Roll-Forward
Non-vested shares, Beginning Balance	12	21
Non-vested shares, Granted	29	4
Non-vested shares, Forfeited, or expired	(1)	(1)
Non-vested shares, vested	(11)	(12)
Stock Options Outstanding, Ending Balance	29	12
Weighted Average Grant Date Fair Value, Options Nonvested at beginning of period	$ 50	$ 50
Weighted Average Grant Date Fair Value, Options nonvested, grants in period	25	50
Weighted Average Grant Date Fair Value, Options nonvested, forfeited in period	25	37.50
Weighted Average Grant Date Fair Value, Options nonvested, vested in period	37.50	50
Weighted Average Grant Date Fair Value, Options nonvested at end of period	$ 25	$ 50

Stockholders' Equity (10K) (D72

Stockholders' Equity (10K) (Details 6) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Annual Dividend	0.00%
Common Shares to be Issued if Fully Converted			706,000
Series A Preferred Stock [Member]
Issue Date			May 1, 2008
Annual Dividend		8.00%	8.00%
Annual Dividend Payable, in Cash or In Kind		Quarterly in Arrears	Quarterly in Arrears
Liquidation preference	$ 1	$ 1	$ 1,000
Conversion price	$ 0.1400	$ 0.1400	$ 0.1400
Total Preferred Shares Outstanding	929,000	929,000	875,000	1,031,000
Common Shares to be Issued if Fully Converted	5,000	5,000	5,000
Series B Preferred Stock [Member]
Issue Date			August 1, 2010
Annual Dividend		10.00%	10.00%
Annual Dividend Payable, in Cash or In Kind		Quarterly in Arrears	Quarterly in Arrears
Liquidation preference	$ 1.50	$ 1.50	$ 1,500
Conversion price	$ 0.0433	$ 0.0433	$ 0.0433
Total Preferred Shares Outstanding	13,191,000	13,191,000	12,251,000	11,102,000
Common Shares to be Issued if Fully Converted	244,000	244,000	226,000
Series C Preferred Stock [Member]
Issue Date			December/March 2011
Annual Dividend		10.00%	10.00%
Annual Dividend Payable, in Cash or In Kind		Quarterly in Arrears	Quarterly in Arrears
Liquidation preference	$ 1.50	$ 1.50	$ 1,500
Conversion price	$ 0.0225	$ 0.0225	$ 0.0225
Total Preferred Shares Outstanding	5,356,000	5,356,000	4,975,000	4,508,000
Common Shares to be Issued if Fully Converted	190,000	190,000	177,000
Series D One Preferred Stock [Member]
Issue Date			November 2012/May and December 2013
Annual Dividend		10.00%	10.00%
Annual Dividend Payable, in Cash or In Kind		Quarterly in Arrears	Quarterly in Arrears
Liquidation preference	$ 1	$ 1	$ 1,000
Conversion price	$ 0.0225	$ 0.0225	$ 0.0225
Total Preferred Shares Outstanding	7,878,000	7,878,000	5,800,000	3,415,000
Common Shares to be Issued if Fully Converted	280,000	280,000	206,000
Series D Two Preferred Stock [Member]
Issue Date			November 2012/May and December 2013
Annual Dividend		10.00%	10.00%
Annual Dividend Payable, in Cash or In Kind		Quarterly in Arrears	Quarterly in Arrears
Liquidation preference	$ 1	$ 1	$ 1,000
Conversion price	$ 0.0500	$ 0.0500	$ 0.0500
Total Preferred Shares Outstanding	6,223,000	6,223,000	5,720,000	4,783,000
Common Shares to be Issued if Fully Converted	100,000	100,000	92,000

Stockholders' Equity (10K) (D73

Stockholders' Equity (10K) (Details 7) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Dividends Net of Beneficial Conversion Feature	$ 819	$ 708	$ 2,335	$ 1,989	$ 2,712	$ 2,088
Accretion of beneficial conversion feature related to dividends		171	29	265	347	250
Series A Preferred Stock [Member]
Dividends Net of Beneficial Conversion Feature	18	22	53	63	82	78
Series B Preferred Stock [Member]
Dividends Net of Beneficial Conversion Feature	324	294	939	852	1,149	1,044
Series C Preferred Stock [Member]
Dividends Net of Beneficial Conversion Feature	132	119	382	345	468	433
Accretion of beneficial conversion feature related to dividends		64	13	114	152	191
Series D One Preferred Stock [Member]
Dividends Net of Beneficial Conversion Feature	192	128	516	329	472	131
Accretion of beneficial conversion feature related to dividends		107	16	151	195	59
Series D Two Preferred Stock [Member]
Dividends Net of Beneficial Conversion Feature	$ 153	$ 145	$ 445	$ 400	$ 541	$ 402
Accretion of beneficial conversion feature related to dividends

Stockholders' Equity (10K) (D74

Stockholders' Equity (10K) (Details 8) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Warrants		10
Common shares issued		3
Cash Received		$ 29
Warrants Group One [Member]
Class of Warrant or Right [Line Items]
Warrants		1
Common shares issued		1
Cash Received		$ 29
Warrants Group Two [Member]
Class of Warrant or Right [Line Items]
Warrants		9
Common shares issued		2
Cash Received

Stockholders' Equity (10K) (D75

Stockholders' Equity (10K) (Details 9) - shares shares in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Warrants issued in connection with Notes				18
Warrants issued with purchase of Series D Preferred			17	16
Warrants issued in the Series D Preferred exchange				8
Warrants issued with line of credit			9
Contingent Warrants issued			97
Number of warrants issued	32	100	123	42
Related Party [Member]
Class of Warrant or Right [Line Items]
Warrants issued in connection with Notes				16
Warrants issued with purchase of Series D Preferred			5	8
Warrants issued in the Series D Preferred exchange				2
Contingent Warrants issued			27
Number of warrants issued			32	26
Other Holders [Member]
Class of Warrant or Right [Line Items]
Warrants issued in connection with Notes				2
Warrants issued with purchase of Series D Preferred			12	8
Warrants issued in the Series D Preferred exchange				6
Warrants issued with line of credit			9
Contingent Warrants issued			70
Number of warrants issued			91	16

Stockholders' Equity (10K) (D76

Stockholders' Equity (10K) (Details 10) shares in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2015$ / sharesshares	Sep. 30, 2014$ / sharesshares	Dec. 31, 2014$ / sharesshares	Dec. 31, 2013$ / sharesshares
Class Of Warrant Or Right Number Of Warrants Or Rights Roll Forward
Number of Warrants Outstanding at beginning of period | shares	171	62	62	121
Number of warrants issued | shares	32	100	123	42
Number Of Warrants Or Rights Exercised | shares				(10)
Number Of Warrants Or Rights Expired | shares	(13)	(22)	(14)	(91)
Number of Warrants Outstanding at end of period | shares	190	139	171	62
Number of Warrants Or Rights Exercisable at end of period | shares	190	139	171	62
Excercise Price of Warrants Outstanding at beginning of period | $ / shares	$ 35.500	$ 36.125	$ 36.125	$ 33.625
Exercise Price Of Warrants Issued | $ / shares	24.125	34.375	34.375	33.375
Exercise Price Of Warrants Exercised | $ / shares				28.125
Exercise Price Of Warrants Expired | $ / shares	62.500	28.125	28.125	28.750
Excercise Price of Warrants Outstanding at end of period | $ / shares	$ 33	$ 35.75	$ 35.500	$ 36.125
Exercise Price Of WarrantsExercisable at end of period | $ / shares	33	35.75	35.50	36.125

Stockholders' Equity (10K) (D77

Stockholders' Equity (10K) (Details 11) - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding and Excercisable	190	171	139	62	121
Weighted Average Remaining Life Of Warrants Or Rights	1 year 5 months 23 days	1 year 10 months 20 days
Warrants Weighted Average Exercise Price	$ 33	$ 35.500	$ 35.75	$ 36.125	$ 33.625
Warrants Group One [Member]
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding and Excercisable	22	7
Weighted Average Remaining Life Of Warrants Or Rights	2 years 6 months 7 days	1 year 11 months 12 days
Warrants Weighted Average Exercise Price	$ 28.125	$ 34.375
Warrants Group Two [Member]
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding and Excercisable	155	164
Weighted Average Remaining Life Of Warrants Or Rights	1 year 3 months 4 days	6 months 7 days
Warrants Weighted Average Exercise Price	$ 34.375	$ 62.500
Warrants Group Three [Member]
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding and Excercisable	3
Weighted Average Remaining Life Of Warrants Or Rights	1 month 17 days
Warrants Weighted Average Exercise Price	$ 62.50

Stockholders' Equity (10K) (D78

Stockholders' Equity (10K) (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Share-based Arrangements with Employees and Nonemployees [Abstract]
Stock Options, Granted		29,000	2,000	3,600	21,000
Weighted average grant date fair value of options granted during period				$ 25	$ 50
Stock Options, Exercised
Total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans	$ 363	$ 363		$ 236
Unrecognized compensation expense amortization period	3 years 2 months 12 days			2 years
Common stock reserved upon issuance of outstanding options					$ 58
Fair value under the cost method of Common Stock received as settlement of 16b claim				$ 325
Treasury Stock, Value	$ 325	$ 325		$ 325	$ 325
Treasury Stock, Shares				5,000	5,000

Stockholders' Equity (10K) (D79

Stockholders' Equity (10K) (Details Textual 1) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended										9 Months Ended		12 Months Ended
	Jul. 31, 2015	Mar. 31, 2015	Nov. 30, 2014	Aug. 31, 2014	Mar. 31, 2014	Feb. 28, 2014	Dec. 31, 2013	Nov. 30, 2013	May. 31, 2013	Jan. 31, 2012	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Jul. 23, 2015	Aug. 05, 2014	Mar. 06, 2014	Feb. 07, 2014	Dec. 31, 2012
Subsidiary, Sale of Stock [Line Items]
Stock Issued During Period, Value, New Issues													$ 29	$ 29
Number of common shares, reserved for issuance upon exercise of outstanding warrants													213,521,000
Debt Instrument, Convertible, Beneficial Conversion Feature											$ 498	$ 337
Treasury Stock, Value							$ 325				$ 325		$ 325	$ 325
Treasury Stock, Shares							5,000						5,000	5,000
Warrants Weighted Average Exercise Price							$ 36.125				$ 33	$ 35.75	$ 35.500	$ 36.125					$ 33.625
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							3,000							3,000
Series A Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Common shares issued in connection with the conversion of preferred shares, shares													(238,000)
Series D Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from sale of stock, net	$ 325	$ 1,200			$ 406	$ 733
Administrative fees paid in cash	$ 4	$ 33			$ 4	$ 47
Warrant coverage, maximum percentage					100.00%	100.00%
Warrants Weighted Average Exercise Price		$ 28.125													$ 15.625
Class Of Warrant Or Right Expiration Date Of Warrants Or Rights	Jul. 22, 2018	Mar. 23, 2018			Dec. 31, 2016	Dec. 31, 2016
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		22,000													11,000
Series D One Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	329,000	1,233,000			273,000	520,000
Debt Instrument, Convertible, Beneficial Conversion Feature													$ 253	$ 958
Series D Two Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of Stock, Number of Shares Issued in Transaction					137,000	260,000
Debt Instrument, Convertible, Beneficial Conversion Feature													$ 52	39
Settlement of the Indemnification Claim [Member] | Series C Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of Stock, Number of Shares Issued in Transaction										278,000
Stock Issued During Period, Value, New Issues										$ 417
Treasury Stock, Value										$ 325
Treasury Stock, Shares										5,000
Private Placement [Member] | Series D Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from sale of stock, net				$ 1,070	$ 406	$ 733	$ 870		$ 1,150
Preferred Units, Issued									230,000
Administrative fees paid in cash				$ 50	$ 4	$ 47	40
Fair value of contingent warrants							1,618							$ 1,618
Debt Instrument, Convertible, Beneficial Conversion Feature							$ 411
Warrant coverage, maximum percentage				100.00%	100.00%	100.00%	100.00%
Warrants Weighted Average Exercise Price																	$ 34.375	$ 34.375
Excercise period of warrants or rights				immediately	immediately	immediately	immediately
Warrants, expiration period				3 years			3 years
Class Of Warrant Or Right Expiration Date Of Warrants Or Rights					Dec. 31, 2016	Dec. 31, 2016
Private Placement [Member] | Series D Preferred Stock [Member] | Administrative Fee Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																2,000
Private Placement [Member] | Series D Preferred Stock [Member] | Finders Fee Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																1,000
Private Placement [Member] | Series D One Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of Stock, Number of Shares Issued in Transaction				1,120,000	273,000	520,000	607,000
Stock exchanged during period							537,000
Preferred Units, Components									1
Private Placement [Member] | Series D Two Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of Stock, Number of Shares Issued in Transaction					137,000	260,000	303,000
Preferred Units, Components									4
Debt Conversion [Member] | Series D Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion of short-term debt and accrued interest, net of offering costs							$ 1,179
Number of contingent warrants							97,000
Warrant coverage, maximum percentage							100.00%
Excercise period of warrants or rights							immediately
Warrants, expiration period							3 years
Debt Conversion [Member] | Series D One Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued in debt conversion							786,000
Debt Conversion [Member] | Series D Two Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued in debt conversion							393,000
Stock Conversion [Member] | Series A Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock converted into common shares during period, shares			238,000
Common shares issued in connection with the conversion of preferred shares, shares			1,000
Stock Conversion [Member] | Series C Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock converted into common shares during period, shares				40				100,000
Common shares issued in connection with the conversion of preferred shares, shares				4,000				4,000

Stockholders' Equity (10K) (D80

Stockholders' Equity (10K) (Details Textual 2) - shares	Dec. 31, 2014	Dec. 31, 2013
Series D-1 Preferred Stock [Member]
Preferred Stock, Shares Authorized	10,000,000	6,000,000
Series D-2 Preferred Stock [Member]
Preferred Stock, Shares Authorized	10,000,000	9,000,000

Commitments and Contingencies81

Commitments and Contingencies (10K) (Details) $ in Thousands	Dec. 31, 2014USD ($)
Contractual Obligations, payments due by period
Contractual obligations, operating lease commitments due in 2015	$ 293
Contractual obligations, operating lease commitments due in 2016	$ 250
Contractual obligations, operating lease commitments due thereafter
Contractual obligations, short-term notes payable	$ 543

Commitments and Contingencies82

Commitments and Contingencies (10K) (Details Textuals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Facilities rent expense	$ 289	$ 275

Income Taxes (10K) (Details)

Income Taxes (10K) (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Deferred Tax Assets, Gross [Abstract]
Net operating loss carry-forwards	$ 23,114	$ 27,266
Credit carry-forwards		137
Accruals and reserves	$ 141
Deferred revenue	382	224
Intangibles	$ 273	1,046
Other, net		$ 373
Fixed Assets	$ 894
Gross tax assets	24,804	$ 29,046
Valuation allowance	$ (24,804)	$ (29,046)
Net deferred tax assets

Income Taxes (10K) (Details 1)

Income Taxes (10K) (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]
Income tax (benefit) at the federal statutory rate	$ (1,364)	$ (2,668)
State income tax benefit	$ (233)	$ (458)
Credits
Prior year true up to return	$ 5,758	$ 1,416
Permanent items and other	81	1,391
Change in valuation allowance	$ (4,242)	$ 319
Income tax expense

Income Taxes (10K) (Details Tex

Income Taxes (10K) (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2014USD ($)
Income Tax Disclosure [Abstract]
Federal net operating loss carry-forward	$ 61,735
State net operating loss carry-forward	$ 36,411
Federal operating loss carryforwards expiration year	2,017
State operating loss carryforwards expiration year	2,025
Circumstances, under which the amounts of, and the benefit from, net operatin losses and tax credit carry-forwards may be impared or limited	Under the Tax Reform Act of 1986, the amounts of, and the benefit from, net operating losses and tax credit carry-forwards may be impaired or limited in certain circumstances. These circumstances include, but are not limited to, a cumulative stock ownership change of greater than 50%, as defined, over a three-year period. During 1997, the Company experienced stock ownership changes which could limit the utilization of its net operating loss and research and investment tax credit carry-forwards in future periods. In addition, a study of recent transactions has not been performed to determine whether any further limitations might apply.

Subsequent Event (10K) (Details

Subsequent Event (10K) (Details Textual) - USD ($)

Jan. 21, 2016

Jan. 20, 2016

Dec. 17, 2015

Dec. 15, 2015

Nov. 25, 2015

Mar. 31, 2015

Feb. 28, 2015

Sep. 30, 2015

Mar. 24, 2015

Dec. 31, 2014

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Subsequent Event [Line Items]

Number of common shares callable by warrants

3,000

Warrants Weighted Average Exercise Price

$ 33

$ 35.500

$ 35.75

$ 36.125

$ 33.625

Subsequent Event [Member]

Subsequent Event [Line Items]

Subsequent Event, Date

Mar. 24, 2015

Feb. 23, 2015

Subsequent Event, Description

the Company entered into subscription agreements with certain investors

the Company and the Lender mutually agreed to terminate the Credit Agreement

Preferred Units, Issued

1,233,000

Share Price

$ 1

Aggregate purchase price

$ 1,233,000

Preferred Units, Description

Each Unit consists of one (1) share of the Company Series D-1 Preferred Stock and one (1) warrant to purchase 22.22 shares of the Company Common Stock

Number of common shares callable by warrants

22,000

Subsequent Event [Member] | Common Stock Warrants [Member]

Subsequent Event [Line Items]

Preferred Units, Components

1

Warrants Weighted Average Exercise Price

$ 28.1250

Exercise period of warrants

3 years

Subsequent Event [Member] | Unsecured Convertible Promissory Notes [Member]

Subsequent Event [Line Items]

Convertible promissory notes aggregate principal amount

$ 268,000

$ 1,000,000

Consideration of gross cash proceeds

750,000

Exchange of demand note

$ 250,000

Convertible promissory notes interest rate percentage

24.00%

Conversion price percentage

30.00%

Common stock public offering term after maturity period of convertible notes

60 days

Amount of pre-money valuation base for conversion price

$ 5,000,000

Cash payment percentage to each note holder upon conversion

1.50%

Value of notes converted of the revenue actually received

$ 100,000

Subsequent Event [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Reverse stock split range of outstanding common stock

1-for-1,250

Subsequent Event [Member] | Common Stock [Member] | Minimum [Member]

Subsequent Event [Line Items]

Reverse stock split range of outstanding common stock

1-for-750

Common stock sale price (in dollars per share)

$ 4

Gross proceeds to conversion price of each series of preferred stock

$ 8,000,000

Subsequent Event [Member] | Common Stock [Member] | Maximum [Member]

Subsequent Event [Line Items]

Reverse stock split range of outstanding common stock

1-for-1,250

Subsequent Event [Member] | Common Stock [Member] | IPO [Member]

Subsequent Event [Line Items]

Common stock issued under public offering (in shares)

10,000,000

Subsequent Event [Member] | Series D One Preferred Stock [Member]

Subsequent Event [Line Items]

Preferred Units, Components

1

Preferred stock initial conversion price

$ 0.0225

Nature of business, basis of 87

Nature of business, basis of presentation and summary of significant accounting policies (10Q) (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and Cash Equivalents, at Carrying Value	$ 358	$ 775	$ 641	$ 945	$ 486
Accumulated deficit	$ (126,082)	$ (123,199)		$ (119,184)

Concentrations (10Q) (Details)

Concentrations (10Q) (Details)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			62.00%	77.00%	73.00%	81.00%
Accounts Receivable [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			38.00%	46.00%	44.00%	47.00%
Accounts Receivable [Member] | Customer Two [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			24.00%			15.00%
Accounts Receivable [Member] | Customer Three [Member]
Concentration Risk [Line Items]
Concentration risk, percentage					19.00%	19.00%
Accounts Receivable [Member] | Customer Four [Member]
Concentration Risk [Line Items]
Concentration risk, percentage				12.00%
Accounts Receivable [Member] | Customer Five [Member]
Concentration Risk [Line Items]
Concentration risk, percentage				19.00%
Sales Revenue, Services, Net [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	27.00%	39.00%	45.00%	35.00%	35.00%	63.00%
Sales Revenue, Services, Net [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		17.00%	12.00%	11.00%		15.00%
Sales Revenue, Services, Net [Member] | Customer Two [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	17.00%					10.00%
Sales Revenue, Services, Net [Member] | Customer Three [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%	12.00%		10.00%	12.00%	16.00%
Sales Revenue, Services, Net [Member] | Customer Four [Member]
Concentration Risk [Line Items]
Concentration risk, percentage						10.00%
Sales Revenue, Services, Net [Member] | Customer Five [Member]
Concentration Risk [Line Items]
Concentration risk, percentage						12.00%
Sales Revenue, Services, Net [Member] | Customer Six [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		10.00%	16.00%		12.00%
Sales Revenue, Services, Net [Member] | Customer Seven [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			17.00%	14.00%	11.00%

Intangible Assets (10Q) (Detail

Intangible Assets (10Q) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Amortizable intangible assets
Finite-lived intangible assets, gross	$ 6,745	$ 6,745
Finite-Lived intangible assets, accumulated amortization	(6,072)	(5,812)	$ (5,455)
Finite-lived intangible assets, net	$ 673	$ 933	$ 1,290

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
Patent amortization expense	$ 87	$ 90	$ 260	$ 270	$ 357	$ 365
Patents impairment	$ 0	$ 0	$ 0	$ 0

Short-term note payable (10Q) (

Short-term note payable (10Q) (Details Textual) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Short-term notes payable [Abstract]
Aggregate amount of demand note	$ 250
Stated percentage of demand short-term note	10.00%
Issuance Date of demand short-term note	Sep. 29, 2015

Net loss per share (10Q) (Detai

Net loss per share (10Q) (Details) - shares shares in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	6,633	7,818	6,252	7,368
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	304,430	275,888	282,750	256,241
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	238,056	215,668	221,104	200,354
Series D One Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	350,127	251,435	257,773	151,766
Series D Two Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	124,470	112,737	114,400	95,682
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	85	57	58	56
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	190	137	171	62

Equity (10Q) (Details)

Equity (10Q) (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]
Risk-free interest rate, minimum	0.04%	0.04%	0.04%	0.40%
Risk-free interest rate, maximum	3.28%	3.73%	3.73%	4.92%
Expected volatility, minimum	120.74%	93.63%	91.99%	91.99%
Expected volatility, maximum	198.38%	198.38%	198.38%	198.38%
Expected dividend yield	$ 0	$ 0	$ 0	$ 0
Minimum [Member]
Fair value assumptions, stock options
Expected life	3 years 3 months 4 days	2 years 9 months 25 days	3 years 3 months 4 days	2 years 9 months 25 days
Maximum [Member]
Fair value assumptions, stock options
Expected life	6 years 3 months 29 days	7 years	7 years	7 years

Equity (10Q) (Details 1)

Equity (10Q) (Details 1) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 116	$ 65	$ 487	$ 242	$ 298	$ 819
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	35	16	148	64	77	262
Selling and Marketing Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	26	17	112	54	72	100
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	47	29	192	112	134	410
Director Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 8	$ 3	$ 35	$ 12	$ 15	$ 47

Equity (10Q) (Details 2)

Equity (10Q) (Details 2) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Summary of stock options outstanding
Stock Options Outstanding, Beginning Balance			58,000	56,000	56,000	36,000
Stock Options, Granted			29,000	2,000	3,600	21,000
Stock Options, Exercised
Stock Options, Forfeited, or expired			(2,000)	(1,000)	(2,000)	(1,000)
Stock Options Outstanding, Ending Balance	85,000	57,000	85,000	57,000	58,000	56,000
Stock Options, Vested and expected to vest at ending balance	83,000	51,000	83,000	51,000
Options exercisable	56,000	44,000	56,000	44,000	46,000	35,000
Weighted Average Exercise Price, Beginning Period			$ 50	$ 62.50	$ 62.50	$ 62.50
Weighted Average Exercise Price, Granted			25	37.50	25	50
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited, or expired			37.50	62.50	137.50	137.50
Weighted Average Exercise Price, Ending Period	$ 50	$ 62.50	50	62.50	50	62.50
Weighted Average Exercise Price, Vested and expected to vest at ending balance	37.50	62.50	37.50	62.50
Weighted Average Exercise Price, Exercisable at ending balance	$ 50	$ 62.50	$ 50	$ 62.50	$ 62.50	$ 62.50	$ 62.50
Weighted Average Remaining Contractual Term, ending balance			4 years 4 months 20 days	4 years 3 months 18 days	4 years 2 months 5 days	5 years 7 days
Weighted Average Remaining Contractual Term, vested and expected to vest at ending balance			3 years 2 months 16 days	4 years 3 months 18 days
Weighted Average Remaining Contractual Term, excercisable at ending balance			3 years 6 months 11 days	3 years 11 months 23 days	3 years 10 months 10 days	4 years 7 months 10 days
Aggregate Intrinsic Value, Beginning Balance
Aggregate Intrinsic Value, Granted					$ 27
Aggregate Intrinsic Value, Exercised
Aggregate Intrinsic Value, Forfeited or expired
Aggregate Intrinsic Value, Ending Balance
Aggregate Intrinsic Value, Vested and expected to vest at ending balance
Aggregate Intrinsic Value, Exercisable at ending balance					$ 7

Equity (10Q) (Details 3)

Equity (10Q) (Details 3) - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Number of Outstanding Options	85
Outstanding Options, Weighted Average Remaining Contractual Term	4 years 4 months 20 days
Outstanding Options, Weighted Average Exercise Price	$ 28		$ 34.125
Exercise Price Range, Number of Exercisable Options	56
Exercisable Options, Weighted Average Exercise Price	$ 50
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, Lower Range Limit	12.50	$ 0
Exercise Price Range, Upper Range Limit	$ 25	$ 625
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Number of Outstanding Options	2	58
Outstanding Options, Weighted Average Remaining Contractual Term	6 years 2 months 23 days	4 years 2 months 5 days
Outstanding Options, Weighted Average Exercise Price	$ 25	$ 50
Exercise Price Range, Number of Exercisable Options	1	46
Exercisable Options, Weighted Average Exercise Price	$ 25	$ 62.50
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, Lower Range Limit	25
Exercise Price Range, Upper Range Limit	$ 37.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Number of Outstanding Options	43
Outstanding Options, Weighted Average Remaining Contractual Term	5 years 2 months 16 days
Outstanding Options, Weighted Average Exercise Price	$ 25
Exercise Price Range, Number of Exercisable Options	18
Exercisable Options, Weighted Average Exercise Price	$ 25
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, Lower Range Limit	37.50
Exercise Price Range, Upper Range Limit	$ 75
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Number of Outstanding Options	25
Outstanding Options, Weighted Average Remaining Contractual Term	4 years 22 days
Outstanding Options, Weighted Average Exercise Price	$ 62.50
Exercise Price Range, Number of Exercisable Options	22
Exercisable Options, Weighted Average Exercise Price	$ 62.50
Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, Lower Range Limit	75
Exercise Price Range, Upper Range Limit	$ 250
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Number of Outstanding Options	15
Outstanding Options, Weighted Average Remaining Contractual Term	2 years 3 months 25 days
Outstanding Options, Weighted Average Exercise Price	$ 87.50
Exercise Price Range, Number of Exercisable Options	15
Exercisable Options, Weighted Average Exercise Price	$ 87.50

Equity (10Q) (Details 4)

Equity (10Q) (Details 4) - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Equity Instruments, Options, Nonvested Shares Roll-Forward
Non-vested shares, Beginning Balance	12	21
Non-vested shares, Granted	29	4
Non-vested shares, Forfeited, or expired	(1)	(1)
Non-vested shares, vested	(11)	(12)
Stock Options Outstanding, Ending Balance	29	12
Weighted Average Grant Date Fair Value, Options Nonvested at beginning of period	$ 50	$ 50
Weighted Average Grant Date Fair Value, Options nonvested, grants in period	25	50
Weighted Average Grant Date Fair Value, Options nonvested, forfeited in period	25	37.50
Weighted Average Grant Date Fair Value, Options nonvested, vested in period	37.50	50
Weighted Average Grant Date Fair Value, Options nonvested at end of period	$ 25	$ 50

Equity (10Q) (Details 5)

Equity (10Q) (Details 5) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Annual Dividend	0.00%
Common Shares to be Issued if Fully Converted			706,000
Series A Preferred Stock [Member]
Annual Dividend		8.00%	8.00%
Annual Dividend Payable, in Cash or In Kind		Quarterly in Arrears	Quarterly in Arrears
Per Share Liquidation preference	$ 1	$ 1	$ 1,000
Conversion price	$ 0.1400	$ 0.1400	$ 0.1400
Total Preferred Shares Outstanding	929,000	929,000	875,000	1,031,000
Common Shares to be Issued if Fully Converted	5,000	5,000	5,000
Series B Preferred Stock [Member]
Annual Dividend		10.00%	10.00%
Annual Dividend Payable, in Cash or In Kind		Quarterly in Arrears	Quarterly in Arrears
Per Share Liquidation preference	$ 1.50	$ 1.50	$ 1,500
Conversion price	$ 0.0433	$ 0.0433	$ 0.0433
Total Preferred Shares Outstanding	13,191,000	13,191,000	12,251,000	11,102,000
Common Shares to be Issued if Fully Converted	244,000	244,000	226,000
Series C Preferred Stock [Member]
Annual Dividend		10.00%	10.00%
Annual Dividend Payable, in Cash or In Kind		Quarterly in Arrears	Quarterly in Arrears
Per Share Liquidation preference	$ 1.50	$ 1.50	$ 1,500
Conversion price	$ 0.0225	$ 0.0225	$ 0.0225
Total Preferred Shares Outstanding	5,356,000	5,356,000	4,975,000	4,508,000
Common Shares to be Issued if Fully Converted	190,000	190,000	177,000
Series D One Preferred Stock [Member]
Annual Dividend		10.00%	10.00%
Annual Dividend Payable, in Cash or In Kind		Quarterly in Arrears	Quarterly in Arrears
Per Share Liquidation preference	$ 1	$ 1	$ 1,000
Conversion price	$ 0.0225	$ 0.0225	$ 0.0225
Total Preferred Shares Outstanding	7,878,000	7,878,000	5,800,000	3,415,000
Common Shares to be Issued if Fully Converted	280,000	280,000	206,000
Series D Two Preferred Stock [Member]
Annual Dividend		10.00%	10.00%
Annual Dividend Payable, in Cash or In Kind		Quarterly in Arrears	Quarterly in Arrears
Per Share Liquidation preference	$ 1	$ 1	$ 1,000
Conversion price	$ 0.0500	$ 0.0500	$ 0.0500
Total Preferred Shares Outstanding	6,223,000	6,223,000	5,720,000	4,783,000
Common Shares to be Issued if Fully Converted	100,000	100,000	92,000

Equity (10Q) (Details 6)

Equity (10Q) (Details 6) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
YTD Dividend Shares in Kind	$ 819	$ 708	$ 2,335	$ 1,989	$ 2,712	$ 2,088
Accretion of beneficial conversion feature related to dividends		171	29	265	347	250
Series A Preferred Stock [Member]
YTD Dividend Shares in Kind	18	22	53	63	82	78
Series B Preferred Stock [Member]
YTD Dividend Shares in Kind	324	294	939	852	1,149	1,044
Series C Preferred Stock [Member]
YTD Dividend Shares in Kind	132	119	382	345	468	433
Accretion of beneficial conversion feature related to dividends		64	13	114	152	191
Series D One Preferred Stock [Member]
YTD Dividend Shares in Kind	192	128	516	329	472	131
Accretion of beneficial conversion feature related to dividends		107	16	151	195	59
Series D Two Preferred Stock [Member]
YTD Dividend Shares in Kind	$ 153	$ 145	$ 445	$ 400	$ 541	$ 402
Accretion of beneficial conversion feature related to dividends

Equity (10Q) (Details 7)

Equity (10Q) (Details 7) shares in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2015$ / sharesshares	Sep. 30, 2014$ / sharesshares	Dec. 31, 2014$ / sharesshares	Dec. 31, 2013$ / sharesshares
Class Of Warrant Or Right Number Of Warrants Or Rights Roll Forward
Number of Warrants Outstanding at beginning of period | shares	171	62	62	121
Number of warrants issued | shares	32	100	123	42
Number Of Warrants Or Rights Exercised | shares				(10)
Number Of Warrants Or Rights Expired | shares	(13)	(22)	(14)	(91)
Number of Warrants Outstanding at end of period | shares	190	139	171	62
Number of Warrants Or Rights Exercisable at end of period | shares	190	139	171	62
Excercise Price of Warrants Outstanding at beginning of period | $ / shares	$ 35.500	$ 36.125	$ 36.125	$ 33.625
Exercise Price Of Warrants Issued | $ / shares	24.125	34.375	34.375	33.375
Exercise Price Of Warrants Exercised | $ / shares				28.125
Exercise Price Of Warrants Expired | $ / shares	62.500	28.125	28.125	28.750
Excercise Price of Warrants Outstanding at end of period | $ / shares	$ 33	$ 35.75	$ 35.500	$ 36.125
Exercise Price Of WarrantsExercisable at end of period | $ / shares	33	35.75	35.50	36.125

Equity (10Q) (Details 8)

Equity (10Q) (Details 8) - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding and Excercisable	190	171	139	62	121
Weighted Average Remaining Life Of Warrants Or Rights	1 year 5 months 23 days	1 year 10 months 20 days
Warrants Weighted Average Exercise Price	$ 33	$ 35.500	$ 35.75	$ 36.125	$ 33.625
Warrants Group One [Member]
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding and Excercisable	22	7
Weighted Average Remaining Life Of Warrants Or Rights	2 years 6 months 7 days	1 year 11 months 12 days
Warrants Weighted Average Exercise Price	$ 28.125	$ 34.375
Warrants Group Two [Member]
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding and Excercisable	155	164
Weighted Average Remaining Life Of Warrants Or Rights	1 year 3 months 4 days	6 months 7 days
Warrants Weighted Average Exercise Price	$ 34.375	$ 62.500
Warrants Group Three [Member]
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding and Excercisable	3
Weighted Average Remaining Life Of Warrants Or Rights	1 month 17 days
Warrants Weighted Average Exercise Price	$ 62.50
Warrants Group Four [Member]
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding and Excercisable	10
Weighted Average Remaining Life Of Warrants Or Rights	2 years 9 months 29 days
Warrants Weighted Average Exercise Price	$ 15.625

Equity (10Q) (Details Textual)

Equity (10Q) (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Share-based Arrangements with Employees and Nonemployees [Abstract]
Estimated average forfeiture rate	7.89%	9.75%			10.00%	10.00%
Stock Options, Granted			29,000	2,000	3,600	21,000
Outstanding Options, Weighted Average Exercise Price	$ 28	$ 34.125	$ 28	$ 34.125
Stock Options, Exercised
Total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans	$ 363		$ 363		$ 236
Unrecognized compensation expense amortization period	3 years 2 months 12 days				2 years

Equity (10Q) (Details Textual 1

Equity (10Q) (Details Textual 1) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended					12 Months Ended
	Jul. 31, 2015	Mar. 31, 2015	Feb. 28, 2015	Mar. 31, 2014	Feb. 28, 2014	Dec. 31, 2014	Sep. 30, 2015	Jul. 23, 2015	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Subsidiary, Sale of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 35.500	$ 33		$ 35.75	$ 36.125	$ 33.625
Number of common shares callable by warrants										3,000
Venture Champion Asia Limited [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant coverage, maximum percentage						50.00%
Number of common shares callable by warrants						9,000
Credit Agreement origination date			May 6, 2014			May 6, 2014
Line of Credit Facility, Current Borrowing Capacity			$ 2,000			$ 2,000
Line of Credit Facility, Fair Value of Amount Outstanding			$ 0
Credit Agreement expiration date			Feb. 23, 2015			Feb. 23, 2015
Warrants Issued to SG Phoenix [Member]
Subsidiary, Sale of Stock [Line Items]
Fair Value Assumptions, Expected Term				3 years
Number of common shares callable by warrants				2,400
Warrants Issued to Unrelated Parties [Member]
Subsidiary, Sale of Stock [Line Items]
Fair Value Assumptions, Expected Term				3 years
Number of common shares callable by warrants				1,300
Series D Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from sale of stock, net	$ 325	$ 1,200		$ 406	$ 733
Administrative fee	$ 4	$ 33		$ 4	$ 47
Warrant coverage, maximum percentage				100.00%	100.00%
Fair Value Assumptions, Expected Term		3 years
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 28.125						$ 15.625
Warrants, expiration date	Jul. 22, 2018	Mar. 23, 2018		Dec. 31, 2016	Dec. 31, 2016
Number of common shares callable by warrants		22,000						11,000
Warrants And Rights Issued Fair Value Initial		$ 366						$ 91
Series D One Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares sold in private placement	329,000	1,233,000		273,000	520,000
Series D Two Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares sold in private placement				137,000	260,000
Note Warrant [Member] | Venture Champion Asia Limited [Member]
Subsidiary, Sale of Stock [Line Items]
Fair Value Assumptions, Expected Term						3 years
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 34.375
Number of common shares callable by warrants			9,000			1,000

Subsequent events (10Q) (Detail

Subsequent events (10Q) (Details Textual) - Subsequent Event [Member] - USD ($) $ / shares in Units, shares in Millions	Jan. 21, 2016	Jan. 20, 2016	Dec. 17, 2015	Dec. 15, 2015	Nov. 25, 2015
Unsecured Convertible Promissory Notes [Member]
Subsequent Event [Line Items]
Convertible promissory notes aggregate principal amount				$ 268,000	$ 1,000,000
Consideration of gross cash proceeds					750,000
Exchange of demand note					$ 250,000
Convertible promissory notes interest rate percentage				24.00%
Conversion price percentage				30.00%
Common stock public offering term after maturity period of convertible notes				60 days
Amount of pre-money valuation base for conversion price				$ 5,000,000
Cash payment percentage to each note holder upon conversion				1.50%
Value of notes converted of the revenue actually received				$ 100,000
Common Stock [Member]
Subsequent Event [Line Items]
Reverse stock split range of outstanding common stock	1-for-1,250
Common Stock [Member] | Minimum [Member]
Subsequent Event [Line Items]
Reverse stock split range of outstanding common stock		1-for-750
Common stock sale price (in dollars per share)		$ 4
Gross proceeds to conversion price of each series of preferred stock		$ 8,000,000
Common Stock [Member] | Maximum [Member]
Subsequent Event [Line Items]
Reverse stock split range of outstanding common stock		1-for-1,250
Common Stock [Member] | IPO [Member]
Subsequent Event [Line Items]
Common stock issued under public offering (in shares)			10